WO2005011805A2 - Apparatus and methods for applying neural stimulation to a patient - Google Patents

Apparatus and methods for applying neural stimulation to a patient Download PDF

Info

Publication number
WO2005011805A2
WO2005011805A2 PCT/US2004/025010 US2004025010W WO2005011805A2 WO 2005011805 A2 WO2005011805 A2 WO 2005011805A2 US 2004025010 W US2004025010 W US 2004025010W WO 2005011805 A2 WO2005011805 A2 WO 2005011805A2
Authority
WO
WIPO (PCT)
Prior art keywords
stimulation
terminal
polarity
pulse generator
patient
Prior art date
Application number
PCT/US2004/025010
Other languages
French (fr)
Other versions
WO2005011805A3 (en
Inventor
Brad Fowler
Bradford Evan Gliner
Original Assignee
Northstar Neuroscience, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northstar Neuroscience, Inc. filed Critical Northstar Neuroscience, Inc.
Priority to CA002534363A priority Critical patent/CA2534363A1/en
Priority to AU2004261290A priority patent/AU2004261290A1/en
Priority to JP2006522666A priority patent/JP2007501067A/en
Priority to EP04779931A priority patent/EP1654032A2/en
Publication of WO2005011805A2 publication Critical patent/WO2005011805A2/en
Publication of WO2005011805A3 publication Critical patent/WO2005011805A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526Head electrodes
    • A61N1/0529Electrodes for brain stimulation
    • A61N1/0531Brain cortex electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526Head electrodes
    • A61N1/0529Electrodes for brain stimulation
    • A61N1/0539Anchoring of brain electrode systems, e.g. within burr hole

Definitions

  • the present disclosure is related to systems and methods for applying stimulation to a target neural population within a patient, for example, a surface site on the patient's cortex.
  • a wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain.
  • the neural-functions in some areas of the brain i.e., the sensory or motor cortices
  • various areas of the brain appear to have distinct functions in most individuals.
  • the occipital lobes relate to vision
  • the left interior frontal lobes relate to language
  • the cerebral cortex appears to be involved with conscious awareness, memory, and intellect.
  • Many problems or abnormalities can be caused by damage, disease and/or disorders in the brain. Effectively treating such abnormalities may be very difficult. For example, a stroke is a common condition that damages the brain.
  • Strokes are generally caused by emboli (e.g., obstruction of a vessel), hemorrhages (e.g., rupture of a vessel), or thrombi (e.g., clotting) in the vascular system of a specific region of the brain. Such events generally result in a loss or impairment of a neural function (e.g., neural functions related to facial muscles, limbs, speech, etc.). Stroke patients are typically treated using various forms of physical therapy to rehabilitate the loss of function of a limb or another affected body part. Stroke patients may also be treated using physical therapy plus an adjunctive therapy such as amphetamine treatment.
  • emboli e.g., obstruction of a vessel
  • hemorrhages e.g., rupture of a vessel
  • thrombi e.g., clotting
  • a neural function e.g., neural functions related to facial muscles, limbs, speech, etc.
  • Stroke patients are typically treated using various forms of physical therapy to rehabilitate
  • Neurological problems or abnormalities are often related to electrical and/or chemical activity in the brain. Neural activity is governed by electrical impulses or "action potentials" generated in neurons and propagated along synaptically connected neurons. When a neuron is in a quiescent state, it is polarized negatively and exhibits a resting membrane potential typically between -70 and -60 mV. Through chemical connections known as synapses, any given neuron receives excitatory and inhibitory input signals or stimuli from other neurons.
  • a neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials when the integration exceeds a threshold potential.
  • a neural firing threshold for example, may be approximately - 55 mV.
  • Transcranial electrical stimulation is one such approach that involves placing an electrode on the exterior of the scalp and delivering an electrical current to the brain through the scalp and skull.
  • transcranial magnetic stimulation involves producing a high-powered magnetic field adjacent to
  • the neural stimulation signals used by these approaches may comprise a series of electrical or magnetic pulses directed toward affecting neurons within a target neural population.
  • Stimulation signals may be defined or described in accordance with stimulation signal parameters including pulse amplitude, pulse frequency, duty cycle, stimulation signal duration, and/or other parameters.
  • Electrical or magnetic stimulation signals applied to a population of neurons can depolarize neurons within the population toward their threshold potentials. Depending upon stimulation signal parameters, this depolarization can cause neurons to generate or fire action potentials.
  • supra-threshold stimulation neural stimulation that fails to elicit action potentials in a functionally significant proportion of the neural population is defined as sub-threshold stimulation.
  • supra-threshold stimulation of a neural population triggers or activates one or more functions associated with the neural population, but sub-threshold stimulation by itself does not trigger or activate such functions.
  • Supra-threshold neural stimulation can induce various types of measurable or monitorable responses in a patient.
  • supra-threshold stimulation applied to a patient's motor cortex can induce muscle fiber contractions in an associated part of the body.
  • electrical or magnetic stimulation of neural tissue may be directed toward producing an intended type of therapeutic, rehabilitative, or restorative neural activity, such stimulation may result in collateral neural activity.
  • neural stimulation delivered beyond a certain intensity, period of time, level, or amplitude can give rise to seizure activity and/or other types of collateral activity.
  • certain types of collateral neural activity may be undesirable and/or inconvenient in a neural stimulation situation. toon
  • Another concern that arises in association with stimulating a surface site on a patient's cortex is conservation or minimization of applied power while operating a stimulation device.
  • IPG implanted pulse generator
  • the electrode assembly generally has a plurality of contacts that are carried by a common support member, such that the
  • the IPG delivers an electrical waveform to the electrode assembly, such that a first set of contacts provides a current delivery path and a second set of contacts provides a current return path.
  • a first set of contacts provides a current delivery path
  • a second set of contacts provides a current return path.
  • at least one contact has a positive bias
  • at least one contact has a negative bias, resulting in the generation of a bipolar field at the surface of the cortex within the area of the stimulation site.
  • the bipolar field has a lower current density in the deeper layers of the cortex compared to the current density at the surface layers, and the bipolar field runs generally parallel to the cranium of the patient in the deeper layers of the cortex.
  • Systems that generate a bipolar field at the stimulation site may require relatively high current levels to achieve an intended or desired therapeutic effect. This may result in increased power consumption, and possibly increase the likelihood of inducing collateral neural activity.
  • Figure 1 is a side view of a system for applying electrical stimulation to a stimulation site on or proximate to the surface of the cortex of a patient in accordance with an embodiment of the invention.
  • Figure 2 is a graph illustrating several parameters that may describe, define, or characterize a stimulation signal.
  • Figure 3A is a front view of a system for applying electrical stimulation to a cortical stimulation site in accordance with Figure 1A showing a different implementation of the system.
  • Figure 3B is a cross-sectional view of a brain of a patient illustrating the implementation of Figure 3A in greater detail.
  • Figure 3C is a schematic illustration of a combined electrode assembly that may be used to apply or deliver unipolar stimulation to a patient.
  • Figure 4 is a schematic illustration showing an exemplary electric field distribution generated by unipolar electrical stimulation using a system for applying electrical stimulation to a cortical stimulation site in accordance with an embodiment of the invention.
  • Figure 5 is a schematic illustration showing an exemplary electrical field distribution generated by bipolar electrical stimulation at a cortical stimulation site.
  • Figure 6 is a side view of a system for applying electrical stimulation to a cortical stimulation site in accordance with another embodiment of the invention.
  • Figure 7 is a side view of a system for applying electrical stimulation to a cortical stimulation site in accordance with another embodiment of the invention.
  • Figures 8A and 8B are an isometric view and a cross sectional view, respectively, of a system for applying electrical stimulation to a site on or proximate to the cortex in accordance with another embodiment of the invention.
  • Figure 8C is a cross sectional view of a system for applying electrical stimulation to a site on or proximate to the cortex according to another embodiment of the invention.
  • Figure 9A is a schematic illustration of a system for applying electrical stimulation to a site on or proximate to the cortex in accordance with another embodiment of the invention.
  • Figure 9B is a schematic illustration of a system for applying electrical stimulation to a site on or proximate to the cortex in accordance with another embodiment of the invention.
  • Figures 10-11 are flow charts illustrating methods for applying electrical stimulation to a stimulation site in accordance with embodiments of the invention.
  • the present disclosure describes systems and methods for neural stimulation that may enhance the efficacy and/or increase the efficiency of neural stimulation procedures.
  • the neural stimulation may comprise a set of stimulation signals applied or delivered to or through target neural structures, target neural projections, and/or one or more target neural populations associated with controlling, influencing, or affecting one or more neurological functions under consideration.
  • the neural stimulation may be directed toward facilitating and/or effectuating at least some degree of symptomatic relief and/or restoration or development of functional
  • neurologic dysfunction may correspond to Parkinson's Disease, essential tremor, Huntington's disease, stroke, traumatic brain injury, Cerebral Palsy, Multiple Sclerosis, a central pain syndrome, a memory disorder, dementia, Alzheimer's disease, an affective disorder, depression, bipolar disorder, anxiety, obsessive/compulsive disorder, Post Traumatic Stress Disorder, an eating disorder, schizophrenia, Tourette's Syndrome, Attention Deficit Disorder, an addiction, autism, epilepsy, a sleep disorder, a hearing disorder (e.g., tinnitis or auditory hallucinations), a speech disorder (e.g., stuttering), and/or one or more other disorders, states, or conditions.
  • Parkinson's Disease essential tremor
  • Huntington's disease Huntington's disease
  • stroke traumatic brain injury
  • Cerebral Palsy Multiple Sclerosis
  • a central pain syndrome a memory disorder
  • dementia Alzheimer's disease
  • an affective disorder depression, bipolar disorder, anxiety, obsessive
  • a target neural population may comprise one or more portions of a patient's motor cortex.
  • a neural location at which or a neural region in which stimulation signals are applied or delivered to or through a target neural population may be defined as a stimulation site.
  • an exemplary stimulation site may comprise a location or region upon the patient's dura mater.
  • a target neural population may correspond to one or more portions of a patient's auditory cortex.
  • a stimulation site may comprise an epidural or subdural cortical region that may facilitate the application, delivery, and/or transfer of stimulation signals to such a target neural population, for example, an epidural site adjacent or proximate to the Sylvian fissure.
  • the application of unipolar stimulation signals to such a stimulation site in accordance with particular embodiments of the invention may increase a likelihood of affecting the target neural population in an intended manner.
  • a stimulation site may be identified in accordance with a variety of techniques, including (1) identification of one or more anatomical landmarks; (2) preoperatively (e.g., using Transcranial Magnetic Stimulation) and/or intraoperatively stimulating one or more brain locations to identify or map particular neural regions that induce or evoke a given type of patient response (for example, a movement or a sensation); (3) estimating a location at which the brain may recruit neurons to carry
  • [33734-8051 /SL042150.254] -6- out a given type of neural activity that was previously performed by a damaged portion of the brain; (4) an electrophysiologic signal measurement and/or analysis procedure (e.g., acquisition and/or analysis of EEG, EMG, MEG, coherence, partial coherence, and/or other signals); and/or (5) a neural imaging procedure.
  • an electrophysiologic signal measurement and/or analysis procedure e.g., acquisition and/or analysis of EEG, EMG, MEG, coherence, partial coherence, and/or other signals
  • a neural imaging procedure e.g., the number and/or location of stimulation sites under consideration may depend upon the nature, number, and/or extent of a patient's neurological condition and/or functional deficits.
  • a unipolar, monopolar, or isopolar stimulation signal that may provide enhanced efficacy or efficiency stimulation using a low current level that reduces power consumption and/or mitigates collateral effects.
  • Various embodiments of the present invention may apply or deliver neural stimulation at a subthreshold level or intensity, that is, at a level that raises or generally raises membrane potentials associated with a target neural population while avoiding the generation of a sufficient or statistically significant number of action potentials capable of triggering a neural function corresponding to the target neural population as a result of neural stimulation alone.
  • Stimulation systems and methods in accordance with the present invention may be used to treat various neurological conditions and/or facilitate particular types of neurological or functional patient outcomes.
  • neural stimulation applied or delivered in accordance with several embodiments of the invention may affect neural firing likelihoods and/or influence, facilitate, and/or effectuate reorganization of interconnections or synapses between neurons to (a) provide at least some degree of functional recovery and/or functional gain; and/or (b) develop one or more compensatory mechanisms to at least partially overcome a functional deficit or shortcoming.
  • Such reorganization of neural interconnections may be achieved, at least in part, by a change in the strength of synaptic connections through a process that corresponds to a mechanism commonly known as Long-Term Potentiation (LTP).
  • LTP Long-Term Potentiation
  • Neural stimulation applied or delivered in accordance with certain embodiments of the invention may alternatively or additionally affect particular neural populations through a process that corresponds to a mechanism commonly known as Long-Term Depression (LTD).
  • LTD Long-Term Depression
  • adjunctive or synergistic therapies may facilitate, effectuate, or enhance therapeutic efficacy, for example, through neural plasticity and the reorganization of synaptic interconnections between neurons.
  • Figure 1 is a side view of a system for applying electrical stimulation to a neural stimulation site or region according to an embodiment of the invention.
  • the stimulation site may be upon, essentially upon, or proximate to the surface of the cortex of a patient P.
  • the stimulation system may comprise a stimulus unit 120 and a patient interface that includes a set of electrodes, electrode arrangements and/or electrode assemblies 160 (hereinafter, "electrode assemblies").
  • the set of electrode assemblies 160 includes a first electrode assembly 160a and a second electrode assembly 160b.
  • Electrode assemblies may include additional electrode assemblies, which may be positioned or implanted at or proximate to a set of stimulation sites, or remote from one or more stimulation sites. Electrode assemblies can stimulate different neural regions, e.g., regions carrying out different neural functions and/or regions carrying out neural functions at different locations of the body, including different extremities of the body.
  • the system may also include a sensing unit 180 (shown schematically) configured to monitor one or more types of patient responses, activities, and/or behaviors. The sensing unit 180 may be further configured to communicate with the stimulus unit 120.
  • the sensing unit 180 may include, for example, electrodes 182 and/or other devices (e.g., an accelerometer or motion detector) configured to sense a patient's neural activity (e.g., an EEG signal), neuromuscular activity (e.g., an EMG signal), behavioral activity (e.g., patient motion), and/or other types of patient activity.
  • a patient's neural activity e.g., an EEG signal
  • neuromuscular activity e.g., an EMG signal
  • behavioral activity e.g., patient motion
  • the stimulus unit 120 generates and outputs stimulation signals, and the set of electrode assemblies 160 facilitates application or delivery of the stimulation signals to the patient P.
  • the stimulus unit 120 may perform, direct, and/or facilitate neural stimulation procedures in a manner that enhances efficacy,
  • the stimulus unit 120 may comprise a pulse generator that is implanted into the patient P.
  • the stimulus unit 120 is an IPG that is implanted in a thoracic, subclavicular, or abdominal location.
  • the stimulus unit 120 can be an IPG implanted in the patient's skull or just under the patient's scalp.
  • the stimulus unit 120 can be implanted above the patient's neckline at a location in or near the patient's cranium.
  • the stimulus unit 120 may comprise a controller 130 and a pulse system 140.
  • the stimulus unit 120 may further comprise a power source, a battery, an energy storage device, and/or power conversion circuitry (not shown).
  • the controller 130 may include a processor, a memory, and a programmable computer medium.
  • the controller 130 may be implemented as a computer or a microcontroller, and the programmable medium may comprise software, instructions, and/or configuration information loaded into the memory and/or hardware that performs, directs, and/or facilitates neural stimulation procedures in accordance with one or more methods of the present invention.
  • the pulse system 140 generates and outputs stimulation signals.
  • Figure 2 is a graph illustrating several parameters that may describe, define, or characterize a stimulation signal.
  • a stimulus start time to may define an initial point at which a stimulation signal is applied to a target neural population.
  • the stimulation signal may be a symmetric or asymmetric biphasic waveform comprising a set or series of biphasic pulses, and which may be defined, characterized, or described by parameters including a pulse width t
  • the parameters can also include a stimulus repetition rate 1/ corresponding to a pulse repetition frequency; a stimulus pulse duty cycle equal to t 3 divided by t ; a stimulus burst time t 5 that defines a number of pulses in a pulse train; and/or a pulse train repetition rate 1/t 6 that defines a stimulus burst frequency.
  • Other parameters include a peak current intensity for the first pulse phase and a peak
  • the pulse system 140 may generate and/or output stimulation signals in accordance with a theta burst pattern.
  • theta burst stimulation may comprise pulse bursts and/or pulse packets separated by quiescent intervals, such that the number of pulse packets per seconds corresponds or approximately corresponds to theta wave frequencies exhibited by the brain.
  • theta wave frequencies may range from approximately 3 to 10 Hz, and more particularly in certain embodiments, 4 to 8 Hz.
  • the pulse system 140 may vary and/or modulate stimulation signals in one or more manners, for example, in accordance with one or more mathematical operations and/or functions upon or corresponding to particular stimulation signal parameters. Exemplary manners of varying stimulation signals are described in detail in U.S. Application No. 60/588,406, filed on July 15, 2004, entitled “System and Method for Enhancing or Affecting Neural Stimulation Efficiency and/or Efficacy," incorporated herein by reference in its entirety.
  • the pulse system 140 may apply or output stimulation signals to, across, or between a first terminal 142a and a second terminal 142b.
  • a stimulation signal may comprise a time-varying waveform
  • a relative polarity of the stimulation signal, and hence that of the first and second terminals 142a-b may change or vary with time.
  • an anode may be defined as a terminal 142a-b to which a positive polarity phase within an initial pulse is first applied.
  • an anode may be designated as the particular terminal 142a-b that first receives a positive polarity phase following the stimulus start time t 0 .
  • a cathode may be defined as a terminal 142a-b that provides electrical continuity for the stimulation signal delivered through the anodal terminal 142a-b.
  • -10- cathode may thus be opposite to that of the anode, or neutral.
  • a cathode may be defined as a terminal 142a-b to which a first negative polarity or lower potential phase within an initial pulse is first applied.
  • anode and cathode could be defined in an opposite or different manner than as defined above, yet such opposite or different definitions would be equivalent, essentially equivalent, or consistent from a mathematical or circuit analysis perspective.
  • the first terminal 142a may be configured as an anode, while the second terminal 142b may be configured as a cathode; (b) the first terminal 142a may be configured as a cathode, while the second terminal 142b may be configured as an anode; or (c) the first and second terminals 142a-b may be selectively or programmably configured as an anode and a cathode, possibly in a predetermined, aperiodic, or pseudo-random time dependent manner.
  • stimulus periods provided by the stimulus unit 120 can have durations of 30 seconds or less, 10 seconds or less, 2-5 seconds, about one second, and/or less than one second.
  • the stimulus periods can include but are not limited to alternating cathodal and anodal periods, alternating unipolar periods, alternating bipolar periods, and/or periods that alternate between unipolar and bipolar.
  • the electrical potential of the stimulation signal can also alternate between subthreshold levels and suprathreshold levels.
  • the first electrode assembly 160a may be positioned or implanted at a stimulation site that is located upon, essentially upon, or proximate to a target neural population upon, within, or near the patient's cerebral cortex.
  • the first electrode assembly 160a may comprise a support member 162a and one or more contacts 164a carried by the support member 162a.
  • the support member 162a may be configured for implantation at a stimulation site upon or at least proximate to the surface of the patient's cortex.
  • the support member 162a for example, can be a flexible or rigid substrate that is implanted under the cranium S such that the contacts 164a are positioned upon or adjacent to the dura mater at the stimulation
  • the support member 162a can be a portion of a cranial screw or a housing that is implanted through the cranium S, in a manner identical or analogous to that described in U.S. Patent Application No. 10/418,796, which is incorporated herein by reference.
  • the first electrode assembly 160a can have one or more contacts 164a arranged or positioned in a desired configuration.
  • the first electrode assembly 160a may include a single contact 164a, or a plurality of contacts 164a arranged as an array, grid, or other pattern.
  • the first electrode assembly 160a also includes a first lead or link 170a that electrically couples some or all of the contacts 164a to the pulse system's first terminal 142a.
  • the first electrode assembly 160a may therefore be configured as an anode or a cathode, in accordance with the anodal or cathodal configuration of the first terminal 142a of the pulse system 140.
  • Contacts 164a that are not coupled to the first terminal 142a at a particular time may electrically float.
  • the first link 170a may be a wired link or a wireless link.
  • the first electrode assembly 160a can comprise a cortical neural-stimulation device, such as any of the devices described in U.S. Patent Application No.
  • the second electrode assembly 160b can be similar to the first electrode assembly 160a, or it can be a different type of electrode assembly.
  • the second electrode assembly 160b may be positioned remotely from the first electrode assembly 160a. Since the second electrode assembly 160b provides electrical continuity with respect to the first electrode assembly 160a, the second electrode assembly 160b may be defined to reside at a circuit completion site.
  • the second electrode assembly 160b comprises a separate electrode array including a support base 162b and one or more contacts 164b.
  • the support base 162b can be configured for positioning at (a) a location or site upon or proximate to the surface of the cortex spaced apart from the stimulation site where the first electrode assembly 160a is located; (b) a deep brain location; or (c) another area in the body above or below the neck.
  • the second electrode assembly 160b can include a second link 170b that couples one or more contacts 164b (i.e., each contact 164b
  • the second electrode assembly 160b may be configured as an anode or a cathode, in accordance with the anodal or cathodal configuration of the pulse system's second terminal 142b.
  • the second electrode assembly 160b, and more particularly the second electrode assembly's contacts 164b, are separate or otherwise detached from the first electrode assembly 160a.
  • the second electrode assembly's contacts 164b are not attached to the first electrode assembly 160a, and the second electrode assembly's contacts 164b may be movable with respect to the contacts 164a of the first electrode assembly 164a before being implanted in the patient.
  • the second electrode assembly 160b may accordingly be configured to be attached to or implanted in the patient at a location spaced apart from a stimulation site on or proximate to the cortex of the patient where electrical stimulation is to be applied to facilitate and/or effectuate a given neurological or neurofunctional outcome, such as neural plasticity or another type of neural reorganization corresponding to one or more neural populations.
  • each contact 164a of the first electrode assembly 160a that is coupled to the pulse system's first terminal 142a i.e., each non-floating contact 164a
  • the pulse system 140 applies an identical polarity signal to each such contact 164a at any given time.
  • each intentionally biased or non- floating contact 164b of the second electrode assembly 160b is biased in accordance with a second signal polarity, where the second signal polarity is opposite or complementary to the first signal polarity, or neutral, to facilitate electrical current flow between the first and second electrode assemblies 160a-b.
  • Neural stimulation in which both an anode and a cathode are positioned, located, or situated within, essentially directly across, or proximate to a stimulation site may be defined as bipolar stimulation.
  • neural stimulation in which one of an anode and a cathode is positioned, located, or situated within or proximate to a stimulation site, while a respective corresponding cathode or anode is positioned, located, or situated remote from the stimulation site to provide electrical continuity may be defined as unipolar, monopolar, or isopolar stimulation.
  • - 13- cathode are positioned, located, or situated in different neurofunctional areas or functionally distinct anatomical regions may be defined as unipolar stimulation.
  • the pulse system 140 applies an identical polarity signal to each non-floating contact 162a-b positioned upon or proximate to a stimulation site.
  • Unipolar stimulation may be defined as anodal unipolar stimulation when an anode is positioned upon or proximate to a stimulation site or a target neural population; and as cathodal unipolar stimulation when a cathode is positioned upon or proximate to a stimulation site or a target neural population.
  • the second electrode assembly 160b is positioned apart or remote from the first electrode assembly 160a to establish an electric field that passes through deep layers of the cortex and/or other neural regions in a direction that is generally perpendicular or oblique with respect to (a) the first electrode assembly's contacts 164a; (b) the surface of the cortex under the first electrode assembly 160a; and/or (c) the cranium of the patient at or proximate to the stimulation site.
  • the electric field for example, is substantially normal to the first electrode assembly 160a in the deep layers of the cortex and/or other neural layers beneath the stimulation site.
  • Figures 3A and 3B illustrate a different implementation of a system for applying electrical stimulation to a neural stimulation site according to an embodiment of the invention.
  • a first electrode assembly 160a may be implanted in the patient at a stimulation site at least proximate to the surface of the cortex C ( Figure 3B) over target neurons or a target neural population N ( Figure 3B).
  • a second electrode assembly 160b may be positioned at a location in the patient that is spaced apart from the stimulation site, for example, at a location that is above the patient's neck, to establish an electric field orientation or distribution that extends in a desired direction relative to the target neurons N.
  • the second electrode assembly 160b may additionally or alternatively be positioned relative to other neural structures to minimize or mitigate collateral neural activity.
  • the second electrode assembly 160b can be spaced apart from the patient's brain as shown in Figure 3A, or the second electrode assembly 160b can be positioned at a different location of the patient's brain as shown in Figure 3B.
  • the stimulus unit 120 may provide an output at a first polarity to the non-floating contacts 164a of the first electrode assembly 160a, and provide an
  • the first electrode assembly's contacts 164a accordingly provide a unipolar, monopolar, or isopolar bias at the stimulation site upon or proximate to the patient's cortex C.
  • the first polarity may be anodal or cathodal
  • the second polarity may respectively be cathodal or anodal (i.e., opposite to the first polarity or neutral).
  • a unipolar signal applied to the first electrode assembly's contacts 164a may establish an electric field that extends through deep layers of the cortex and/or other neural regions along a vector V extending generally perpendicular to, or at least oblique with respect to, the orientation of (a) the first electrode assembly 160a; (b) the surface of the cortex C at or proximate to the stimulation site; and/or (c) the cranium of the patient adjacent to the stimulation site ( Figure 3A).
  • Certain systems and/or methods in accordance with the present invention may utilize or rely upon a single electrode assembly having a design that is suitable for providing unipolar stimulation rather than relying upon separate electrode assemblies.
  • Figure 3C is a schematic illustration of a combined electrode assembly 260 capable of applying or delivering unipolar stimulation to a patient.
  • the combined electrode assembly 260 includes a support member 262 having a local portion 263a, a remote portion 263b, and a separation portion 263c.
  • the local portion 263a carries a first set of contacts 264a
  • the remote portion 263b carries a second set of contacts 264b.
  • the support member 262 may be formed from one or more flexible or generally flexible biocompatible materials (e.g., plastic and/or silicone), and the first and second sets of contacts 264a-b may be formed from one or more biocompatible conductive materials (e.g., Titanium and/or Platinum).
  • the first set of contacts 264a may be configured as an anode or a cathode
  • the second set of contacts 264b may respectively be configured as a cathode or an anode to facilitate unipolar stimulation.
  • the combined electrode assembly 260 may be implanted into a patient such that the local portion 263a resides at, upon, or proximate to a stimulation site, while the remote portion 263b resides at a circuit completion site that is distant or remote from the stimulation site.
  • the separation portion 263c may have a length L that is sufficient to ensure that in a typical patient, an electric field
  • the value of L may be roughly an order of magnitude greater than the distance between the stimulation site and a target neural population or neural region that is deepest or farthest from the stimulation site.
  • an exemplary value of L may be roughly an order of magnitude or more greater than approximately 2.5 to 3.0 mm; and for epidural stimulation, an exemplary value of L may be roughly an order of magnitude greater than approximately 4.0 to 6.0 mm.
  • FIG. 4 is a schematic illustration showing an exemplary electric field distribution generated by unipolar stimulation using a system in accordance with an embodiment of the invention.
  • a first contact 164a is positioned at a stimulation site corresponding to a target neural population, while a second contact (not shown) is positioned distant or remote from the first contact 164a at a different neurofunctional or anatomical region.
  • the first contact 164a may be biased as an anode, for example, and the second contact may be biased as a cathode to establish an electrical potential gradient or difference that facilitates the flow of electrical current (i.e., a net movement of charged particles or ions).
  • a unipolar electric field distribution may be represented as a plurality of field lines 300 that extend through, for example, targeted deep layers of the cortex C and possibly other neural regions in a direction that is at least substantially perpendicular to (1) the surface of the cortex at or proximate to the stimulation site; and/or (2) the first electrode assembly's contacts 164a.
  • FIG. 5 is a schematic illustration showing an exemplary electric field distribution generated by bipolar stimulation, which may be selectively produced in accordance with particular embodiments of the invention as further described below.
  • a first contact 410a and a second contact 410b are configured to deliver bipolar stimulation to one or more portions of a target neural population.
  • the first and second contacts 410a, 410b are located proximate to each other, within or upon a stimulation site that corresponds to the spatial extent of the target neural population.
  • contacts 410a-b positioned at and/or near the stimulation site are biased at different polarities.
  • the first contact 410a is biased as an anode, while a second contact 410b is biased as a cathode.
  • a bipolar electric field distribution may be represented as a plurality of field lines 400 having field components that are generally parallel to (1 ) the surface of the cortex at or proximate to the stimulation site; and/or (2) a support member (not shown) configured to carry the first and second contacts 410a-b.
  • an electrical potential gradient or difference between an anode and a cathode configured to provide unipolar stimulation exists over a longer or greater distance than an electrical potential gradient between an anode and a cathode configured to provide bipolar stimulation.
  • an anode to cathode electrical current pathway associated with unipolar stimulation will typically be longer than an electrical current pathway associated with bipolar stimulation.
  • Unipolar stimulation may therefore provide a greater degree of therapeutic efficacy than bipolar stimulation when stimulation of neural regions, structures, and/or projections that are deeper or more distant than those just beneath and/or in the near vicinity of the stimulation site may be of importance.
  • unipolar stimulation may deliver more current to such deeper or more distant neural regions at a lower power level than bipolar stimulation, which may result in greater stimulation efficiency and/or a reduced likelihood of inducing collateral neural activity.
  • Enhanced stimulation efficiency may be important when treating chronic, near-chronic, and/or longer-term conditions, for example, movement disorders or central pain syndrome.
  • an electric field polarity, orientation and/or distribution relative to particular types of neurons, neural projections, neural structures, and/or neurofunctional regions may influence or affect neural stimulation efficiency and/or efficacy.
  • the cortex C may be organized as a
  • -17- set of 6 layers where layer 1 maintains a boundary corresponding to the cortical surface. Successive cortical layers exist or reside at increasing depths relative to the cortical surface. Thus, layer 6 corresponds to a deepest cortical layer.
  • the thickness or extent of any given cortical layer, and the type, number, and/or size of neurons, neural projections, and/or neural structures therein depends upon the cortical neurofunctional region under consideration.
  • Neurons convey input signals along their dendrites toward their cell bodies. Neurons in the cortex C include pyramidal cells 302 and intemeurons 304.
  • pyramidal cells 320 In the motor cortex, the largest pyramidal cells 320 have soma or cell bodies that reside in deep cortical layer 5. Pyramidal cells 302 have dendrites that project away from their cell bodies into overlying or superficial cortical layers, toward the cortical surface in a manner that is approximately perpendicular or normal to the layer structure of the cortex C. Intemeurons 304 have cell bodies that commonly reside in cortical layers 2, 3, and 4, and include dendrites that tend to project away from their cell bodies within the same layer or into an adjacent layer in a manner that is generally lateral or parallel with respect to the layer structure of the cortex C.
  • An optimal, near optimal, or desirable electric field orientation for therapeutic neural stimulation may be based upon or determined by the orientation of one or more types of neurons, neural structures, and/or neural projections within or associated with a target neural population N.
  • an electric field that is oriented generally parallel to a main or overall direction in which pyramidal cell dendrites project that is, generally perpendicular or normal to the cortical layer structure (or equivalently, generally perpendicular or normal to the surface of the cortex C or the cranium), may preferentially influence or exert a more significant effect upon pyramidal cells 302 than intemeurons 304, which include dendrites that generally project lateral to the cortical layer structure.
  • an electric field that is oriented generally parallel to a typical or overall direction in which interneuron dendrites project, that is, generally parallel or lateral to the cortical layer structure, may preferentially influence or exert a more significant effect upon intemeurons 304 than pyramidal cells 302.
  • systems and/or methods in accordance with particular embodiments of the invention may apply or deliver stimulation signals having one or more polarities that may enhance a likelihood of facilitating or
  • [33734-8051/SL042150.254] -18- effectuating a desired neurological and/or functional outcome based upon the types of neurons, neural structures, and/or neural projections involved in subserving such an outcome.
  • specific embodiments of the invention may apply unipolar stimulation at one or more times to patients experiencing certain types of central pain syndrome.
  • various embodiments of the invention may apply unipolar stimulation, possibly in conjunction with a behavioral therapy, to patients having functional deficits associated with stroke, traumatic brain injury, cerebral palsy, and/or other disorders (e.g., tinnitus).
  • unipolar stimulation may more effectively facilitate or effectuate neural disinhibition and/or neuroplastic change associated with a target neural population than bipolar stimulation, thereby enhancing the extent to which such patients can recover lost functional abilities and/or develop new abilities.
  • Unipolar stimulation may facilitate or effectuate enhanced recovery or development of functional abilities in patients experiencing particular types of neurologic dysfunction when compared to bipolar stimulation.
  • cathodal unipolar stimulation in conjunction or association with a behavioral therapy such as an Activity of Daily Living (ADL) may facilitate or effectuate a greater degree of functional development and/or recovery in a patient experiencing functional deficits associated with stroke, traumatic brain injury, and/or neurological damage than bipolar stimulation either alone or in association or conjunction with such a behavioral therapy.
  • ADL Activity of Daily Living
  • Certain systems and/or methods in accordance with the invention may deliver unipolar stimulation during a unipolar stimulation period and bipolar stimulation during a bipolar stimulation period.
  • both pyramidal cells 302 and intemeurons 304 may play a role in neural reorganization.
  • a system and/or method may deliver unipolar stimulation to more selectively influence or affect pyramidal cells 302 during a unipolar stimulation period, and deliver bipolar stimulation to more selectively influence or affect intemeurons 304 during a bipolar stimulation period.
  • One or more unipolar and/or bipolar stimulation periods may be identical or different in duration
  • any given unipolar stimulation period, bipolar stimulation period, and/or interruption period between unipolar and/or bipolar stimulation periods may correspond to a subseconds-based, a seconds-based, an hours-based, and/or another type of time domain.
  • alternation between unipolar and/or bipolar stimulation periods and/or intervals between such periods may temporally occur in a predetermined, aperiodic, or pseudo-random manner.
  • Neural stimulation may be delivered during one or more unipolar and/or bipolar stimulation periods in conjunction or association with one or more adjunctive or synergistic therapies, for example, a behavioral therapy and/or a drug therapy.
  • An adjunctive therapy corresponding to a unipolar stimulation period may be identical to or different from an adjunctive therapy corresponding to a bipolar stimulation period.
  • pyramidal cell axons that project into the spinal cord, brain stem, basal ganglia, and/or other areas may serve as cortical outputs involved in facilitating or controlling movement.
  • a given type of unipolar neural stimulation may elicit or generate a patient response or movement at a different (e.g., lower) current level or intensity than bipolar stimulation.
  • unipolar stimulation may provide or induce an intended or desired effect at a lower current level than bipolar stimulation, thereby conserving power and/or reducing a likelihood of inducing collateral activity.
  • unipolar stimulation may facilitate determination of a therapeutic current level using lower amplitude test stimulation signals than required by bipolar stimulation.
  • a therapeutic current level corresponding to a given type of unipolar stimulation may be mapped to a therapeutic current level that corresponds to a different type of unipolar stimulation and/or bipolar stimulation in accordance with a mapping function and/or empirical data.
  • certain types of neural cells may exhibit different types of signal conductance properties based upon whether the motion of electrical charges or electrically charged particles (i.e., ions) is toward or away from the axon hillock, the initial axonal region proximate to the cell body through which dendritic inputs are integrated. For instance, in pyramidal cells 302, intracellular ions
  • anodal unipolar stimulation may affect or influence a neural population, neural structures, and/or neural projections differently than cathodal unipolar stimulation.
  • Stimulation signal polarity characteristics may influence or affect an extent to which and/or a manner in which particular neural structures experience a potential difference and/or depolarization or polarization relative to each other, which may affect neural stimulation efficacy and/or efficiency. For example, due to the existence of a potential gradient between a cathode and an anode, a relative dendrite to axon hillock or axon depolarization or hyperpolarization state may give rise to neural stimulation efficacy differences between cathodal unipolar stimulation and anodal unipolar stimulation.
  • a positive first pulse phase applied at a stimulation site may give rise to an enhanced extracellular concentration of negative ions in a localized region at, just beneath, just around, and/or in the near vicinity of the stimulation site.
  • a localized region may correspond, for example, to a small, relatively small, or generally small neural tissue and/or neural structure volume within shallow or superficial layers of the cortex.
  • dendrites within the localized region may experience an enhanced intracellular concentration of positive ions, thereby shifting the electrical state of such dendrites toward a more depolarized state than, for example, axon hillocks corresponding to such dendrites.
  • a negative first pulse phase applied at a stimulation site may give rise to an enhanced extracellular concentration of positive ions in a localized region at, just beneath, just around, and/or in near proximity to the stimulation site.
  • dendrites within the localized region may experience an enhanced intracellular concentration of negative ions, thereby shifting the electrical state of such dendrites toward a more hyperpolarized state than axon hillocks corresponding to such dendrites.
  • a dendritic potential shift toward a more depolarized state and/or a more hyperpolarized state may affect dendritic signal processing and/or signal generation and/or signal transfer mechanisms. Such a potential shift may affect neural stimulation efficacy, for example, by influencing an extent to and/or manner in which postsynaptic dendrites react or respond to and/or process presynaptic input.
  • cathodal unipolar stimulation may increase a likelihood that dendrites within a target neural population respond to and/or process neurofunctionally relevant synaptic input in a manner that enhances a likelihood of generating action potentials that may subserve the development and/or recovery of one or more functional abilities.
  • Neurofunctionally relevant synaptic input may arise from or correspond to an adjunctive or synergistic therapy, for example, a behavioral therapy.
  • the aforementioned neural stimulation situations may include, for example, neural stimulation directed toward rehabilitation of patients experiencing symptoms associated with neurological damage (e.g., arising from stroke or traumatic brain injury), neurodegenerative disorders (e.g., Parkinson's disease, Alzheimer's disease), neuropsychiatric disorders (e.g., depression, OCD), and/or other types of neurologic dysfunction.
  • neurological damage e.g., arising from stroke or traumatic brain injury
  • neurodegenerative disorders e.g., Parkinson's disease, Alzheimer's disease
  • neuropsychiatric disorders e.g., depression, OCD
  • other types of neurologic dysfunction e.g., depression, OCD
  • anodal or cathodal unipolar stimulation may be more efficacious and/or efficient than cathodal or anodal unipolar stimulation, respectively, or bipolar stimulation in the context of particular neural stimulation situations, which may include, for example, neural stimulation directed toward traumatic brain injury, cerebral palsy, movement disorders, central pain syndrome, tinnitus, neuropsychiatric disorders, auditory hallucinations, and/or other conditions.
  • neural stimulation situations may include, for example, neural stimulation directed toward traumatic brain injury, cerebral palsy, movement disorders, central pain syndrome, tinnitus, neuropsychiatric disorders, auditory hallucinations, and/or other conditions.
  • a likelihood of realizing a given type of neurofunctional outcome may be enhanced through multiple anodal unipolar, cathodal unipolar, and/or bipolar stimulation procedures, which may be applied in a simultaneous, alternating, and/or varying manner.
  • Such stimulation procedures may correspond to identical, generally identical, or different stimulation sites and/or stimulation parameters (e.g., pulse repetition frequency, first phase pulse width, a peak current and/or voltage amplitude or magnitude, theta burst characteristics, a waveform variation and/or modulation function, and/or other parameters) depending upon the nature of a patient's neurologic dysfunction, patient
  • stimulation parameters e.g., pulse repetition frequency, first phase pulse width, a peak current and/or voltage amplitude or magnitude, theta burst characteristics, a waveform variation and/or modulation function, and/or other parameters
  • any given stimulation procedure and/or an interval between stimulation procedures may correspond to a subseconds- based, a seconds-based, an hours-based, and/or another type of time period or domain.
  • an anodal unipolar stimulation procedure may be directed toward a second target neural population.
  • the first and second target neural populations may reside in the same or different brain hemispheres.
  • Figure 6 is a side view of a system for applying electrical stimulation to a surface site on the cortex in accordance with an embodiment of the invention.
  • the system includes a stimulus unit 520 and a patient interface including a first electrode assembly 560a and a second electrode assembly 560b.
  • the stimulus unit 520 can include a controller 530 and a pulse system 540 similar to the controller 130 and pulse system 140 of the stimulation unit 120 described above with reference to Figure 1.
  • the stimulus unit 520 can also include a housing 580 that is configured to be implanted or otherwise attached to the patient.
  • the first electrode assembly 560a can be similar to the first electrode assembly 160a described above with reference to Figure 1.
  • the first electrode assembly 560a can accordingly include a support member 562a configured to be implanted proximate to the cortex of the patient and at least one surface contact 564a.
  • the surface contacts 564a can be coupled to a first terminal 542a of the stimulus unit 520 by a link 570.
  • the second electrode assembly 560b can be a separate item or element attached to the stimulus unit 520, or the second electrode assembly 560b can be an integral component of the stimulus unit 520.
  • the second electrode assembly 560b for example, can be a conductive portion of the housing 580 of the stimulus unit 520.
  • the entire housing 580 of the stimulus unit 520 can be a conductive material that defines the second electrode assembly 560b, or a portion of the housing 580 can be covered with an appropriate type of dielectric or insulating material or be composed of such a material to limit the conductive surface area of the second electrode assembly 560b to a desired shape or area.
  • the second electrode assembly 560b is a separate set of
  • the second electrode assembly 560b is coupled to a second terminal 542b of the pulse system 540.
  • the system shown in Figure 6 operates by electrically biasing the surface contacts 564a at an identical polarity, and biasing the second electrode assembly 560b with an opposite or neutral polarity.
  • the system may be configured to deliver anodal unipolar stimulation to a stimulation site by biasing the surface contacts 564a as an anode, and biasing the second electrode assembly 560b as a cathode.
  • FIG. 6 accordingly provides a unipolar signal at the stimulation site on or proximate to the surface of the cortex of the patient.
  • Another aspect of the invention may involve configuring a neural stimulation system to induce a desired electrical field and/or current density at or proximate to a stimulation site as well as a remote circuit completion site.
  • the aggregate surface area of conductive surfaces that provide circuit completion or electrical continuity remote or generally remote from the stimulation site is approximately 200% - 1500% of the aggregate surface area of conductive surfaces that apply or deliver stimulation signals to one or more stimulation sites (e.g., contacts 164a or 564a carried by a first electrode assembly 160a or 560a), and more specifically 250% - 450%.
  • the larger conductive surface area corresponding to the circuit completion site reduces the current density at the current completion site compared to the stimulation site; this is expected to reduce collateral neural activity, muscle activity, and/or patient sensation in the region of the circuit completion site.
  • FIG. 7 is a side view illustrating a system for applying electrical stimulation to a surface site on the cortex in accordance with another embodiment of the invention.
  • the system includes the stimulus unit 120, the second electrode assembly 160b, and a surface electrode assembly 660.
  • the surface electrode assembly 660 can comprise an array including a support member 662 configured to be implanted at the cortical stimulation site, a plurality of first surface contacts 664 carried by one portion of the support member 662, and a
  • the first surface contacts 664 are coupled to the first link 170a to electrically couple the first surface contacts 664 to the first terminal 142a of the stimulus unit 120.
  • the second surface contacts 665 can be coupled to the second link 170b to electrically couple the second surface contacts 665 to the second terminal 142b of the stimulus unit 120.
  • the first surface contacts 664 can be biased as an anode, and the second surface contacts 665 can be biased as a cathode, or vice versa.
  • the second surface contacts 665 can be connected to a separate link to be coupled to a third terminal of the stimulus unit 120.
  • the second surface contacts 665 can accordingly be biased independently of either the first surface contacts 664 or the second electrode assembly's contacts 164b.
  • the embodiment of the system illustrated in Figure 7 can provide a combination of unipolar and bipolar stimulation.
  • the first surface contacts 664 can be biased at a first polarity while the second surface contacts 665 or the return contacts 164b are biased at a second polarity.
  • the second surface contacts 665 are coupled to another terminal on the stimulus unit 120 so that the second surface contacts 665 can be biased separately from the return contacts 164b.
  • Figure 8A is an isometric view and Figure 8B is a cross sectional view of a system for applying electrical stimulation to a surface site on or proximate to the cortex in accordance with another embodiment of the invention.
  • the system comprises a support member 800 that may carry a control unit 830 and a pulse system 840, plus a first electrode assembly 860a and a second electrode assembly 860b.
  • the support member 800 may include a housing 802 configured for
  • the first electrode assembly 860a may comprise a biasing element 862 that carries a first set of electrical contacts 864a.
  • the biasing element 862 may be formed using a soft, conformable, and/or compressible biocompatible material.
  • the first electrode assembly 860a is coupled to a first terminal 842a of the pulse system 840.
  • the second electrode assembly 860b may comprise one or more exposed conductive portions of the housing 802 and/or the attachment element 804, and/or a second set of electrical contacts 864b that are carried by the housing 802 and/or the attachment element 804.
  • the second electrode assembly 860b may be coupled to a second terminal 842b of the pulse system 840.
  • the pulse system's first and second terminals 842a-b may be configured as an anode and a cathode, possibly in a selectable or programmable manner. Additionally, configuration or establishment of an anodal and a cathodal relationship between the pulse system's first and second terminals 842a-b may occur in a predetermined, aperiodic, or pseudo-random time-varying manner.
  • the support member 800 may be implanted into or through a craniotomy that is above a stimulation site, such that one or more portions of the biasing element 862 and/or the first set of contacts 864a reside upon, essentially upon, or proximate to the stimulation site. Following implantation, the attachment element 804 may be covered by the patient's scalp 892.
  • the first electrode assembly 860a may be biased in accordance with a first polarity to apply or deliver unipolar stimulation to a target neural population, neural projections, and/or neural structures associated with the stimulation site.
  • the second electrode assembly 860b may be biased in accordance with a second polarity to provide electrical continuity for stimulation signals delivered by the first electrode assembly 860a.
  • an electrical current pathway between the first and second electrode assemblies 842a-b may include one or more portions of the patient's cortex, one or more neural regions below the cortex, vasculature, and/or portions of the patient's scalp.
  • an electrical current pathway between the first and second electrode assemblies 842a-b may include one or more portions of the patient's cortex, one or more neural regions below the cortex, vasculature, and/or portions of the patient's scalp.
  • FIG. 8C is a cross sectional view of a system for applying electrical stimulation to a surface site on or proximate to the cortex according to another embodiment of the invention. Relative to Figures 8A and 8B, like reference numbers indicate like elements.
  • the first electrode assembly 860a includes a first subset of contacts 865 coupled to the pulse system's first terminal 842a.
  • the pulse system 840 includes a signal selection module 880 capable of selectively coupling (1) a second subset of contacts 866 to the first or second terminal 842a-b of the pulse system 830; and/or (2) the second electrode assembly 860b to the pulse system's second terminal 842b (in a manner that avoids simultaneous coupling of the second subset of contacts 866 to the first and second terminals 842a-b).
  • Figure 8C may thus be configured to provide unipolar stimulation by biasing the first subset of contacts 865 and possibly the second subset of contacts 866 at a first polarity, and biasing the second electrode assembly 842b at a second polarity; or bipolar stimulation by biasing the first subset of contacts 865 at a first polarity and the second subset of contacts 866 at a second polarity.
  • Figure 9A is a schematic illustration of a system for applying electrical stimulation to a surface site on or proximate to the cortex in accordance with another embodiment of the invention. Relative to Figures 8A, 8B, and 8C, like reference numbers indicate like elements.
  • the system comprises a support member 800 that carries a controller 830, a pulse system 840, and a local electrode assembly 860.
  • the system may further include at least one remote electrode assembly 960.
  • the support member 800 may include a housing 802 and an attachment element 804 as described above.
  • the local electrode assembly 860 may comprise a biasing element 862 that carries a first set of contacts 864.
  • the local electrode assembly 860 is coupled to the pulse system's first terminal 842a.
  • the remote electrode assembly 960 may comprise a support member 962 that carries a second set of contacts 964, and may have a structure analogous to one or more types of
  • the remote electrode assembly 960 may comprise a cranial screw or peg type electrode as described in U.S. Patent Application No. 10/418,796 (previously incorporated herein by reference); or a depth, deep brain, or other type of electrode.
  • the remote electrode assembly 960 may provide an active or aggregate conductive surface area that is greater than an active or aggregate conductive surface area associated with the local electrode assembly 860 in a manner analogous to that described above.
  • the remote electrode assembly 960 may be coupled to the pulse system's second terminal 842b by a link 970.
  • the pulse system's first and second terminals 842a-b may be configured as an anode and a cathode, possibly in a selective, programmable, deterministic, and/or pseudorandom manner.
  • the support member 800 may be implanted into or through a craniotomy that is above a stimulation site in a manner analogous to that described above.
  • the remote electrode assembly 960 may be implanted or positioned distant or remote from the support member 800.
  • the remote electrode assembly 960 may be positioned upon or beneath the patient's skin at an anatomical location that is above or below the patient's neck; or within the patient's cranium at a cortical, subcortical, or deep brain location that is distant, distinct, or remote from the local electrode assembly 860.
  • the local electrode assembly 860 may be biased in accordance with a first signal polarity
  • the remote electrode assembly 960 may be biased in accordance with a second signal polarity to provide unipolar stimulation.
  • Figure 9B is a schematic illustration of a system for applying electrical stimulation to a surface site on or proximate to the cortex in accordance with another embodiment of the invention. Relative to Figure 9A, like reference numbers indicate like elements.
  • the embodiment shown in Figure 9B includes a first and a second remote electrode assembly 960a-b, which may be identical, essentially identical, or different in structure. Any given remote electrode assembly 960a-b may comprise an electrode of a type indicated above. Depending upon embodiment details, the first and/or the second remote electrode assembly 960a-b may provide an active or aggregate conductive surface area that is greater than an active or aggregate conductive surface area associated with the local electrode assembly 860 in a
  • the first and second remote electrode assemblies 960a-b are respectively coupled to the pulse system's second terminal 842b by a first and a second link 970a-b.
  • the embodiment shown in Figure 9B may further include a signal selection module 980 that facilitates selectable or programmable coupling of the first and/or second remote electrode assembly 960a-b to the pulse system's second terminal 842b.
  • first and second remote electrode assemblies 960a-b may be coupled to the pulse system's second terminal 842b at any given time; or the first and second remote electrode assemblies 960a-b may be coupled to the second terminal 842b simultaneously.
  • the support member 800 may be implanted at a stimulation site in a manner analogous to that described above.
  • the first and second remote electrode assemblies 960a-b may be respectively positioned or implanted at a first and a second anatomical location that is distant, remote, or distinct from the stimulation site.
  • the local electrode assembly 860 may be biased in accordance with a first signal polarity, while one or both of the remote electrode assemblies 960a-b may be biased in accordance with a second signal polarity at any given time to provide unipolar stimulation.
  • the use of multiple remote electrode assemblies 960a-b positioned at different anatomical locations may provide multiple current pathways through which neural stimulation may affect or influence particular target cortical and/or subcortical neural populations, neural structures, and/or neural projections, possibly in an alternating or time-dependent manner.
  • unipolar stimulation delivered or applied along or with respect to a first current pathway may be directed toward affecting neural activity in a first hemisphere of the brain
  • unipolar stimulation applied with respect to a second current pathway may be directed toward affecting neural activity in a second hemisphere of the brain.
  • Neural activity in each hemisphere may influence the development, recovery, and/or retention of functional abilities, possibly through neuroplastic mechanisms.
  • one or more stimulation parameters such as stimulation signal frequency, amplitude, and/or polarity may differ or vary in accordance with a current pathway that is active or under consideration at any given time.
  • One or more embodiments described above may be modified to include or exclude elements or features described in association with other embodiments, for example a signal selection module 880, 980. Additionally or alternatively, particular embodiments may include multiple local electrode assemblies positioned at multiple stimulation sites, in conjunction with one or more remote electrode assemblies positioned distant from such stimulation sites to provide electrical continuity for unipolar stimulation.
  • Figures 10-11 are flow charts illustrating various methods for applying neural stimulation to a stimulation site in accordance with the present invention.
  • Figure 10 more specifically, illustrates a method 1000 including a start procedure 1002, at least one unipolar stimulation procedure 1004, and a decision procedure 1008.
  • the unipolar stimulation procedure 1004 includes establishing an electrical field by applying an electrical signal having an identical first signal polarity to a first set of contacts located at a stimulation site while applying a second signal polarity to a second set of contacts that is spaced apart or remote from the stimulation site.
  • the unipolar stimulation procedure 1004 may involve the application of anodal unipolar stimulation and/or cathodal unipolar stimulation to the patient, possibly in a manner that increases or enhances a likelihood or rate of patient functional recovery and/or development. Moreover, the unipolar stimulation procedure 1004 may involve the application or delivery of stimulation signals at a subthreshold and/or a suprathreshold level relative to the generation of a statistically and/or functionally significant number of action potentials in one or more target neural populations. The unipolar stimulation procedure 1004 may also involve the application or theta burst stimulation signals during one or more time periods. [0092] The unipolar stimulation procedure 1004 can be performed using any of the systems set forth above with respect to Figures 1-9B.
  • the second set of contacts can be located apart from the stimulation site along a vector that passes through deep layers of the cortex and/or other neural regions in a direction that is oblique, and generally approximately normal, with respect to the first set of contacts at the stimulation site.
  • the unipolar stimulation procedure 1004 may involve applying a cathodal and/or an anodal signal to a set of active surface
  • An optional or alternative embodiment of the method 1000 can further include at least one bipolar stimulation procedure 1006 in which a first set of contacts at a stimulation site are biased at a first signal polarity, while a second set of contacts at a stimulation site are biased at a second signal polarity.
  • the bipolar stimulation procedure 1006 may be performed in a manner identical or analogous to that described above, and may involve the delivery of stimulation signals at a subthreshold and/or a suprathreshold level.
  • the bipolar stimulation procedure 1006 may also involve the application of theta burst stimulation signals during one or more time periods.
  • the decision procedure 1008 may decide whether the stimulation has been of sufficient or adequate duration and/or effect.
  • the decision procedure 1008 may involve monitoring or measuring patient progress and/or functional capabilities through one or more standardized measures, tests, or tasks.
  • Such standardized measures may include or be based upon, for example, a Fugl-Meyer Assessment of Sensorimotor Impairment; a National Institute of Health (NIH) Stroke Scale; a Stroke Impact Scale (SIS); an ADL scale; a Quality of Life (QoL) scale; physical measures such as grip strength or finger tapping speed; a neuropsychological testing battery; a walking, movement, and/or dexterity test; a behavioral test; a language test; a comprehension test; and/or other measures of patient functional ability.
  • the decision procedure 1008 may alternatively or additionally involve an electrophysiological signal acquisition and/or analysis procedure, and/or a neural imaging procedure (e.g., MRI, fMRI, or PET).
  • the decision procedure 1008 may direct the method 1000 to apply either a unipolar stimulation procedure 1004 and/or a bipolar stimulation procedure 1006 depending upon the particular characteristics of the therapy and/or the nature or extent of the patient's neurofunctional condition.
  • One or more stimulation sites and/or stimulation parameters e.g., pulse repetition frequency, first phase pulse width, peak current and/or voltage amplitude, theta burst characteristics, a waveform variation and/or modulation function, and/or other parameters
  • corresponding to particular unipolar and/or bipolar stimulation procedures 1004, 1006 may be identical, generally identical, or different depending upon the nature of a patient's neurologic
  • FIG. 11 illustrates a method 1100 in accordance with another embodiment of the invention.
  • the method 1100 includes a start procedure 1102, a unipolar stimulation procedure 1104, and possibly a first adjunctive or synergistic therapy procedure 1106.
  • the unipolar stimulation procedure 1104 may involve the application or delivery of anodal and/or cathodal unipolar stimulation signals to the patient, possibly in a manner that increases or enhances a likelihood and/or rate of patient functional recovery and/or development.
  • the unipolar stimulation procedure 1104 may involve subthreshold and/or suprathreshold stimulation, and/or theta burst stimulation during one or more time periods.
  • the unipolar stimulation procedure 1104 and the first adjunctive therapy procedure 1106 can be performed concurrently or serially depending upon the nature and/or extent of a patient's neurologic dysfunction, patient condition, and/or embodiment details.
  • the first adjunctive therapy procedure 1106 may comprise a behavioral therapy procedure that can include a physical therapy, an activity of daily living, an intentional use of an affected body part, a speech therapy, a vision therapy, an auditory task or therapy (e.g., an auditory discrimination task), a reading task, a memory task, a visualization, imagination, or thought task, and/or another type of task or therapy.
  • a subthreshold unipolar stimulation procedure 1104 may be performed concurrent with a first behavioral therapy procedure 1106 to enhance or maximize a likelihood generating action potentials that may subserve the development and/or recovery of one or more functional abilities.
  • the method 1100 may additionally include a first decision procedure 1108 that may decide whether the unipolar stimulation procedure 1104 and/or the first adjunctive therapy procedure 1106 have been of sufficient or adequate duration and/or effect.
  • the first decision procedure 1108 may involve measurement or assessment of patient status, progress, and/or functional capabilities using one or more standardized measures, tests, or tasks; an electrophysiological signal acquisition and/or analysis procedure; and/or a neural imaging procedure. If additional unipolar stimulation and/or adjunctive therapy is warranted, the method
  • -32- 1100 may continue, resume, or restart a unipolar stimulation procedure 1104 and/or a first adjunctive therapy procedure 1106.
  • the method 1100 may further include a bipolar stimulation procedure 1110, and/or a second adjunctive or synergistic therapy procedure 1112.
  • the bipolar stimulation procedure 1110 may involve the application or delivery of stimulation signals at a subthreshold and/or suprathreshold level, and may possibly involve theta burst stimulation at one or more times.
  • the bipolar stimulation procedure 1110 may be directed toward the same, essentially the same, or different target neural structures, target neural projections, and/or target neural populations than the unipolar stimulation procedure 1104.
  • the bipolar stimulation procedure 1110 may deliver or apply stimulation signals to the same or a different stimulation site than the unipolar stimulation procedure 1104, either in the same and/or a different brain hemisphere.
  • both the unipolar and bipolar stimulation procedures 1104, 1110 may deliver stimulation signals to identical or essentially identical portions of a patient's motor cortex; or the unipolar stimulation procedure 1104 may apply stimulation signals to portions of the patient's motor cortex, while the bipolar stimulation procedure 1110 may apply stimulation signals to portions of the patient's premotor cortex or another region of the brain.
  • the second adjunctive therapy procedure 1112 may involve, for example, a drug therapy and/or a behavioral therapy that is identical or essentially identical to or different from a therapy associated with the first adjunctive therapy procedure 1106.
  • the second adjunctive therapy procedure 1112 may involve, for example, a visualization procedure such as thinking about performing one or more types of motions and/or tasks, while the first adjunctive therapy procedure 1106 may involve attempting to actually perform such motions and/or tasks.
  • the bipolar stimulation procedure 1110 and the second adjunctive therapy procedure 1112 may be performed concurrently or serially, in a manner analogous to that described above for the unipolar stimulation procedure 1104 and the first adjunctive therapy procedure 1106.
  • the bipolar stimulation procedure 1110 and/or the second adjunctive therapy procedure 1112 may precede or follow the unipolar
  • the method 1100 may further include a second decision procedure 1114 that may decide whether the bipolar stimulation procedure 1110 and/or the second adjunctive therapy procedure 1112 have been of sufficient or adequate duration and/or effect.
  • the second decision procedure 1114 may involve measurement or assessment of patient status, progress, and/or functional capabilities using one or more standardized measures, tests, or tasks; an electrophysiological signal acquisition and/or analysis procedure; and/or a neural imaging procedure.
  • a method 1100 may continue, resume, or restart a bipolar stimulation procedure 1110 and/or a second adjunctive therapy procedure 1112. Finally, the method 1100 may include a termination procedure 1116 that may be performed based upon an outcome of the first and/or second decision procedure 1108, 1116.
  • a method 1100 may.comprise a number of anodal unipolar, cathodal unipolar, and/or bipolar stimulation procedures 1104, 1110, where the number, duration of, and/or time between such procedures and/or the particular stimulation sites to which such procedures are directed may be identical, essentially identical, or different.
  • one or more stimulation signal parameters e.g., pulse repetition frequency, first phase pulse width, peak current and/or voltage amplitude, theta burst characteristics, a waveform variation and/or modulation function, and/or other parameters
  • stimulation signal parameters e.g., pulse repetition frequency, first phase pulse width, peak current and/or voltage amplitude, theta burst characteristics, a waveform variation and/or modulation function, and/or other parameters
  • one or more procedures described herein may form portions of a limited duration treatment program, in a manner analogous to that described in U.S. Application No. 10/606,202, incorporated herein by reference.
  • a limited duration treatment program may apply or deliver unipolar stimulation, and possibly bipolar stimulation, to a patient for a limited period of time to facilitate or effectuate complete, essentially complete, significant, or partial rehabilitation, restoration, or functional healing of or recovery from a neurological condition such as a neurological

Abstract

Systems and methods for neural stimulation may include a stimulus unit; a first electrode assembly having a first set of contacts; and a second set of contacts. The stimulus unit can be an implantable pulse generator including a first terminal that can be biased at a first signal polarity and a second terminal that can be biased at a second signal polarity. The first electrode assembly includes a support member configured to be placed at the stimulation site, the first set of contacts carried by the support member, and a first lead configured to be attached to the first terminal of the implantable pulse generator for biasing the surface contacts at the first polarity. The second set of contacts is detached from the surface electrode assembly. The second set of contacts can be one or more conductive elements fixed to or forming portions of the implantable pulse generator, or a separate electrode array.

Description

APPARATUS AND METHODS FOR APPLYING NEURAL STIMULATION TO A PATIENT
[0001] This application claims priority to pending U.S. Provisional Application No. 60/492,273, filed on August 1 , 2003, and incorporated herein in its entirety by reference.
INCORPORATION OF RELATED APPLICATIONS
[0002] This application is related to U.S. Patent Application Serial No. 09/802,808 entitled "Methods and Apparatus for Effectuating a Lasting Change in a Neural-Function of a Patient," which claims the benefit of U.S. Provisional Application 60/217,981 , filed July 31 , 2000, both of which are herein incorporated by reference. Additional applications are incorporated by reference in other portions of this application.
TECHNICAL FIELD
[0003] The present disclosure is related to systems and methods for applying stimulation to a target neural population within a patient, for example, a surface site on the patient's cortex.
BACKGROUND
[ooo4] A wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain. The neural-functions in some areas of the brain (i.e., the sensory or motor cortices) are organized according to physical or cognitive functions, and various areas of the brain appear to have distinct functions in most individuals. In the majority of people, for example, the occipital lobes relate to vision, the left interior frontal lobes relate to language, and the cerebral cortex appears to be involved with conscious awareness, memory, and intellect. [0005] Many problems or abnormalities can be caused by damage, disease and/or disorders in the brain. Effectively treating such abnormalities may be very difficult. For example, a stroke is a common condition that damages the brain. Strokes are generally caused by emboli (e.g., obstruction of a vessel), hemorrhages (e.g., rupture of a vessel), or thrombi (e.g., clotting) in the vascular system of a specific region of the brain. Such events generally result in a loss or impairment of a neural function (e.g., neural functions related to facial muscles, limbs, speech, etc.). Stroke patients are typically treated using various forms of physical therapy to rehabilitate the loss of function of a limb or another affected body part. Stroke patients may also be treated using physical therapy plus an adjunctive therapy such as amphetamine treatment. For most patients, however, such treatments are minimally effective and little can be done to improve the function of an affected body part beyond the recovery that occurs naturally without intervention. [0006] Neurological problems or abnormalities are often related to electrical and/or chemical activity in the brain. Neural activity is governed by electrical impulses or "action potentials" generated in neurons and propagated along synaptically connected neurons. When a neuron is in a quiescent state, it is polarized negatively and exhibits a resting membrane potential typically between -70 and -60 mV. Through chemical connections known as synapses, any given neuron receives excitatory and inhibitory input signals or stimuli from other neurons. A neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials when the integration exceeds a threshold potential. A neural firing threshold, for example, may be approximately - 55 mV. [0007] It follows that neural activity in the brain can be influenced by electrical energy supplied from an external source such as a waveform generator. Various neural functions can be promoted or disrupted by applying an electrical current to the cortex or other region of the brain. As a result, researchers have attempted to treat physical damage, disease and disorders in the brain using electrical or magnetic stimulation signals to control or affect brain functions. [0008] Transcranial electrical stimulation is one such approach that involves placing an electrode on the exterior of the scalp and delivering an electrical current to the brain through the scalp and skull. Another treatment approach, transcranial magnetic stimulation, involves producing a high-powered magnetic field adjacent to
[33734-8051/SL042150.254] -2- the exterior of the scalp over an area of the cortex. Yet another treatment approach involves direct electrical stimulation of neural tissue using implanted electrodes. [0009] The neural stimulation signals used by these approaches may comprise a series of electrical or magnetic pulses directed toward affecting neurons within a target neural population. Stimulation signals may be defined or described in accordance with stimulation signal parameters including pulse amplitude, pulse frequency, duty cycle, stimulation signal duration, and/or other parameters. Electrical or magnetic stimulation signals applied to a population of neurons can depolarize neurons within the population toward their threshold potentials. Depending upon stimulation signal parameters, this depolarization can cause neurons to generate or fire action potentials. Neural stimulation that elicits or induces action potentials in a functionally significant proportion of the neural population to which the stimulation is applied is referred to as supra-threshold stimulation; neural stimulation that fails to elicit action potentials in a functionally significant proportion of the neural population is defined as sub-threshold stimulation. In general, supra-threshold stimulation of a neural population triggers or activates one or more functions associated with the neural population, but sub-threshold stimulation by itself does not trigger or activate such functions. Supra-threshold neural stimulation can induce various types of measurable or monitorable responses in a patient. For example, supra-threshold stimulation applied to a patient's motor cortex can induce muscle fiber contractions in an associated part of the body. [0010] Although electrical or magnetic stimulation of neural tissue may be directed toward producing an intended type of therapeutic, rehabilitative, or restorative neural activity, such stimulation may result in collateral neural activity. In particular, neural stimulation delivered beyond a certain intensity, period of time, level, or amplitude can give rise to seizure activity and/or other types of collateral activity. It will be appreciated that certain types of collateral neural activity may be undesirable and/or inconvenient in a neural stimulation situation. toon] Another concern that arises in association with stimulating a surface site on a patient's cortex is conservation or minimization of applied power while operating a stimulation device. Various types of systems have an implanted pulse generator ("IPG") and an electrode assembly. The electrode assembly generally has a plurality of contacts that are carried by a common support member, such that the
[33734-8051/SL042150.254] -3- contacts are positionally fixed in close or generally close proximity relative to each other. In operation, the IPG delivers an electrical waveform to the electrode assembly, such that a first set of contacts provides a current delivery path and a second set of contacts provides a current return path. Thus, at any given time during waveform delivery, at least one contact has a positive bias and at least one contact has a negative bias, resulting in the generation of a bipolar field at the surface of the cortex within the area of the stimulation site. The bipolar field has a lower current density in the deeper layers of the cortex compared to the current density at the surface layers, and the bipolar field runs generally parallel to the cranium of the patient in the deeper layers of the cortex. Systems that generate a bipolar field at the stimulation site may require relatively high current levels to achieve an intended or desired therapeutic effect. This may result in increased power consumption, and possibly increase the likelihood of inducing collateral neural activity.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 is a side view of a system for applying electrical stimulation to a stimulation site on or proximate to the surface of the cortex of a patient in accordance with an embodiment of the invention. [0013] Figure 2 is a graph illustrating several parameters that may describe, define, or characterize a stimulation signal. [0014] Figure 3A is a front view of a system for applying electrical stimulation to a cortical stimulation site in accordance with Figure 1A showing a different implementation of the system. [0015] Figure 3B is a cross-sectional view of a brain of a patient illustrating the implementation of Figure 3A in greater detail. [0016] Figure 3C is a schematic illustration of a combined electrode assembly that may be used to apply or deliver unipolar stimulation to a patient. [0017] Figure 4 is a schematic illustration showing an exemplary electric field distribution generated by unipolar electrical stimulation using a system for applying electrical stimulation to a cortical stimulation site in accordance with an embodiment of the invention.
[33734-8051/SL042150.254] [0018] Figure 5 is a schematic illustration showing an exemplary electrical field distribution generated by bipolar electrical stimulation at a cortical stimulation site. [0019] Figure 6 is a side view of a system for applying electrical stimulation to a cortical stimulation site in accordance with another embodiment of the invention. [0020] Figure 7 is a side view of a system for applying electrical stimulation to a cortical stimulation site in accordance with another embodiment of the invention. [0021] Figures 8A and 8B are an isometric view and a cross sectional view, respectively, of a system for applying electrical stimulation to a site on or proximate to the cortex in accordance with another embodiment of the invention. [0022] Figure 8C is a cross sectional view of a system for applying electrical stimulation to a site on or proximate to the cortex according to another embodiment of the invention. [0023] Figure 9A is a schematic illustration of a system for applying electrical stimulation to a site on or proximate to the cortex in accordance with another embodiment of the invention. [0024] Figure 9B is a schematic illustration of a system for applying electrical stimulation to a site on or proximate to the cortex in accordance with another embodiment of the invention. [0025] Figures 10-11 are flow charts illustrating methods for applying electrical stimulation to a stimulation site in accordance with embodiments of the invention.
DETAILED DESCRIPTION
[0026] The present disclosure describes systems and methods for neural stimulation that may enhance the efficacy and/or increase the efficiency of neural stimulation procedures. The neural stimulation may comprise a set of stimulation signals applied or delivered to or through target neural structures, target neural projections, and/or one or more target neural populations associated with controlling, influencing, or affecting one or more neurological functions under consideration. The neural stimulation may be directed toward facilitating and/or effectuating at least some degree of symptomatic relief and/or restoration or development of functional
[33734-8051/SL042150.254] -5- abilities in patients experiencing neurologic dysfunction arising from neurological damage, neurologic disease, neurodegenerative conditions, neuropsychiatric disorders, cognitive or learning disorders, and/or other conditions. Such neurologic dysfunction may correspond to Parkinson's Disease, essential tremor, Huntington's disease, stroke, traumatic brain injury, Cerebral Palsy, Multiple Sclerosis, a central pain syndrome, a memory disorder, dementia, Alzheimer's disease, an affective disorder, depression, bipolar disorder, anxiety, obsessive/compulsive disorder, Post Traumatic Stress Disorder, an eating disorder, schizophrenia, Tourette's Syndrome, Attention Deficit Disorder, an addiction, autism, epilepsy, a sleep disorder, a hearing disorder (e.g., tinnitis or auditory hallucinations), a speech disorder (e.g., stuttering), and/or one or more other disorders, states, or conditions. [0027] For example, relative to controlling, influencing, stabilizing, restoring, enhancing, or gaining a motor function, a target neural population may comprise one or more portions of a patient's motor cortex. A neural location at which or a neural region in which stimulation signals are applied or delivered to or through a target neural population may be defined as a stimulation site. Thus, for a target neural population corresponding to the motor cortex, an exemplary stimulation site may comprise a location or region upon the patient's dura mater. [0028] As another example, relative to controlling, influencing, stabilizing, restoring, or enhancing an auditory function, a target neural population may correspond to one or more portions of a patient's auditory cortex. A stimulation site may comprise an epidural or subdural cortical region that may facilitate the application, delivery, and/or transfer of stimulation signals to such a target neural population, for example, an epidural site adjacent or proximate to the Sylvian fissure. The application of unipolar stimulation signals to such a stimulation site in accordance with particular embodiments of the invention may increase a likelihood of affecting the target neural population in an intended manner. [0029] A stimulation site may be identified in accordance with a variety of techniques, including (1) identification of one or more anatomical landmarks; (2) preoperatively (e.g., using Transcranial Magnetic Stimulation) and/or intraoperatively stimulating one or more brain locations to identify or map particular neural regions that induce or evoke a given type of patient response (for example, a movement or a sensation); (3) estimating a location at which the brain may recruit neurons to carry
[33734-8051 /SL042150.254] -6- out a given type of neural activity that was previously performed by a damaged portion of the brain; (4) an electrophysiologic signal measurement and/or analysis procedure (e.g., acquisition and/or analysis of EEG, EMG, MEG, coherence, partial coherence, and/or other signals); and/or (5) a neural imaging procedure. In general, the number and/or location of stimulation sites under consideration may depend upon the nature, number, and/or extent of a patient's neurological condition and/or functional deficits. [0030] Several embodiments of such systems and methods apply or deliver a unipolar, monopolar, or isopolar stimulation signal that may provide enhanced efficacy or efficiency stimulation using a low current level that reduces power consumption and/or mitigates collateral effects. Various embodiments of the present invention may apply or deliver neural stimulation at a subthreshold level or intensity, that is, at a level that raises or generally raises membrane potentials associated with a target neural population while avoiding the generation of a sufficient or statistically significant number of action potentials capable of triggering a neural function corresponding to the target neural population as a result of neural stimulation alone. [0031] Stimulation systems and methods in accordance with the present invention may be used to treat various neurological conditions and/or facilitate particular types of neurological or functional patient outcomes. Depending upon the nature of a particular condition, neural stimulation applied or delivered in accordance with several embodiments of the invention may affect neural firing likelihoods and/or influence, facilitate, and/or effectuate reorganization of interconnections or synapses between neurons to (a) provide at least some degree of functional recovery and/or functional gain; and/or (b) develop one or more compensatory mechanisms to at least partially overcome a functional deficit or shortcoming. Such reorganization of neural interconnections may be achieved, at least in part, by a change in the strength of synaptic connections through a process that corresponds to a mechanism commonly known as Long-Term Potentiation (LTP). Neural stimulation applied or delivered in accordance with certain embodiments of the invention may alternatively or additionally affect particular neural populations through a process that corresponds to a mechanism commonly known as Long-Term Depression (LTD). Neural stimulation delivered or applied to one or more target neural populations either alone or in conjunction or association with one or more behavioral activities
[33734-8051/SL042150.254] -7- and/or other types of adjunctive or synergistic therapies (e.g., a drug or chemical substance therapy, a neurotrophic or growth factor therapy, and/or a cell implantation therapy) may facilitate, effectuate, or enhance therapeutic efficacy, for example, through neural plasticity and the reorganization of synaptic interconnections between neurons.
A. Systems for Applying Electrical Stimulation [0032] Figure 1 is a side view of a system for applying electrical stimulation to a neural stimulation site or region according to an embodiment of the invention. In various embodiments, the stimulation site may be upon, essentially upon, or proximate to the surface of the cortex of a patient P. The stimulation system may comprise a stimulus unit 120 and a patient interface that includes a set of electrodes, electrode arrangements and/or electrode assemblies 160 (hereinafter, "electrode assemblies"). In one embodiment, the set of electrode assemblies 160 includes a first electrode assembly 160a and a second electrode assembly 160b. Various alternate embodiments may include additional electrode assemblies, which may be positioned or implanted at or proximate to a set of stimulation sites, or remote from one or more stimulation sites. Electrode assemblies can stimulate different neural regions, e.g., regions carrying out different neural functions and/or regions carrying out neural functions at different locations of the body, including different extremities of the body. [0033] Depending upon embodiment details, the system may also include a sensing unit 180 (shown schematically) configured to monitor one or more types of patient responses, activities, and/or behaviors. The sensing unit 180 may be further configured to communicate with the stimulus unit 120. The sensing unit 180 may include, for example, electrodes 182 and/or other devices (e.g., an accelerometer or motion detector) configured to sense a patient's neural activity (e.g., an EEG signal), neuromuscular activity (e.g., an EMG signal), behavioral activity (e.g., patient motion), and/or other types of patient activity. [0034] The stimulus unit 120 generates and outputs stimulation signals, and the set of electrode assemblies 160 facilitates application or delivery of the stimulation signals to the patient P. The stimulus unit 120 may perform, direct, and/or facilitate neural stimulation procedures in a manner that enhances efficacy,
[33734-8051/SL042150.254] -8- mitigates a likelihood of inducing collateral neural activity, and/or conserves power, as described in detail below. [0035] The stimulus unit 120 may comprise a pulse generator that is implanted into the patient P. In the embodiment shown in Figure 1 , the stimulus unit 120 is an IPG that is implanted in a thoracic, subclavicular, or abdominal location. In other embodiments, the stimulus unit 120 can be an IPG implanted in the patient's skull or just under the patient's scalp. For example, the stimulus unit 120 can be implanted above the patient's neckline at a location in or near the patient's cranium. Examples stimulus units 120 suitable for implantation in a patient's cranium are set forth in U.S. Patent Application 09/802,808 (previously incorporated by reference), as well as herein with reference to Figures 8A through 9B. [0036] The stimulus unit 120 may comprise a controller 130 and a pulse system 140. The stimulus unit 120 may further comprise a power source, a battery, an energy storage device, and/or power conversion circuitry (not shown). The controller 130 may include a processor, a memory, and a programmable computer medium. The controller 130 may be implemented as a computer or a microcontroller, and the programmable medium may comprise software, instructions, and/or configuration information loaded into the memory and/or hardware that performs, directs, and/or facilitates neural stimulation procedures in accordance with one or more methods of the present invention. [0037] The pulse system 140 generates and outputs stimulation signals. Figure 2 is a graph illustrating several parameters that may describe, define, or characterize a stimulation signal. A stimulus start time to may define an initial point at which a stimulation signal is applied to a target neural population. In one embodiment, the stimulation signal may be a symmetric or asymmetric biphasic waveform comprising a set or series of biphasic pulses, and which may be defined, characterized, or described by parameters including a pulse width t| for a first pulse phase; a pulse width t2 for a second pulse phase; and a pulse width t3 for a single biphasic pulse. The parameters can also include a stimulus repetition rate 1/ corresponding to a pulse repetition frequency; a stimulus pulse duty cycle equal to t3 divided by t ; a stimulus burst time t5 that defines a number of pulses in a pulse train; and/or a pulse train repetition rate 1/t6 that defines a stimulus burst frequency. Other parameters include a peak current intensity for the first pulse phase and a peak
[33734-8051/SL042150.254] -9- current intensity l2 for the second pulse phase. Those skilled in the art will understand that pulse intensity or amplitude may decay during one or both pulse phases, and a pulse may be a charge-balanced waveform. Those skilled in the art will further understand that in an alternate embodiment, pulses can be monophasic or polyphasic. [0038] In certain embodiments, the pulse system 140 may generate and/or output stimulation signals in accordance with a theta burst pattern. In general, theta burst stimulation may comprise pulse bursts and/or pulse packets separated by quiescent intervals, such that the number of pulse packets per seconds corresponds or approximately corresponds to theta wave frequencies exhibited by the brain. In general, theta wave frequencies may range from approximately 3 to 10 Hz, and more particularly in certain embodiments, 4 to 8 Hz. [0039] In particular embodiments, the pulse system 140 may vary and/or modulate stimulation signals in one or more manners, for example, in accordance with one or more mathematical operations and/or functions upon or corresponding to particular stimulation signal parameters. Exemplary manners of varying stimulation signals are described in detail in U.S. Application No. 60/588,406, filed on July 15, 2004, entitled "System and Method for Enhancing or Affecting Neural Stimulation Efficiency and/or Efficacy," incorporated herein by reference in its entirety. [0040] The pulse system 140 may apply or output stimulation signals to, across, or between a first terminal 142a and a second terminal 142b. Since a stimulation signal may comprise a time-varying waveform, a relative polarity of the stimulation signal, and hence that of the first and second terminals 142a-b, may change or vary with time. With respect to outputting one or more stimulation signals having phases that differ in polarity, an anode may be defined as a terminal 142a-b to which a positive polarity phase within an initial pulse is first applied. For example, for a stimulation signal comprising a series of biphasic pulses where each pulse includes a positive polarity phase followed by a negative polarity phase, where positive and negative may respectively be defined relative to a zero potential level or a potential offset, an anode may be designated as the particular terminal 142a-b that first receives a positive polarity phase following the stimulus start time t0. A cathode may be defined as a terminal 142a-b that provides electrical continuity for the stimulation signal delivered through the anodal terminal 142a-b. The polarity of the
[33734-8051/SL042150.254] -10- cathode may thus be opposite to that of the anode, or neutral. Depending upon embodiment details, a cathode may be defined as a terminal 142a-b to which a first negative polarity or lower potential phase within an initial pulse is first applied. Those skilled in the art will recognize that the terms anode and cathode could be defined in an opposite or different manner than as defined above, yet such opposite or different definitions would be equivalent, essentially equivalent, or consistent from a mathematical or circuit analysis perspective. [0041] Depending upon embodiment details, (a) the first terminal 142a may be configured as an anode, while the second terminal 142b may be configured as a cathode; (b) the first terminal 142a may be configured as a cathode, while the second terminal 142b may be configured as an anode; or (c) the first and second terminals 142a-b may be selectively or programmably configured as an anode and a cathode, possibly in a predetermined, aperiodic, or pseudo-random time dependent manner. Such anode/cathode selectivity may occur on a subseconds-based, a seconds-based, an hours-based, and/or another type of time domain, and/or may be facilitated by signal selection circuitry (e.g., a multiplexor or a switch matrix) and/or redundant output circuitry within the stimulus unit 120. In particular embodiments, stimulus periods provided by the stimulus unit 120 can have durations of 30 seconds or less, 10 seconds or less, 2-5 seconds, about one second, and/or less than one second. The stimulus periods can include but are not limited to alternating cathodal and anodal periods, alternating unipolar periods, alternating bipolar periods, and/or periods that alternate between unipolar and bipolar. The electrical potential of the stimulation signal can also alternate between subthreshold levels and suprathreshold levels. [0042] The first electrode assembly 160a may be positioned or implanted at a stimulation site that is located upon, essentially upon, or proximate to a target neural population upon, within, or near the patient's cerebral cortex. The first electrode assembly 160a may comprise a support member 162a and one or more contacts 164a carried by the support member 162a. The support member 162a may be configured for implantation at a stimulation site upon or at least proximate to the surface of the patient's cortex. The support member 162a, for example, can be a flexible or rigid substrate that is implanted under the cranium S such that the contacts 164a are positioned upon or adjacent to the dura mater at the stimulation
[33734-8051 /SL042150.254] -1 1 - site. In other embodiments, the support member 162a can be a portion of a cranial screw or a housing that is implanted through the cranium S, in a manner identical or analogous to that described in U.S. Patent Application No. 10/418,796, which is incorporated herein by reference. [0043] The first electrode assembly 160a can have one or more contacts 164a arranged or positioned in a desired configuration. For example, the first electrode assembly 160a may include a single contact 164a, or a plurality of contacts 164a arranged as an array, grid, or other pattern. In the embodiment shown in Figure 1 , the first electrode assembly 160a also includes a first lead or link 170a that electrically couples some or all of the contacts 164a to the pulse system's first terminal 142a. The first electrode assembly 160a may therefore be configured as an anode or a cathode, in accordance with the anodal or cathodal configuration of the first terminal 142a of the pulse system 140. Contacts 164a that are not coupled to the first terminal 142a at a particular time may electrically float. The first link 170a may be a wired link or a wireless link. The first electrode assembly 160a can comprise a cortical neural-stimulation device, such as any of the devices described in U.S. Patent Application No. 09/802,808 (previously incorporated herein by reference), and U.S. Patent Application No. 10/418,976, which is also incorporated by reference herein. [0044] The second electrode assembly 160b can be similar to the first electrode assembly 160a, or it can be a different type of electrode assembly. The second electrode assembly 160b may be positioned remotely from the first electrode assembly 160a. Since the second electrode assembly 160b provides electrical continuity with respect to the first electrode assembly 160a, the second electrode assembly 160b may be defined to reside at a circuit completion site. In the embodiment shown in Figure 1 , the second electrode assembly 160b comprises a separate electrode array including a support base 162b and one or more contacts 164b. In accordance with particular embodiment details, the support base 162b can be configured for positioning at (a) a location or site upon or proximate to the surface of the cortex spaced apart from the stimulation site where the first electrode assembly 160a is located; (b) a deep brain location; or (c) another area in the body above or below the neck. The second electrode assembly 160b can include a second link 170b that couples one or more contacts 164b (i.e., each contact 164b
[33734-8051/SL042150.254] -12- that is not electrically floating) to the second terminal 142b of the pulse system 140. Thus, the second electrode assembly 160b may be configured as an anode or a cathode, in accordance with the anodal or cathodal configuration of the pulse system's second terminal 142b. [0045] In the embodiment shown, the second electrode assembly 160b, and more particularly the second electrode assembly's contacts 164b, are separate or otherwise detached from the first electrode assembly 160a. Thus, the second electrode assembly's contacts 164b are not attached to the first electrode assembly 160a, and the second electrode assembly's contacts 164b may be movable with respect to the contacts 164a of the first electrode assembly 164a before being implanted in the patient. The second electrode assembly 160b may accordingly be configured to be attached to or implanted in the patient at a location spaced apart from a stimulation site on or proximate to the cortex of the patient where electrical stimulation is to be applied to facilitate and/or effectuate a given neurological or neurofunctional outcome, such as neural plasticity or another type of neural reorganization corresponding to one or more neural populations. [0046] In the embodiment shown in Figure 1 , each contact 164a of the first electrode assembly 160a that is coupled to the pulse system's first terminal 142a (i.e., each non-floating contact 164a) is biased in accordance with a first signal polarity. Thus, the pulse system 140 applies an identical polarity signal to each such contact 164a at any given time. Correspondingly, each intentionally biased or non- floating contact 164b of the second electrode assembly 160b is biased in accordance with a second signal polarity, where the second signal polarity is opposite or complementary to the first signal polarity, or neutral, to facilitate electrical current flow between the first and second electrode assemblies 160a-b. [0047] Neural stimulation in which both an anode and a cathode are positioned, located, or situated within, essentially directly across, or proximate to a stimulation site may be defined as bipolar stimulation. In contrast, neural stimulation in which one of an anode and a cathode is positioned, located, or situated within or proximate to a stimulation site, while a respective corresponding cathode or anode is positioned, located, or situated remote from the stimulation site to provide electrical continuity may be defined as unipolar, monopolar, or isopolar stimulation. Thus, neural stimulation characterized by a biasing configuration in which an anode and a
[33734-8051 /SL042150.254] - 13- cathode are positioned, located, or situated in different neurofunctional areas or functionally distinct anatomical regions may be defined as unipolar stimulation. In a unipolar configuration, the pulse system 140 applies an identical polarity signal to each non-floating contact 162a-b positioned upon or proximate to a stimulation site. Unipolar stimulation may be defined as anodal unipolar stimulation when an anode is positioned upon or proximate to a stimulation site or a target neural population; and as cathodal unipolar stimulation when a cathode is positioned upon or proximate to a stimulation site or a target neural population. [0048] In several embodiments, the second electrode assembly 160b is positioned apart or remote from the first electrode assembly 160a to establish an electric field that passes through deep layers of the cortex and/or other neural regions in a direction that is generally perpendicular or oblique with respect to (a) the first electrode assembly's contacts 164a; (b) the surface of the cortex under the first electrode assembly 160a; and/or (c) the cranium of the patient at or proximate to the stimulation site. The electric field, for example, is substantially normal to the first electrode assembly 160a in the deep layers of the cortex and/or other neural layers beneath the stimulation site. [0049] Figures 3A and 3B illustrate a different implementation of a system for applying electrical stimulation to a neural stimulation site according to an embodiment of the invention. In this embodiment, a first electrode assembly 160a may be implanted in the patient at a stimulation site at least proximate to the surface of the cortex C (Figure 3B) over target neurons or a target neural population N (Figure 3B). A second electrode assembly 160b may be positioned at a location in the patient that is spaced apart from the stimulation site, for example, at a location that is above the patient's neck, to establish an electric field orientation or distribution that extends in a desired direction relative to the target neurons N. The second electrode assembly 160b may additionally or alternatively be positioned relative to other neural structures to minimize or mitigate collateral neural activity. The second electrode assembly 160b can be spaced apart from the patient's brain as shown in Figure 3A, or the second electrode assembly 160b can be positioned at a different location of the patient's brain as shown in Figure 3B. [0050] The stimulus unit 120 may provide an output at a first polarity to the non-floating contacts 164a of the first electrode assembly 160a, and provide an
[33734-8051/SL042150.254] -14- output at a second polarity to the non-floating contacts 164b of the second electrode assembly 160b. The first electrode assembly's contacts 164a accordingly provide a unipolar, monopolar, or isopolar bias at the stimulation site upon or proximate to the patient's cortex C. The first polarity may be anodal or cathodal, and the second polarity may respectively be cathodal or anodal (i.e., opposite to the first polarity or neutral). A unipolar signal applied to the first electrode assembly's contacts 164a may establish an electric field that extends through deep layers of the cortex and/or other neural regions along a vector V extending generally perpendicular to, or at least oblique with respect to, the orientation of (a) the first electrode assembly 160a; (b) the surface of the cortex C at or proximate to the stimulation site; and/or (c) the cranium of the patient adjacent to the stimulation site (Figure 3A). [0051] Certain systems and/or methods in accordance with the present invention may utilize or rely upon a single electrode assembly having a design that is suitable for providing unipolar stimulation rather than relying upon separate electrode assemblies. Figure 3C is a schematic illustration of a combined electrode assembly 260 capable of applying or delivering unipolar stimulation to a patient. In one embodiment, the combined electrode assembly 260 includes a support member 262 having a local portion 263a, a remote portion 263b, and a separation portion 263c. The local portion 263a carries a first set of contacts 264a, and the remote portion 263b carries a second set of contacts 264b. The support member 262 may be formed from one or more flexible or generally flexible biocompatible materials (e.g., plastic and/or silicone), and the first and second sets of contacts 264a-b may be formed from one or more biocompatible conductive materials (e.g., Titanium and/or Platinum). Through appropriate couplings to a pulse system's first and second terminals 142a-b (for example, via a first and a second link 170a-b), the first set of contacts 264a may be configured as an anode or a cathode, while the second set of contacts 264b may respectively be configured as a cathode or an anode to facilitate unipolar stimulation. [0052] The combined electrode assembly 260 may be implanted into a patient such that the local portion 263a resides at, upon, or proximate to a stimulation site, while the remote portion 263b resides at a circuit completion site that is distant or remote from the stimulation site. The separation portion 263c may have a length L that is sufficient to ensure that in a typical patient, an electric field
[33734-8051/SL042150.254] -15- generated at or in the vicinity of the local portion 263a is substantially perpendicular to the patient's cranium, cortical surface, and/or targeted neural tissues (which may include deep cortical layers or regions, as discussed below) beneath the stimulation site. In one embodiment, the value of L may be roughly an order of magnitude greater than the distance between the stimulation site and a target neural population or neural region that is deepest or farthest from the stimulation site. For subdural stimulation, an exemplary value of L may be roughly an order of magnitude or more greater than approximately 2.5 to 3.0 mm; and for epidural stimulation, an exemplary value of L may be roughly an order of magnitude greater than approximately 4.0 to 6.0 mm. [0053] The location, depth, and/or spatial boundaries of target neural structures and/or a target neural population may depend upon the nature of a neurological condition or disorder under consideration. The extent to which an electric field reaches, penetrates, and/or travels into or through target neural structures and/or a target neural population may affect neural stimulation efficiency and/or efficacy. An electric field generated by unipolar stimulation may reach or penetrate deeper neural regions at a lower current level than an electric field generated by bipolar stimulation, as further described hereafter. [0054] Figure 4 is a schematic illustration showing an exemplary electric field distribution generated by unipolar stimulation using a system in accordance with an embodiment of the invention. In Figure 4, a first contact 164a is positioned at a stimulation site corresponding to a target neural population, while a second contact (not shown) is positioned distant or remote from the first contact 164a at a different neurofunctional or anatomical region. The first contact 164a may be biased as an anode, for example, and the second contact may be biased as a cathode to establish an electrical potential gradient or difference that facilitates the flow of electrical current (i.e., a net movement of charged particles or ions). A unipolar electric field distribution may be represented as a plurality of field lines 300 that extend through, for example, targeted deep layers of the cortex C and possibly other neural regions in a direction that is at least substantially perpendicular to (1) the surface of the cortex at or proximate to the stimulation site; and/or (2) the first electrode assembly's contacts 164a.
[33734-8051/SL042150.254] -16- [0055] Figure 5 is a schematic illustration showing an exemplary electric field distribution generated by bipolar stimulation, which may be selectively produced in accordance with particular embodiments of the invention as further described below. In Figure 5, a first contact 410a and a second contact 410b are configured to deliver bipolar stimulation to one or more portions of a target neural population. The first and second contacts 410a, 410b are located proximate to each other, within or upon a stimulation site that corresponds to the spatial extent of the target neural population. In a bipolar configuration, contacts 410a-b positioned at and/or near the stimulation site are biased at different polarities. In Figure 5, the first contact 410a is biased as an anode, while a second contact 410b is biased as a cathode. A bipolar electric field distribution may be represented as a plurality of field lines 400 having field components that are generally parallel to (1 ) the surface of the cortex at or proximate to the stimulation site; and/or (2) a support member (not shown) configured to carry the first and second contacts 410a-b. [0056] In general, an electrical potential gradient or difference between an anode and a cathode configured to provide unipolar stimulation exists over a longer or greater distance than an electrical potential gradient between an anode and a cathode configured to provide bipolar stimulation. Thus, an anode to cathode electrical current pathway associated with unipolar stimulation will typically be longer than an electrical current pathway associated with bipolar stimulation. Unipolar stimulation may therefore provide a greater degree of therapeutic efficacy than bipolar stimulation when stimulation of neural regions, structures, and/or projections that are deeper or more distant than those just beneath and/or in the near vicinity of the stimulation site may be of importance. Moreover, unipolar stimulation may deliver more current to such deeper or more distant neural regions at a lower power level than bipolar stimulation, which may result in greater stimulation efficiency and/or a reduced likelihood of inducing collateral neural activity. Enhanced stimulation efficiency may be important when treating chronic, near-chronic, and/or longer-term conditions, for example, movement disorders or central pain syndrome. [0057] In addition to or association with the foregoing, an electric field polarity, orientation and/or distribution relative to particular types of neurons, neural projections, neural structures, and/or neurofunctional regions may influence or affect neural stimulation efficiency and/or efficacy. The cortex C may be organized as a
[33734-8051/SL042150.254] -17- set of 6 layers, where layer 1 maintains a boundary corresponding to the cortical surface. Successive cortical layers exist or reside at increasing depths relative to the cortical surface. Thus, layer 6 corresponds to a deepest cortical layer. The thickness or extent of any given cortical layer, and the type, number, and/or size of neurons, neural projections, and/or neural structures therein depends upon the cortical neurofunctional region under consideration. [0058] Neurons convey input signals along their dendrites toward their cell bodies. Neurons in the cortex C include pyramidal cells 302 and intemeurons 304. In the motor cortex, the largest pyramidal cells 320 have soma or cell bodies that reside in deep cortical layer 5. Pyramidal cells 302 have dendrites that project away from their cell bodies into overlying or superficial cortical layers, toward the cortical surface in a manner that is approximately perpendicular or normal to the layer structure of the cortex C. Intemeurons 304 have cell bodies that commonly reside in cortical layers 2, 3, and 4, and include dendrites that tend to project away from their cell bodies within the same layer or into an adjacent layer in a manner that is generally lateral or parallel with respect to the layer structure of the cortex C. [0059] An optimal, near optimal, or desirable electric field orientation for therapeutic neural stimulation may be based upon or determined by the orientation of one or more types of neurons, neural structures, and/or neural projections within or associated with a target neural population N. For example, an electric field that is oriented generally parallel to a main or overall direction in which pyramidal cell dendrites project, that is, generally perpendicular or normal to the cortical layer structure (or equivalently, generally perpendicular or normal to the surface of the cortex C or the cranium), may preferentially influence or exert a more significant effect upon pyramidal cells 302 than intemeurons 304, which include dendrites that generally project lateral to the cortical layer structure. In an analogous manner, an electric field that is oriented generally parallel to a typical or overall direction in which interneuron dendrites project, that is, generally parallel or lateral to the cortical layer structure, may preferentially influence or exert a more significant effect upon intemeurons 304 than pyramidal cells 302. [0060] In view of the foregoing, systems and/or methods in accordance with particular embodiments of the invention may apply or deliver stimulation signals having one or more polarities that may enhance a likelihood of facilitating or
[33734-8051/SL042150.254] -18- effectuating a desired neurological and/or functional outcome based upon the types of neurons, neural structures, and/or neural projections involved in subserving such an outcome. For example, specific embodiments of the invention may apply unipolar stimulation at one or more times to patients experiencing certain types of central pain syndrome. As another example, various embodiments of the invention may apply unipolar stimulation, possibly in conjunction with a behavioral therapy, to patients having functional deficits associated with stroke, traumatic brain injury, cerebral palsy, and/or other disorders (e.g., tinnitus). In certain situations, unipolar stimulation may more effectively facilitate or effectuate neural disinhibition and/or neuroplastic change associated with a target neural population than bipolar stimulation, thereby enhancing the extent to which such patients can recover lost functional abilities and/or develop new abilities. [0061] Unipolar stimulation may facilitate or effectuate enhanced recovery or development of functional abilities in patients experiencing particular types of neurologic dysfunction when compared to bipolar stimulation. For example, cathodal unipolar stimulation in conjunction or association with a behavioral therapy such as an Activity of Daily Living (ADL) may facilitate or effectuate a greater degree of functional development and/or recovery in a patient experiencing functional deficits associated with stroke, traumatic brain injury, and/or neurological damage than bipolar stimulation either alone or in association or conjunction with such a behavioral therapy. Moreover, such enhanced recovery may occur using lower current or average power levels than would be required for bipolar stimulation, thereby conserving power and/or reducing a likelihood of inducing collateral neural activity. [0062] Certain systems and/or methods in accordance with the invention may deliver unipolar stimulation during a unipolar stimulation period and bipolar stimulation during a bipolar stimulation period. For example, relative to facilitating or effectuating neuroplasticity, both pyramidal cells 302 and intemeurons 304 may play a role in neural reorganization. Thus, a system and/or method may deliver unipolar stimulation to more selectively influence or affect pyramidal cells 302 during a unipolar stimulation period, and deliver bipolar stimulation to more selectively influence or affect intemeurons 304 during a bipolar stimulation period. One or more unipolar and/or bipolar stimulation periods may be identical or different in duration,
[33734-8051/SL042150.254] -19- and may occur in a successive or generally successive manner, with or without one or more types of intervening delays, interruptions, or cessations. Any given unipolar stimulation period, bipolar stimulation period, and/or interruption period between unipolar and/or bipolar stimulation periods may correspond to a subseconds-based, a seconds-based, an hours-based, and/or another type of time domain. Depending upon embodiment details, alternation between unipolar and/or bipolar stimulation periods and/or intervals between such periods may temporally occur in a predetermined, aperiodic, or pseudo-random manner. Neural stimulation may be delivered during one or more unipolar and/or bipolar stimulation periods in conjunction or association with one or more adjunctive or synergistic therapies, for example, a behavioral therapy and/or a drug therapy. An adjunctive therapy corresponding to a unipolar stimulation period may be identical to or different from an adjunctive therapy corresponding to a bipolar stimulation period. [0063] In cortical regions associated with motor control, pyramidal cell axons that project into the spinal cord, brain stem, basal ganglia, and/or other areas may serve as cortical outputs involved in facilitating or controlling movement. In view of manners in which pyramidal cell dendrites and axons project as described above, a given type of unipolar neural stimulation may elicit or generate a patient response or movement at a different (e.g., lower) current level or intensity than bipolar stimulation. Thus, unipolar stimulation may provide or induce an intended or desired effect at a lower current level than bipolar stimulation, thereby conserving power and/or reducing a likelihood of inducing collateral activity. Similarly, unipolar stimulation may facilitate determination of a therapeutic current level using lower amplitude test stimulation signals than required by bipolar stimulation. In some embodiments, a therapeutic current level corresponding to a given type of unipolar stimulation may be mapped to a therapeutic current level that corresponds to a different type of unipolar stimulation and/or bipolar stimulation in accordance with a mapping function and/or empirical data. [0064] In addition to the foregoing, certain types of neural cells may exhibit different types of signal conductance properties based upon whether the motion of electrical charges or electrically charged particles (i.e., ions) is toward or away from the axon hillock, the initial axonal region proximate to the cell body through which dendritic inputs are integrated. For instance, in pyramidal cells 302, intracellular ions
[33734-8051/SL042150.254] -20- diffusing toward the axon hillock experience a lower impedance than intracellular ions diffusing toward the dendritic tree, thereby giving rise to an intracellular differential impedance (Neurophysiological Techniques: Applications to Neural Systems, Neuromethods 15, Eds. A. A. Boulton, G.B. Baker, and CH. Vanderwolf). As a result, anodal unipolar stimulation may affect or influence a neural population, neural structures, and/or neural projections differently than cathodal unipolar stimulation. [0065] Stimulation signal polarity characteristics may influence or affect an extent to which and/or a manner in which particular neural structures experience a potential difference and/or depolarization or polarization relative to each other, which may affect neural stimulation efficacy and/or efficiency. For example, due to the existence of a potential gradient between a cathode and an anode, a relative dendrite to axon hillock or axon depolarization or hyperpolarization state may give rise to neural stimulation efficacy differences between cathodal unipolar stimulation and anodal unipolar stimulation. [0066] During cathodal unipolar stimulation, a positive first pulse phase applied at a stimulation site may give rise to an enhanced extracellular concentration of negative ions in a localized region at, just beneath, just around, and/or in the near vicinity of the stimulation site. Such a localized region may correspond, for example, to a small, relatively small, or generally small neural tissue and/or neural structure volume within shallow or superficial layers of the cortex. As a result of the enhanced extracellular concentration of negative ions, dendrites within the localized region may experience an enhanced intracellular concentration of positive ions, thereby shifting the electrical state of such dendrites toward a more depolarized state than, for example, axon hillocks corresponding to such dendrites. [0067] In an analogous manner, during anodal unipolar stimulation, a negative first pulse phase applied at a stimulation site may give rise to an enhanced extracellular concentration of positive ions in a localized region at, just beneath, just around, and/or in near proximity to the stimulation site. As a result, dendrites within the localized region may experience an enhanced intracellular concentration of negative ions, thereby shifting the electrical state of such dendrites toward a more hyperpolarized state than axon hillocks corresponding to such dendrites.
[33734-8051/SL042150.254] -21- [0068] A dendritic potential shift toward a more depolarized state and/or a more hyperpolarized state may affect dendritic signal processing and/or signal generation and/or signal transfer mechanisms. Such a potential shift may affect neural stimulation efficacy, for example, by influencing an extent to and/or manner in which postsynaptic dendrites react or respond to and/or process presynaptic input. [0069] In certain neural stimulation situations directed toward facilitating and/or effectuating neural plasticity, cathodal unipolar stimulation may increase a likelihood that dendrites within a target neural population respond to and/or process neurofunctionally relevant synaptic input in a manner that enhances a likelihood of generating action potentials that may subserve the development and/or recovery of one or more functional abilities. Neurofunctionally relevant synaptic input may arise from or correspond to an adjunctive or synergistic therapy, for example, a behavioral therapy. The aforementioned neural stimulation situations may include, for example, neural stimulation directed toward rehabilitation of patients experiencing symptoms associated with neurological damage (e.g., arising from stroke or traumatic brain injury), neurodegenerative disorders (e.g., Parkinson's disease, Alzheimer's disease), neuropsychiatric disorders (e.g., depression, OCD), and/or other types of neurologic dysfunction. [0070] In general, anodal or cathodal unipolar stimulation may be more efficacious and/or efficient than cathodal or anodal unipolar stimulation, respectively, or bipolar stimulation in the context of particular neural stimulation situations, which may include, for example, neural stimulation directed toward traumatic brain injury, cerebral palsy, movement disorders, central pain syndrome, tinnitus, neuropsychiatric disorders, auditory hallucinations, and/or other conditions. [0071] In particular neural stimulation situations, a likelihood of realizing a given type of neurofunctional outcome may be enhanced through multiple anodal unipolar, cathodal unipolar, and/or bipolar stimulation procedures, which may be applied in a simultaneous, alternating, and/or varying manner. Such stimulation procedures may correspond to identical, generally identical, or different stimulation sites and/or stimulation parameters (e.g., pulse repetition frequency, first phase pulse width, a peak current and/or voltage amplitude or magnitude, theta burst characteristics, a waveform variation and/or modulation function, and/or other parameters) depending upon the nature of a patient's neurologic dysfunction, patient
[33734-8051/SL042150.254] -22- condition, and/or embodiment details. Moreover, any given stimulation procedure and/or an interval between stimulation procedures may correspond to a subseconds- based, a seconds-based, an hours-based, and/or another type of time period or domain. In one embodiment, before, during, and/or after one or more portions of a cathodal stimulation procedure directed toward a first target neural population, an anodal unipolar stimulation procedure may be directed toward a second target neural population. The first and second target neural populations may reside in the same or different brain hemispheres. [0072] Figure 6 is a side view of a system for applying electrical stimulation to a surface site on the cortex in accordance with an embodiment of the invention. In this embodiment, the system includes a stimulus unit 520 and a patient interface including a first electrode assembly 560a and a second electrode assembly 560b. The stimulus unit 520 can include a controller 530 and a pulse system 540 similar to the controller 130 and pulse system 140 of the stimulation unit 120 described above with reference to Figure 1. The stimulus unit 520 can also include a housing 580 that is configured to be implanted or otherwise attached to the patient. [0073] The first electrode assembly 560a can be similar to the first electrode assembly 160a described above with reference to Figure 1. The first electrode assembly 560a can accordingly include a support member 562a configured to be implanted proximate to the cortex of the patient and at least one surface contact 564a. The surface contacts 564a can be coupled to a first terminal 542a of the stimulus unit 520 by a link 570. [0074] The second electrode assembly 560b can be a separate item or element attached to the stimulus unit 520, or the second electrode assembly 560b can be an integral component of the stimulus unit 520. The second electrode assembly 560b, for example, can be a conductive portion of the housing 580 of the stimulus unit 520. In other embodiments, the entire housing 580 of the stimulus unit 520 can be a conductive material that defines the second electrode assembly 560b, or a portion of the housing 580 can be covered with an appropriate type of dielectric or insulating material or be composed of such a material to limit the conductive surface area of the second electrode assembly 560b to a desired shape or area. In still other embodiments, the second electrode assembly 560b is a separate set of
[33734-8051/SL042150.254] -23- contacts attached to the housing 580. The second electrode assembly 560b is coupled to a second terminal 542b of the pulse system 540. [0075] The system shown in Figure 6 operates by electrically biasing the surface contacts 564a at an identical polarity, and biasing the second electrode assembly 560b with an opposite or neutral polarity. For example, the system may be configured to deliver anodal unipolar stimulation to a stimulation site by biasing the surface contacts 564a as an anode, and biasing the second electrode assembly 560b as a cathode. It will be appreciated that the surface contacts 564a could alternatively be biased as a cathode while the second electrode assembly 560b is biased as an anode. The system shown in Figure 6 accordingly provides a unipolar signal at the stimulation site on or proximate to the surface of the cortex of the patient. [0076] Another aspect of the invention may involve configuring a neural stimulation system to induce a desired electrical field and/or current density at or proximate to a stimulation site as well as a remote circuit completion site. In one embodiment, the aggregate surface area of conductive surfaces that provide circuit completion or electrical continuity remote or generally remote from the stimulation site (e.g., contacts 164b carried by a second electrode assembly 160b or 560b, or an exposed conductive surface of a housing 580) is approximately 200% - 1500% of the aggregate surface area of conductive surfaces that apply or deliver stimulation signals to one or more stimulation sites (e.g., contacts 164a or 564a carried by a first electrode assembly 160a or 560a), and more specifically 250% - 450%. The larger conductive surface area corresponding to the circuit completion site reduces the current density at the current completion site compared to the stimulation site; this is expected to reduce collateral neural activity, muscle activity, and/or patient sensation in the region of the circuit completion site. [0077] Figure 7 is a side view illustrating a system for applying electrical stimulation to a surface site on the cortex in accordance with another embodiment of the invention. In this embodiment, the system includes the stimulus unit 120, the second electrode assembly 160b, and a surface electrode assembly 660. The surface electrode assembly 660 can comprise an array including a support member 662 configured to be implanted at the cortical stimulation site, a plurality of first surface contacts 664 carried by one portion of the support member 662, and a
[33734-8051/SL042150.254] -24- plurality of second surface contacts 665 carried by another section of the support member 662. The first surface contacts 664 are coupled to the first link 170a to electrically couple the first surface contacts 664 to the first terminal 142a of the stimulus unit 120. The second surface contacts 665 can be coupled to the second link 170b to electrically couple the second surface contacts 665 to the second terminal 142b of the stimulus unit 120. The first surface contacts 664 can be biased as an anode, and the second surface contacts 665 can be biased as a cathode, or vice versa. In an alternate embodiment, the second surface contacts 665 can be connected to a separate link to be coupled to a third terminal of the stimulus unit 120. The second surface contacts 665 can accordingly be biased independently of either the first surface contacts 664 or the second electrode assembly's contacts 164b. [0078] The embodiment of the system illustrated in Figure 7 can provide a combination of unipolar and bipolar stimulation. For example, the first surface contacts 664 can be biased at a first polarity while the second surface contacts 665 or the return contacts 164b are biased at a second polarity. In another embodiment, the second surface contacts 665 are coupled to another terminal on the stimulus unit 120 so that the second surface contacts 665 can be biased separately from the return contacts 164b. This particular embodiment operates in a manner in which the first surface contacts 664 and the second electrode assembly's contacts 164b can be biased while not biasing the second surface contacts 665 during a unipolar stimulation period, and then the first surface contacts 664 can be biased at the first polarity while the second surface contacts 665 are biased at the second polarity during a bipolar stimulation period. The stimulus unit 120 can alternate unipolar stimulation and bipolar stimulation periods according to a desired sequence to provide a combination of unipolar and bipolar stimulation. [0079] Figure 8A is an isometric view and Figure 8B is a cross sectional view of a system for applying electrical stimulation to a surface site on or proximate to the cortex in accordance with another embodiment of the invention. In one embodiment, the system comprises a support member 800 that may carry a control unit 830 and a pulse system 840, plus a first electrode assembly 860a and a second electrode assembly 860b. The support member 800 may include a housing 802 configured for
[33734-8051/SL042150.254] -25- implantation into the skull 890, and an attachment element 804 configured for connection to the skull 890 by fasteners, an adhesive, and/or an anchor. [0080] The first electrode assembly 860a may comprise a biasing element 862 that carries a first set of electrical contacts 864a. The biasing element 862 may be formed using a soft, conformable, and/or compressible biocompatible material. In one embodiment, the first electrode assembly 860a is coupled to a first terminal 842a of the pulse system 840. The second electrode assembly 860b may comprise one or more exposed conductive portions of the housing 802 and/or the attachment element 804, and/or a second set of electrical contacts 864b that are carried by the housing 802 and/or the attachment element 804. The second electrode assembly 860b may be coupled to a second terminal 842b of the pulse system 840. Depending upon embodiment details, the pulse system's first and second terminals 842a-b may be configured as an anode and a cathode, possibly in a selectable or programmable manner. Additionally, configuration or establishment of an anodal and a cathodal relationship between the pulse system's first and second terminals 842a-b may occur in a predetermined, aperiodic, or pseudo-random time-varying manner. [0081] The support member 800 may be implanted into or through a craniotomy that is above a stimulation site, such that one or more portions of the biasing element 862 and/or the first set of contacts 864a reside upon, essentially upon, or proximate to the stimulation site. Following implantation, the attachment element 804 may be covered by the patient's scalp 892. The first electrode assembly 860a may be biased in accordance with a first polarity to apply or deliver unipolar stimulation to a target neural population, neural projections, and/or neural structures associated with the stimulation site. The second electrode assembly 860b may be biased in accordance with a second polarity to provide electrical continuity for stimulation signals delivered by the first electrode assembly 860a. In such a configuration, an electrical current pathway between the first and second electrode assemblies 842a-b may include one or more portions of the patient's cortex, one or more neural regions below the cortex, vasculature, and/or portions of the patient's scalp. In order to eliminate, essentially eliminate, or minimize electrical current flow from the first electrode assembly 860a to the second electrode assembly 860b along a current path that includes an interface between the skull 890 and the edge of the
[33734-8051/SL042150.254] -26- housing 802 and/or the attachment element 804, one or more portions of the housing 802 and/or the attachment element 804 may comprise or include an insulating material that forms a nonconductive seal or barrier between the skull 890 and the housing 802 and/or the attachment element 804. [0082] Figure 8C is a cross sectional view of a system for applying electrical stimulation to a surface site on or proximate to the cortex according to another embodiment of the invention. Relative to Figures 8A and 8B, like reference numbers indicate like elements. In the embodiment shown in Figure 8C, the first electrode assembly 860a includes a first subset of contacts 865 coupled to the pulse system's first terminal 842a. Additionally, the pulse system 840 includes a signal selection module 880 capable of selectively coupling (1) a second subset of contacts 866 to the first or second terminal 842a-b of the pulse system 830; and/or (2) the second electrode assembly 860b to the pulse system's second terminal 842b (in a manner that avoids simultaneous coupling of the second subset of contacts 866 to the first and second terminals 842a-b). The embodiment shown in Figure 8C may thus be configured to provide unipolar stimulation by biasing the first subset of contacts 865 and possibly the second subset of contacts 866 at a first polarity, and biasing the second electrode assembly 842b at a second polarity; or bipolar stimulation by biasing the first subset of contacts 865 at a first polarity and the second subset of contacts 866 at a second polarity. [0083] Figure 9A is a schematic illustration of a system for applying electrical stimulation to a surface site on or proximate to the cortex in accordance with another embodiment of the invention. Relative to Figures 8A, 8B, and 8C, like reference numbers indicate like elements. In one embodiment, the system comprises a support member 800 that carries a controller 830, a pulse system 840, and a local electrode assembly 860. The system may further include at least one remote electrode assembly 960. The support member 800 may include a housing 802 and an attachment element 804 as described above. [0084] The local electrode assembly 860 may comprise a biasing element 862 that carries a first set of contacts 864. In one embodiment, the local electrode assembly 860 is coupled to the pulse system's first terminal 842a. The remote electrode assembly 960 may comprise a support member 962 that carries a second set of contacts 964, and may have a structure analogous to one or more types of
[33734-8051/SL042150.254] -27- electrodes described in U.S. Patent Application No. 10/877,830, which is incorporated herein by reference. Alternatively, the remote electrode assembly 960 may comprise a cranial screw or peg type electrode as described in U.S. Patent Application No. 10/418,796 (previously incorporated herein by reference); or a depth, deep brain, or other type of electrode. In certain embodiments, the remote electrode assembly 960 may provide an active or aggregate conductive surface area that is greater than an active or aggregate conductive surface area associated with the local electrode assembly 860 in a manner analogous to that described above. The remote electrode assembly 960 may be coupled to the pulse system's second terminal 842b by a link 970. Depending upon embodiment details, the pulse system's first and second terminals 842a-b may be configured as an anode and a cathode, possibly in a selective, programmable, deterministic, and/or pseudorandom manner. [0085] The support member 800 may be implanted into or through a craniotomy that is above a stimulation site in a manner analogous to that described above. The remote electrode assembly 960 may be implanted or positioned distant or remote from the support member 800. The remote electrode assembly 960, for example, may be positioned upon or beneath the patient's skin at an anatomical location that is above or below the patient's neck; or within the patient's cranium at a cortical, subcortical, or deep brain location that is distant, distinct, or remote from the local electrode assembly 860. The local electrode assembly 860 may be biased in accordance with a first signal polarity, and the remote electrode assembly 960 may be biased in accordance with a second signal polarity to provide unipolar stimulation. [0086] Figure 9B is a schematic illustration of a system for applying electrical stimulation to a surface site on or proximate to the cortex in accordance with another embodiment of the invention. Relative to Figure 9A, like reference numbers indicate like elements. The embodiment shown in Figure 9B includes a first and a second remote electrode assembly 960a-b, which may be identical, essentially identical, or different in structure. Any given remote electrode assembly 960a-b may comprise an electrode of a type indicated above. Depending upon embodiment details, the first and/or the second remote electrode assembly 960a-b may provide an active or aggregate conductive surface area that is greater than an active or aggregate conductive surface area associated with the local electrode assembly 860 in a
[33734-8051/SL042150.254] -28- manner analogous to that described above. The first and second remote electrode assemblies 960a-b are respectively coupled to the pulse system's second terminal 842b by a first and a second link 970a-b. [0087] The embodiment shown in Figure 9B may further include a signal selection module 980 that facilitates selectable or programmable coupling of the first and/or second remote electrode assembly 960a-b to the pulse system's second terminal 842b. Depending upon embodiment details and/or the nature of the patient's neurological condition, only one of the first and second remote electrode assemblies 960a-b may be coupled to the pulse system's second terminal 842b at any given time; or the first and second remote electrode assemblies 960a-b may be coupled to the second terminal 842b simultaneously. [0088] In various embodiments, the support member 800 may be implanted at a stimulation site in a manner analogous to that described above. The first and second remote electrode assemblies 960a-b may be respectively positioned or implanted at a first and a second anatomical location that is distant, remote, or distinct from the stimulation site. The local electrode assembly 860 may be biased in accordance with a first signal polarity, while one or both of the remote electrode assemblies 960a-b may be biased in accordance with a second signal polarity at any given time to provide unipolar stimulation. [0089] The use of multiple remote electrode assemblies 960a-b positioned at different anatomical locations may provide multiple current pathways through which neural stimulation may affect or influence particular target cortical and/or subcortical neural populations, neural structures, and/or neural projections, possibly in an alternating or time-dependent manner. For example, unipolar stimulation delivered or applied along or with respect to a first current pathway may be directed toward affecting neural activity in a first hemisphere of the brain, while unipolar stimulation applied with respect to a second current pathway may be directed toward affecting neural activity in a second hemisphere of the brain. Neural activity in each hemisphere may influence the development, recovery, and/or retention of functional abilities, possibly through neuroplastic mechanisms. In certain embodiments, one or more stimulation parameters such as stimulation signal frequency, amplitude, and/or polarity may differ or vary in accordance with a current pathway that is active or under consideration at any given time.
[33734-8051/SL042150.254] -29- [0090] One or more embodiments described above may be modified to include or exclude elements or features described in association with other embodiments, for example a signal selection module 880, 980. Additionally or alternatively, particular embodiments may include multiple local electrode assemblies positioned at multiple stimulation sites, in conjunction with one or more remote electrode assemblies positioned distant from such stimulation sites to provide electrical continuity for unipolar stimulation.
B. Methods for Applying Electrical Stimulation [0091] Figures 10-11 are flow charts illustrating various methods for applying neural stimulation to a stimulation site in accordance with the present invention. Figure 10, more specifically, illustrates a method 1000 including a start procedure 1002, at least one unipolar stimulation procedure 1004, and a decision procedure 1008. The unipolar stimulation procedure 1004 includes establishing an electrical field by applying an electrical signal having an identical first signal polarity to a first set of contacts located at a stimulation site while applying a second signal polarity to a second set of contacts that is spaced apart or remote from the stimulation site. The unipolar stimulation procedure 1004 may involve the application of anodal unipolar stimulation and/or cathodal unipolar stimulation to the patient, possibly in a manner that increases or enhances a likelihood or rate of patient functional recovery and/or development. Moreover, the unipolar stimulation procedure 1004 may involve the application or delivery of stimulation signals at a subthreshold and/or a suprathreshold level relative to the generation of a statistically and/or functionally significant number of action potentials in one or more target neural populations. The unipolar stimulation procedure 1004 may also involve the application or theta burst stimulation signals during one or more time periods. [0092] The unipolar stimulation procedure 1004 can be performed using any of the systems set forth above with respect to Figures 1-9B. The second set of contacts can be located apart from the stimulation site along a vector that passes through deep layers of the cortex and/or other neural regions in a direction that is oblique, and generally approximately normal, with respect to the first set of contacts at the stimulation site. The unipolar stimulation procedure 1004, for example, may involve applying a cathodal and/or an anodal signal to a set of active surface
[33734-8051/SL042150.254] -30- contacts 164a to restore or at least partially recover speech, movement, and/or other functions that have been impaired by stroke or other brain damage. [0093] An optional or alternative embodiment of the method 1000 can further include at least one bipolar stimulation procedure 1006 in which a first set of contacts at a stimulation site are biased at a first signal polarity, while a second set of contacts at a stimulation site are biased at a second signal polarity. The bipolar stimulation procedure 1006 may be performed in a manner identical or analogous to that described above, and may involve the delivery of stimulation signals at a subthreshold and/or a suprathreshold level. The bipolar stimulation procedure 1006 may also involve the application of theta burst stimulation signals during one or more time periods. [0094] The decision procedure 1008 may decide whether the stimulation has been of sufficient or adequate duration and/or effect. In particular embodiments, the decision procedure 1008 may involve monitoring or measuring patient progress and/or functional capabilities through one or more standardized measures, tests, or tasks. Such standardized measures may include or be based upon, for example, a Fugl-Meyer Assessment of Sensorimotor Impairment; a National Institute of Health (NIH) Stroke Scale; a Stroke Impact Scale (SIS); an ADL scale; a Quality of Life (QoL) scale; physical measures such as grip strength or finger tapping speed; a neuropsychological testing battery; a walking, movement, and/or dexterity test; a behavioral test; a language test; a comprehension test; and/or other measures of patient functional ability. In certain embodiments, the decision procedure 1008 may alternatively or additionally involve an electrophysiological signal acquisition and/or analysis procedure, and/or a neural imaging procedure (e.g., MRI, fMRI, or PET). The decision procedure 1008 may direct the method 1000 to apply either a unipolar stimulation procedure 1004 and/or a bipolar stimulation procedure 1006 depending upon the particular characteristics of the therapy and/or the nature or extent of the patient's neurofunctional condition. One or more stimulation sites and/or stimulation parameters (e.g., pulse repetition frequency, first phase pulse width, peak current and/or voltage amplitude, theta burst characteristics, a waveform variation and/or modulation function, and/or other parameters) corresponding to particular unipolar and/or bipolar stimulation procedures 1004, 1006 may be identical, generally identical, or different depending upon the nature of a patient's neurologic
[33734-8051/SL042150.254] -31 - dysfunction, patient condition, and/or embodiment details. The method 1000 may further include a termination procedure 1010 that is performed based upon the outcome of the decision procedure 1008. [0095] Figure 11 illustrates a method 1100 in accordance with another embodiment of the invention. In one embodiment, the method 1100 includes a start procedure 1102, a unipolar stimulation procedure 1104, and possibly a first adjunctive or synergistic therapy procedure 1106. The unipolar stimulation procedure 1104 may involve the application or delivery of anodal and/or cathodal unipolar stimulation signals to the patient, possibly in a manner that increases or enhances a likelihood and/or rate of patient functional recovery and/or development. Moreover, the unipolar stimulation procedure 1104 may involve subthreshold and/or suprathreshold stimulation, and/or theta burst stimulation during one or more time periods. [0096] The unipolar stimulation procedure 1104 and the first adjunctive therapy procedure 1106 can be performed concurrently or serially depending upon the nature and/or extent of a patient's neurologic dysfunction, patient condition, and/or embodiment details. The first adjunctive therapy procedure 1106 may comprise a behavioral therapy procedure that can include a physical therapy, an activity of daily living, an intentional use of an affected body part, a speech therapy, a vision therapy, an auditory task or therapy (e.g., an auditory discrimination task), a reading task, a memory task, a visualization, imagination, or thought task, and/or another type of task or therapy. A subthreshold unipolar stimulation procedure 1104 may be performed concurrent with a first behavioral therapy procedure 1106 to enhance or maximize a likelihood generating action potentials that may subserve the development and/or recovery of one or more functional abilities. [0097] The method 1100 may additionally include a first decision procedure 1108 that may decide whether the unipolar stimulation procedure 1104 and/or the first adjunctive therapy procedure 1106 have been of sufficient or adequate duration and/or effect. The first decision procedure 1108 may involve measurement or assessment of patient status, progress, and/or functional capabilities using one or more standardized measures, tests, or tasks; an electrophysiological signal acquisition and/or analysis procedure; and/or a neural imaging procedure. If additional unipolar stimulation and/or adjunctive therapy is warranted, the method
[33734-8051/SL042150.254] -32- 1100 may continue, resume, or restart a unipolar stimulation procedure 1104 and/or a first adjunctive therapy procedure 1106. [0098] In certain embodiments, the method 1100 may further include a bipolar stimulation procedure 1110, and/or a second adjunctive or synergistic therapy procedure 1112. The bipolar stimulation procedure 1110 may involve the application or delivery of stimulation signals at a subthreshold and/or suprathreshold level, and may possibly involve theta burst stimulation at one or more times. The bipolar stimulation procedure 1110 may be directed toward the same, essentially the same, or different target neural structures, target neural projections, and/or target neural populations than the unipolar stimulation procedure 1104. Thus, the bipolar stimulation procedure 1110 may deliver or apply stimulation signals to the same or a different stimulation site than the unipolar stimulation procedure 1104, either in the same and/or a different brain hemisphere. For example, both the unipolar and bipolar stimulation procedures 1104, 1110 may deliver stimulation signals to identical or essentially identical portions of a patient's motor cortex; or the unipolar stimulation procedure 1104 may apply stimulation signals to portions of the patient's motor cortex, while the bipolar stimulation procedure 1110 may apply stimulation signals to portions of the patient's premotor cortex or another region of the brain. [0099] The second adjunctive therapy procedure 1112 may involve, for example, a drug therapy and/or a behavioral therapy that is identical or essentially identical to or different from a therapy associated with the first adjunctive therapy procedure 1106. The second adjunctive therapy procedure 1112 may involve, for example, a visualization procedure such as thinking about performing one or more types of motions and/or tasks, while the first adjunctive therapy procedure 1106 may involve attempting to actually perform such motions and/or tasks. [00100] Depending upon the nature and/or extent of a patient's neurologic dysfunction, patient condition, and/or embodiment details, the bipolar stimulation procedure 1110 and the second adjunctive therapy procedure 1112 may be performed concurrently or serially, in a manner analogous to that described above for the unipolar stimulation procedure 1104 and the first adjunctive therapy procedure 1106. Moreover, the bipolar stimulation procedure 1110 and/or the second adjunctive therapy procedure 1112 may precede or follow the unipolar
[33734-8051/SL042150.254] -33- stimulation procedure 1104 and/or the first adjunctive therapy procedure 1106 in either a generally continuous or an interrupted manner. [00101] The method 1100 may further include a second decision procedure 1114 that may decide whether the bipolar stimulation procedure 1110 and/or the second adjunctive therapy procedure 1112 have been of sufficient or adequate duration and/or effect. The second decision procedure 1114 may involve measurement or assessment of patient status, progress, and/or functional capabilities using one or more standardized measures, tests, or tasks; an electrophysiological signal acquisition and/or analysis procedure; and/or a neural imaging procedure. If additional bipolar stimulation and/or adjunctive therapy is warranted, the method 1100 may continue, resume, or restart a bipolar stimulation procedure 1110 and/or a second adjunctive therapy procedure 1112. Finally, the method 1100 may include a termination procedure 1116 that may be performed based upon an outcome of the first and/or second decision procedure 1108, 1116. [00102] Depending upon embodiment details, a method 1100 may.comprise a number of anodal unipolar, cathodal unipolar, and/or bipolar stimulation procedures 1104, 1110, where the number, duration of, and/or time between such procedures and/or the particular stimulation sites to which such procedures are directed may be identical, essentially identical, or different. Moreover, one or more stimulation signal parameters (e.g., pulse repetition frequency, first phase pulse width, peak current and/or voltage amplitude, theta burst characteristics, a waveform variation and/or modulation function, and/or other parameters) corresponding to particular unipolar and/or bipolar stimulation procedures 1104, 1110 may be identical, generally identical, or different depending upon the nature of a patient's neurologic dysfunction, patient condition, and/or embodiment details. [00103] In certain embodiments, one or more procedures described herein may form portions of a limited duration treatment program, in a manner analogous to that described in U.S. Application No. 10/606,202, incorporated herein by reference. In accordance with various embodiments of the present invention, a limited duration treatment program may apply or deliver unipolar stimulation, and possibly bipolar stimulation, to a patient for a limited period of time to facilitate or effectuate complete, essentially complete, significant, or partial rehabilitation, restoration, or functional healing of or recovery from a neurological condition such as a neurological
[33734-8051/SL042150.254] -34- malfunction and/or a neurologically based deficit or disorder. Depending upon the extent or nature of the patient's neurological condition and/or functional deficits, a limited duration treatment program may last, for example, a number of weeks, months, or possibly one or more years. [00104] From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. For example, aspects of the invention described in the context of particular embodiments can be combined or eliminated in other embodiments. Accordingly, the invention is not limited except as by the appended claims.
[33734-8051/SL042150.254] -35-

Claims

CLAIMSI/We claim:
1. A system for applying electrical stimulation to a cortical stimulation site proximate to the surface of the cortex of a patient, the system comprising: a stimulus unit having a pulse system including a first terminal that can be biased at a first polarity and a second terminal that can be biased at a second polarity; a surface electrode assembly having a support member configured to be implanted in the patient at the stimulation site, a plurality of surface contacts carried by the support member, and a first lead attached to the surface contacts, wherein the first lead is configured to be attached to the first terminal of the pulse system for biasing the surface contacts at the first polarity; and a return contact detached from the surface electrode assembly and configured to be coupled to the second terminal of the pulse system to be biased at the second polarity, wherein the return contact is configured to be spaced apart from the stimulation site in operation.
2. The system of claim 1 wherein the surface electrode assembly has only a single row of surface contacts.
3. The system of claim 1 wherein the surface electrode assembly comprises a plurality of rows of surface contacts and the first lead is electrically coupled to a plurality of the surface contacts in at least one of the rows.
4. The system of claim 1 wherein: the stimulus unit is an implantable pulse generator comprising a housing, the pulse system in the housing, and a controller in the housing; and the return contact is attached to the implantable pulse generator.
[33734-8051/SL042150.254] -36-
5. The system of claim 1 wherein: the stimulus unit is an implantable pulse generator comprising a housing having an electrically conductive section, the pulse system and a controller, and wherein the pulse system and the controller are carried by the housing; and the return contact is at least a portion of the electrically conductive section of the housing that is electrically coupled to the second terminal to be biased at the second polarity.
6. The system of claim 1 wherein the return contact is a component of a return contact assembly comprising a support base that carries the return contact and a second lead attached to the return contact, the support base being detached from the support member of the surface electrode assembly, and the second lead being configured to be attached to the second terminal of the implantable pulse generatorTor biasing the return contact at the second polarity.
7. The system of claim 6 wherein the return contact assembly comprises a plurality of return contacts carried by the support base.
8. The system of claim 1 wherein: the first lead is attached to the first terminal of the pulse system; the return contact is attached to a second lead, and the second lead is attached to the second terminal of the pulse generator; and the first terminal provides an anodal potential and the second terminal provides a cathodal potential.
9. The system of claim 1 wherein: the first lead is attached to the first terminal of the pulse system; the return contact is attached to a second lead, and the second lead is attached to the se.cond terminal of the pulse generator; and the first terminal provides a cathodal potential and the second terminal provides an anodal potential.
[33734-8051/SL042150.254] -37-
10. The system of claim 1 wherein: the stimulus unit is an implantable pulse generator configured to be implanted in a human being, and the stimulus unit further comprises a controller operatively coupled to the pulse system, and the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at a return site spaced apart from the stimulation site at the second polarity for a unipolar stimulation period.
11. The system of claim 1 wherein: the stimulus unit is an implantable pulse generator configured to be implanted in a human being, and the stimulus unit further comprises a controller operatively coupled to the pulse system, and the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at the second polarity for a unipolar stimulation period to generate an electrical field extending site through deep layers of the cortex in a direction generally normal with respect to the surface contact at the stimulation site.
12. The system of claim 1 wherein: the stimulus unit is an implantable pulse generator configured to be implanted in a human being, and the stimulus unit further comprises a controller operatively coupled to the pulse system, and the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at the second polarity for a unipolar stimulation period to generate an electrical field
[33734-8051/SL042150.254] -38- extending through deep layers of the cortex running generally perpendicular to a cortical layer structure.
13. A system for applying electrical stimulation to a cortical stimulation site, comprising: an implantable pulse generator having a first terminal configured to be biased at a first polarity and a second terminal configured to be biased at a second polarity; a cortical electrode assembly having a plurality of surface contacts configured to be implanted at least substantially proximate to a surface layer of the cortex at the stimulation site, wherein the surface contacts are electrically coupled to the first terminal of the implantable pulse generator; and a return contact that is not attached to the cortical electrode assembly, the return contact being movable with respect to the surface contact and configured to be attached to the patient at a return location spaced apart from the stimulation site.
14. The system of claim 13 wherein the cortical electrode assembly comprises a plurality of rows of the surface contacts, and the surface contacts are electrically coupled to the first terminal of the implantable pulse generator to be biased at the first polarity.
15. The system of claim 13 wherein: the implantable pulse generator further comprises a housing, a pulse system in the housing, and a controller in the housing; and the return contact is attached to the implantable pulse generator.
16. The system of claim 13 wherein: the implantable pulse generator further comprises a housing having an electrically conductive section, a pulse system carried by the housing, and a controller carried by the housing, and wherein the electrically
[33734-8051/SL042150.254] -39- conductive section of the housing is electrically coupled to the second terminal; and the return contact comprises the electrically conductive section of the housing.
17. The system of claim 13 wherein the return contact is a component of a return contact assembly comprising a support base that carries the return contact, the support base being detached from the cortical electrode assembly; and the return contact is coupled to the second terminal of the pulse generator to be biased at the second polarity.
18. The system of claim 17 wherein the return contact assembly comprises a plurality of return contacts carried by the support base.
19. The system of claim 13 wherein: the implantable pulse generator further comprises a pulse system and a controller operatively coupled to the pulse system, wherein the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at the second polarity for a unipolar stimulation period to generate an electrical field extending through deep layers of the cortex in a direction generally normal with respect to the surface contact at the stimulation site.
20. The system of claim 13 wherein: the implantable pulse generator further comprises a pulse system and a controller operatively coupled to the pulse system, wherein the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at the second polarity for a unipolar stimulation period to generate an electrical field
[33734-8051 /SL042150.254] -40- extending through deep layers of the cortex running generally in a direction generally perpendicular to a cortical layer structure.
21. A system for applying electrical stimulation to a cortical stimulation site, comprising: an implantable pulse generator having a first terminal configured to be biased at a first polarity and a second terminal configured to be biased at a second polarity; a cortical electrode assembly having a support member and a plurality of first surface contacts carried by the support member, wherein the first surface contacts are electrically coupled to the first terminal of the implantable pulse generator to be biased at the first polarity; and a return electrode assembly having a support base and a return contact carried by the support base, wherein the support base is not attached to the support member so that the support base is attachable to the patient at a return location separate from the stimulation site, and wherein the return contact is electrically coupled to the second terminal of the implantable pulse generator to be biased at the second polarity.
22. The system of claim 21 wherein the cortical electrode assembly comprises a plurality of second surface contacts carried by the support member, and the second surface contacts are electrically coupled to the second terminal of the implantable pulse generator to be biased at the second polarity.
23. The system of claim 21 wherein: the implantable pulse generator further comprises a pulse system and a controller operatively coupled to the pulse system, wherein the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at the second polarity for a unipolar stimulation period to generate an electrical field
[33734-8051/SL042150.254] -41 - extending through deep layers of the cortex in a direction generally normal with respect to the surface contact at the stimulation site.
24. The system of claim 21 wherein: the implantable pulse generator further comprises a pulse system and a controller operatively coupled to the pulse system, wherein the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at the second polarity for a unipolar stimulation period to generate an electrical field extending through deep layers of the cortex in a direction running generally in a direction generally perpendicular to a cortical layer structure.
25. A system for applying electrical stimulation to a surface site on a cortex of a patient, comprising: an implantable pulse generator having a first terminal configured to be biased at a first polarity, a second terminal configured to be biased at a second polarity, and a return contact coupled to the second terminal to be biased at the second polarity; and a cortical electrode assembly having a support member and a plurality of surface contacts carried by the support member, wherein the surface contacts are coupled to the first terminal of the implantable pulse generator to be biased at the first polarity.
26. The system of claim 25 wherein the cortical electrode assembly comprises a plurality of surface contacts, and the surface contacts are electrically coupled to the first terminal of the implantable pulse generator to be biased at the first polarity.
[33734-8051/SL042150.254] -42-
27. The system of claim 25 wherein: the implantable pulse generator further comprises a housing, a pulse system in the housing, and a controller in the housing; and the return contact comprises an electrode fixedly attached to the implantable pulse generator.
28. The system of claim 25 wherein: the implantable pulse generator further comprises a housing having an electrically conductive section, a pulse system carried by the housing, and a controller carried by the housing, and wherein the electrically conductive section of the housing is electrically coupled to the second terminal; and the return contact comprises the electrically conductive section of the housing.
29. The system of claim 25 wherein: the implantable pulse generator further comprises a pulse system and a controller operatively coupled to the pulse system, wherein the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at the second polarity for a unipolar stimulation period to generate an electrical field extending through deep layers of the cortex in a direction generally normal with respect to the surface contact at the stimulation site.
30. The system of claim 25 wherein: the implantable pulse generator further comprises a pulse system and a controller operatively coupled to the pulse system, wherein the controller includes a programmable medium; and the programmable medium contains instructions that cause the pulse system to concurrently electrically bias the surface contact at the stimulation site at the first polarity while biasing the return contact at the second polarity for a unipolar stimulation period to generate an electrical field
[33734-8051/SL042150.254] -43- extending through deep layers of the cortex running generally in a direction generally perpendicular to a cortical layer structure.
31. A system for applying electrical stimulation to a cortex of a patient, comprising: an implantable housing having a first portion and a second portion; a pulse generator carried by the implantable housing; at least one first electrode arrangement carried by the first portion of the housing so as to be positioned at a cortical stimulation site of the patient located at least approximately at or below an inner surface of the patient's skull when the housing is implanted; and at least one second electrode arrangement carried by the second portion of the housing so as to be positioned at least approximately at or above an outer surface of the patient's skull and beneath the patient's scalp when the housing is implanted.
32. The system of claim 31 wherein the pulse generator includes a first terminal and a second terminal, with at least one of the first and second terminals configured to be biased to a different polarity than the other, and wherein the at least one first electrode arrangement is coupled to the first terminal and the at least one second electrode arrangement is coupled to the second terminal.
33. The system of claim 31 wherein the pulse generator includes a current delivery terminal and a current return terminal, and wherein the at least one first electrode arrangement is coupled to the current delivery terminal and the at least one second electrode arrangement is coupled to the current return terminal.
34. The system of claim 31 wherein the pulse generator includes a first terminal and a second terminal, with at least one of the first and second terminals configured to be biased to a different polarity than the other, and wherein the at least one first electrode arrangement includes two first electrode contacts, and wherein the system further comprises a switching device operatively coupled to the first and second terminals, the switching device having a first configuration with both first
[33734-805 /SL042150.254] -44- electrode contacts electrically coupled to the first terminal and the at least one second electrode arrangement coupled to the second terminal, the switching device further having a second configuration with one first electrode contact electrically coupled to the first terminal and the other first electrode contact coupled to the second terminal.
35. A system for applying electrical stimulation to a patient's brain, comprising: an implantable housing; a pulse generator carried by the implantable housing, the pulse generator having a first terminal and a second terminal, the pulse generator being configured to deliver to at least one of the first and second terminals a stimulation signal having a plurality of stimulation periods with at least one of the stimulation periods having a duration of about 30 seconds or less; at least one first electrode carried by the housing and operatively coupled to at least one of the first and second terminals; and at least one second electrode carried by the housing and operatively coupled to at least one of the first and second terminals.
36. The system of claim 35 wherein the plurality of stimulation periods includes a unipolar stimulation period and a bipolar stimulation period.
37. The system of claim 35 wherein the plurality of stimulation periods includes a first stimulation period at a first polarity and a second stimulation period at a second polarity different than the first.
38. The system of claim 35 wherein the plurality of stimulation periods includes an anodal unipolar stimulation period and a cathodal unipolar stimulation period.
39. The system of claim 35 wherein the plurality of stimulation periods includes different unipolar stimulation periods.
[33734-8051 /SL042150.254] -45-
40. The system of claim 35 wherein the pulse generator is configured to deliver the plurality of stimulation periods with a plurality of interruption periods between temporally neighboring stimulation periods, and wherein at least one of the interruption periods, at least one of the stimulation periods, or at least one of both the interruption periods and the stimulation periods has a duration of 30 seconds or less.
41. The system of claim 35 wherein the pulse generator is configured to deliver the stimulation signal with at least one of the stimulation periods having a duration of about 10 seconds or less.
42. The system of claim 35 wherein the pulse generator is configured to deliver the stimulation signal with at least one of the stimulation periods having a duration of about one second or less.
43. The system of claim 35 wherein the pulse generator is configured to deliver the stimulation signal with at least one of the stimulation periods having a duration of less than one second.
44. The system of claim 35 wherein the housing includes a first portion and a second portion, and wherein the at least one first electrode is carried by the first portion of the housing so as to be positioned at a cortical stimulation site of the patient located at least approximately at or below an inner surface of the patient's skull when the housing is implanted, and wherein the at least one second electrode is carried by the second portion of the housing so as to be positioned at least approximately at or above an outer surface of the patient's skull and beneath the patient's scalp when the housing is implanted.
45. A system for applying electrical stimulation to a patient's brain, comprising: an implantable housing; a pulse generator carried by the implantable housing, the pulse generator having a first terminal and a second terminal and being configured to
[33734-8051/SL042150.254] -46- provide a stimulation signal to at least one of the first and second terminals; a first electrode arrangement coupled to the first terminal so as to be positioned proximate to a first neural region of the patient's brain when the housing is implanted; and a second electrode arrangement coupled to the second terminal so as to be positioned proximate to a second neural region of the patient's brain when the housing is implanted.
46. The system of claim 45, further comprising a return electrode arrangement coupled to the pulse generator so as to be positioned remotely from the first and second electrode arrangements.
47. The system of claim 45 wherein the first electrode assembly is coupled to the first terminal so as to be positioned proximate to a first neural region that carries out a first neural function, and wherein the second electrode assembly is coupled to the second terminal so as to be positioned proximate to a second neural region that carries out a second neural function different than the first.
48. The system of claim 45 wherein the first electrode assembly is coupled to the first terminal so as to be positioned proximate to a first neural region that carries out a first neural function at a first extremity of the patient, and wherein the second electrode assembly is coupled to the second terminal so as to be positioned proximate to a second neural region that carries out a second neural function at a second extremity of the patient.
49. The system of claim 45 wherein the second electrode arrangement is coupled to the second terminal so as to be positioned remotely from the first electrode arrangement when the housing is implanted.
50. A system for applying electrical stimulation to a patient's brain, comprising: an implantable housing;
[33734-8051/SL042150.254] -47- a pulse generator carried by the implantable housing, the pulse generator having a first terminal and a second terminal and being configured to provide a stimulation signal to at least one of the first and second terminals, the stimulation signal including a plurality of groups of pulses, wherein the pulses within a group are provided at first frequency and the groups are provided at a second frequency less than the first frequency; a first electrode arrangement coupled to the first terminal so as to be positioned proximate to a neural region of the patient's brain when the housing is implanted; and a second electrode arrangement coupled to the second terminal.
51. The system of claim 50 wherein the pulse generator is configured to provide pulses at a potential corresponding to a subthreshold level.
52. The system of claim 50 wherein the pulse generator is configured to provide first pulses at a potential corresponding to a subthreshold level and second pulses at a potential corresponding to a suprathreshold level.
53. A system for applying electrical stimulation to a patient's brain, comprising: an implantable housing; a pulse generator carried by the implantable housing, the pulse generator having a first terminal and a second terminal and being configured to provide a stimulation signal to the first and second terminals, the stimulation signal including a first portion wherein an electrical potential is applied to the first terminal at a first polarity and an electrical potential is applied to the second terminal at a second polarity opposite from the first polarity, the stimulation signal further including a second portion wherein an electrical potential is applied to the first terminal at the second polarity and an electrical potential is applied to the second terminal at the first polarity;
[33734-8051/SL042150.254] -48- a first electrode arrangement coupled to the first terminal so as to be positioned proximate to a neural region of the patient's brain when the housing is implanted; and a second electrode arrangement coupled to the second terminal.
54. The system of claim 53 wherein the pulse generator is configured to provide pulses at a potential corresponding to a subthreshold level.
55. The system of claim 53 wherein the pulse generator is configured to provide first pulses at a potential corresponding to a subthreshold level and second pulses at a potential corresponding to a suprathreshold level.
56. A method of applying electrical stimulation to a cortical stimulation site at a cortex of a patient, comprising: electrically biasing a plurality of surface contacts at the cortical stimulation site at a single first polarity for a unipolar stimulation period; and electrically biasing a return site at a second polarity opposite to the first polarity during the unipolar stimulation period, the return site being located apart from the cortical stimulation site along a vector that passes through layers 5 and 6 of the cortex of the patient in a direction that is oblique with respect to a surface contact at the stimulation site.
57. The method of claim 56 wherein: electrically biasing the stimulation site comprises applying an anodal potential to the surface contacts at the stimulation site; and electrically biasing the return site comprises applying a cathodal potential to a return contact at the return site to establish an electrical field that passes through layers 5 and 6 of the cortex at the stimulation site in a direction at least substantially normal with respect to the surface contact at the stimulation site.
[33734-8051/SL042150.254] -49-
58. A method of applying electrical stimulation to a cortical stimulation site on a cortex of a patient, comprising: applying an electrical bias having a single first polarity to a surface contact of a surface electrode assembly positioned at the cortical stimulation site for a unipolar stimulation period; and applying an electrical bias having a second polarity opposite to the first polarity to a return contact during the unipolar stimulation period to establish an electrical field between the surface contact and the return contact, wherein the return contact is positioned apart from the surface contact assembly so that the electrical field passes through layers 5 and 6 of the cortex in a direction at least substantially normal with respect to a section of the cranium of the patient at the surface stimulation site.
59. The method of claim 58 wherein: electrically biasing the surface site comprises applying an anodal potential to a plurality of surface contacts at the stimulation site; and electrically biasing the return site comprises applying a cathodal potential to a return contact at the return site to establish an electrical field that passes through deep layers of the cortex at the stimulation site in a direction at least substantially normal with respect to the section of the cranium of the patient at the stimulation site.
60. A method of applying electrical stimulation to a cortical stimulation site on a cortex of a patient, comprising: positioning a plurality of surface contacts in a human so that the surface contacts are at least substantially proximate to a surface region of the cortex at the stimulation site; positioning a return contact at a location spaced apart from the surface contacts; and applying a unipolar electrical stimulation signal to the surface contacts.
[33734-8051/SL042150.254] -50-
61. The method of claim 60 wherein applying a unipolar electrical signal to the surface contacts comprises electrically biasing the surface contacts with an anodal potential.
62. The method of claim 60 wherein applying a unipolar electrical signal to the surface contacts comprises electrically biasing the surface contacts with a cathodal potential.
63. The method of claim 60 wherein positioning the plurality of surface contacts comprises identifying the stimulation site at an area where neuroplasticity is occurring or expected to occur for recovery of an impaired neural function and placing the plurality of contacts at least approximately within the area.
64. The method of claim 60, further comprising performing a behavioral therapy on the patient.
65. The method of claim 64, wherein the behavioral therapy comprises at least one from the group of a physical therapy, an activity of daily living, an intentional use of an affected body part, a speech therapy, a vision therapy, a reading task, and a memory task.
66. The method of claim 60, further comprising performing a behavioral therapy on the patient concurrently while applying the unipolar electrical stimulation signal to the surface contacts.
67. The method of claim 66, wherein the behavioral therapy comprises at least one from the group of a physical therapy, an activity of daily living, an intentional use of an affected body part, a speech therapy, a vision therapy, an auditory therapy, a reading task, and a memory task.
68. The method of claim 60, wherein the patient has an impaired neural function caused by damage to the brain, and wherein applying the unipolar electrical
[33734-8051/SL042150.254] -51- stimulation signal to the surface contacts comprises electrically biasing the surface contacts with an anodal potential.
69. A method of applying electrical stimulation to a cortical stimulation site on a cortex of a patient, comprising: positioning a surface electrode assembly so that a surface contact of the surface electrode assembly is at least substantially proximate to a surface region of the cortex at the stimulation site; positioning a return contact at a location spaced apart from the surface electrode assembly and not in a deep brain region of the brain; and establishing an electrical field between the surface contact and the return contact that extends through deep layers of the cortex in a direction oblique with respect to the surface contacts.
70. The method of claim 69 wherein establishing the electrical field comprises electrically biasing the surface contact with an anodal potential.
71. The method of claim 69 wherein establishing the electrical field comprises electrically biasing the surface contact with an cathodal potential.
72. The method of claim 69 wherein positioning the surface electrode assembly comprises identifying the stimulation site at an area where neuroplasticity is occurring or expected to occur for recovery of an impaired neural function and placing the surface electrode assembly at least approximately within the area.
73. The method of claim 69, further comprising performing a behavioral therapy on the patient.
74. The method of claim 73, wherein the behavioral therapy comprises at least one from the group of a physical therapy, an activity of daily living, an intentional use of an affected body part, a speech therapy, a vision therapy, a reading task, and a memory task.
[33734-8051/SL042150.254] -52-
75. The method of claim 69, wherein the patient has an impaired neural function caused by damage to the brain, and wherein establishing the electrical field comprises applying a unipolar electrical stimulation signal to the surface contact with an anodal potential.
[33734-8051/SL042150.254] -53-
PCT/US2004/025010 2003-08-01 2004-08-02 Apparatus and methods for applying neural stimulation to a patient WO2005011805A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002534363A CA2534363A1 (en) 2003-08-01 2004-08-02 Apparatus and methods for applying neural stimulation to a patient
AU2004261290A AU2004261290A1 (en) 2003-08-01 2004-08-02 Apparatus and methods for applying neural stimulation to a patient
JP2006522666A JP2007501067A (en) 2003-08-01 2004-08-02 Apparatus and method for applying neural stimulation to patient
EP04779931A EP1654032A2 (en) 2003-08-01 2004-08-02 Apparatus and methods for applying neural stimulation to a patient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49227303P 2003-08-01 2003-08-01
US60/492,273 2003-08-01

Publications (2)

Publication Number Publication Date
WO2005011805A2 true WO2005011805A2 (en) 2005-02-10
WO2005011805A3 WO2005011805A3 (en) 2005-10-27

Family

ID=34115612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025010 WO2005011805A2 (en) 2003-08-01 2004-08-02 Apparatus and methods for applying neural stimulation to a patient

Country Status (6)

Country Link
US (3) US7684866B2 (en)
EP (1) EP1654032A2 (en)
JP (1) JP2007501067A (en)
AU (1) AU2004261290A1 (en)
CA (1) CA2534363A1 (en)
WO (1) WO2005011805A2 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007021225A (en) * 2005-07-20 2007-02-01 Cyberonics Inc Vagal stimulation by electrical signal for controlling cerebellar tremor
EP1786508A2 (en) * 2004-07-15 2007-05-23 Northstar Neuroscience, Inc. Methods and systems for intracranial neurostimulation and/or sensing
WO2008018067A2 (en) * 2006-08-07 2008-02-14 Alpha Omega Engineering Ltd. Cerebral electrodes and methods of operating same
EP1948300A2 (en) * 2005-10-19 2008-07-30 Northstar Neuroscience, Inc. Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders
JP2009531154A (en) * 2006-03-29 2009-09-03 カソリック ヘルスケア ウエスト Cranial nerve microburst electrical stimulation for medical treatment
JP2010501269A (en) * 2006-08-25 2010-01-21 カーディアック ペースメイカーズ, インコーポレイテッド System for sedating the side effects of neural stimulation
US8116875B2 (en) 2006-06-16 2012-02-14 Neuropoint Medical, Inc. Implantable neurostimulation systems
US8577458B1 (en) 2011-12-07 2013-11-05 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with leadless heart rate monitoring
US8688212B2 (en) 2012-07-20 2014-04-01 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation
US8700150B2 (en) 2012-01-17 2014-04-15 Cyberonics, Inc. Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
US9643008B2 (en) 2012-11-09 2017-05-09 Cyberonics, Inc. Implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation
US9643022B2 (en) 2013-06-17 2017-05-09 Nyxoah SA Flexible control housing for disposable patch
US9643011B2 (en) 2013-03-14 2017-05-09 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation
US9849289B2 (en) 2009-10-20 2017-12-26 Nyxoah SA Device and method for snoring detection and control
US9855032B2 (en) 2012-07-26 2018-01-02 Nyxoah SA Transcutaneous power conveyance device
US9943686B2 (en) 2009-10-20 2018-04-17 Nyxoah SA Method and device for treating sleep apnea based on tongue movement
US10052097B2 (en) 2012-07-26 2018-08-21 Nyxoah SA Implant unit delivery tool
US10188856B1 (en) 2011-12-07 2019-01-29 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US10751537B2 (en) 2009-10-20 2020-08-25 Nyxoah SA Arced implant unit for modulation of nerves
US10814137B2 (en) 2012-07-26 2020-10-27 Nyxoah SA Transcutaneous power conveyance device
US10898716B2 (en) 2015-10-29 2021-01-26 Rainbow Medical Ltd. Electrical substance clearance from the brain
US11202905B2 (en) 2018-03-14 2021-12-21 Rainbow Medical Ltd. Electrical substance clearance from the brain
US11253712B2 (en) 2012-07-26 2022-02-22 Nyxoah SA Sleep disordered breathing treatment apparatus
US11285317B2 (en) 2015-12-29 2022-03-29 Rainbow Medical Ltd. Disc therapy
US11298530B1 (en) 2021-05-03 2022-04-12 Discure Technologies Ltd. Synergistic therapies for intervertebral disc degeneration
US11344721B1 (en) 2021-08-16 2022-05-31 Rainbow Medical Ltd. Cartilage treatment
US11376422B2 (en) 2015-07-08 2022-07-05 Rainbow Medical Ltd. Electrical treatment of Alzheimer's disease
US11484706B2 (en) 2015-12-29 2022-11-01 Discure Technologies Ltd Disc therapy

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217782A1 (en) * 1998-10-26 2006-09-28 Boveja Birinder R Method and system for cortical stimulation to provide adjunct (ADD-ON) therapy for stroke, tinnitus and other medical disorders using implantable and external components
US7062330B1 (en) * 1998-10-26 2006-06-13 Boveja Birinder R Electrical stimulation adjunct (Add-ON) therapy for urinary incontinence and urological disorders using implanted lead stimulus-receiver and an external pulse generator
US7305268B2 (en) * 2000-07-13 2007-12-04 Northstar Neurscience, Inc. Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US7146217B2 (en) * 2000-07-13 2006-12-05 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a change in a neural-function of a patient
US7672730B2 (en) * 2001-03-08 2010-03-02 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7756584B2 (en) * 2000-07-13 2010-07-13 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US20030125786A1 (en) * 2000-07-13 2003-07-03 Gliner Bradford Evan Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7010351B2 (en) * 2000-07-13 2006-03-07 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7024247B2 (en) 2001-10-15 2006-04-04 Northstar Neuroscience, Inc. Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures
US7831305B2 (en) * 2001-10-15 2010-11-09 Advanced Neuromodulation Systems, Inc. Neural stimulation system and method responsive to collateral neural activity
US7299096B2 (en) * 2001-03-08 2007-11-20 Northstar Neuroscience, Inc. System and method for treating Parkinson's Disease and other movement disorders
WO2003026738A1 (en) * 2001-09-28 2003-04-03 Northstar Neuroscience, Inc. Methods and apparatus for electrically stimulating cells implanted in the nervous system
US7221981B2 (en) * 2002-03-28 2007-05-22 Northstar Neuroscience, Inc. Electrode geometries for efficient neural stimulation
US20050075679A1 (en) * 2002-09-30 2005-04-07 Gliner Bradford E. Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system
US7236830B2 (en) 2002-12-10 2007-06-26 Northstar Neuroscience, Inc. Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders
US7302298B2 (en) * 2002-11-27 2007-11-27 Northstar Neuroscience, Inc Methods and systems employing intracranial electrodes for neurostimulation and/or electroencephalography
US7596408B2 (en) * 2002-12-09 2009-09-29 Medtronic, Inc. Implantable medical device with anti-infection agent
AU2003297761A1 (en) * 2002-12-09 2004-06-30 Northstar Neuroscience, Inc. Methods for treating neurological language disorders
US6959215B2 (en) * 2002-12-09 2005-10-25 Northstar Neuroscience, Inc. Methods for treating essential tremor
EP1578494B1 (en) * 2002-12-09 2010-05-26 Medtronic, Inc. Lead connection module of a modular implantable medical device
US20050004637A1 (en) * 2003-05-16 2005-01-06 Ruchika Singhal Explantation of implantable medical device
US7317947B2 (en) * 2003-05-16 2008-01-08 Medtronic, Inc. Headset recharger for cranially implantable medical devices
US7263401B2 (en) 2003-05-16 2007-08-28 Medtronic, Inc. Implantable medical device with a nonhermetic battery
US20050003268A1 (en) * 2003-05-16 2005-01-06 Scott Erik R. Battery housing configuration
CA2534363A1 (en) 2003-08-01 2005-02-10 Brad Fowler Apparatus and methods for applying neural stimulation to a patient
US20060161219A1 (en) * 2003-11-20 2006-07-20 Advanced Neuromodulation Systems, Inc. Electrical stimulation system and method for stimulating multiple locations of target nerve tissue in the brain to treat multiple conditions in the body
WO2005051480A2 (en) * 2003-11-20 2005-06-09 Advanced Neuromodulation Systems, Inc. Electrical stimulation system, lead, and method providing reduced neuroplasticity effects
WO2005051479A2 (en) * 2003-11-20 2005-06-09 Advanced Neuromodulation Systems, Inc. Electrical stimulation system and method for treating tinnitus
US9050469B1 (en) 2003-11-26 2015-06-09 Flint Hills Scientific, Llc Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US7596399B2 (en) * 2004-04-29 2009-09-29 Medtronic, Inc Implantation of implantable medical device
US20050245984A1 (en) * 2004-04-30 2005-11-03 Medtronic, Inc. Implantable medical device with lubricious material
NL1026137C2 (en) * 2004-05-07 2005-11-08 Vanderlande Ind Nederland Device for sorting products.
EP1786510A4 (en) 2004-07-15 2009-12-02 Northstar Neuroscience Inc Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
US8014870B2 (en) * 2004-08-11 2011-09-06 Seidman Michael D Method and apparatus for the treatment of tinnitus
US20090105521A1 (en) * 2004-09-13 2009-04-23 Jonathan Bentwich Systems and methods for assessing and treating medical conditions related to the central nervous system and for enhancing cognitive functions
US20060058853A1 (en) * 2004-09-13 2006-03-16 Jonathan Bentwich Integrated system and method for treating disease using cognitive-training and brain stimulation and computerized magnetic photo-electric stimulator (cmpes)
US20090099623A1 (en) * 2004-09-13 2009-04-16 Neuronix Ltd. Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions
US7613519B2 (en) * 2004-10-21 2009-11-03 Advanced Neuromodulation Systems, Inc. Peripheral nerve stimulation to treat auditory dysfunction
US7613520B2 (en) 2004-10-21 2009-11-03 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
US9358393B1 (en) * 2004-11-09 2016-06-07 Andres M. Lozano Stimulation methods and systems for treating an auditory dysfunction
US7565200B2 (en) 2004-11-12 2009-07-21 Advanced Neuromodulation Systems, Inc. Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects
US8260426B2 (en) 2008-01-25 2012-09-04 Cyberonics, Inc. Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US8244347B2 (en) * 2005-03-04 2012-08-14 Andres M. Lozano Methods and apparatus for effectuating a lasting change in a neural function of a patient, including via mechanical force on neural tissue
US7840272B2 (en) * 2005-06-03 2010-11-23 Medrelief Inc. Methods for modulating osteochondral development using bioelectrical stimulation
ES2352144T3 (en) * 2005-08-02 2011-02-16 Neurotherm, Inc. DEVICE FOR DIAGNOSING AND TREATING NEURONAL DYSFUNCTION.
EP1937352B1 (en) * 2005-09-19 2012-03-14 Second Sight Medical Products, Inc. Sub-threshold stimulation to precondition neurons for supra-threshold stimulation
US8929991B2 (en) 2005-10-19 2015-01-06 Advanced Neuromodulation Systems, Inc. Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits
US7729773B2 (en) 2005-10-19 2010-06-01 Advanced Neuromodualation Systems, Inc. Neural stimulation and optical monitoring systems and methods
US20070100377A1 (en) * 2005-10-28 2007-05-03 Cyberonics, Inc. Providing multiple signal modes for a medical device
US7996079B2 (en) 2006-01-24 2011-08-09 Cyberonics, Inc. Input response override for an implantable medical device
US7974697B2 (en) 2006-01-26 2011-07-05 Cyberonics, Inc. Medical imaging feedback for an implantable medical device
US7801601B2 (en) 2006-01-27 2010-09-21 Cyberonics, Inc. Controlling neuromodulation using stimulus modalities
US8926676B2 (en) * 2006-04-11 2015-01-06 Advanced Neuromodulation Systems, Inc. Systems and methods for applying signals, including contralesional signals, to neural populations
US7962220B2 (en) 2006-04-28 2011-06-14 Cyberonics, Inc. Compensation reduction in tissue stimulation therapy
US7869885B2 (en) * 2006-04-28 2011-01-11 Cyberonics, Inc Threshold optimization for tissue stimulation therapy
US9084901B2 (en) * 2006-04-28 2015-07-21 Medtronic, Inc. Cranial implant
US8014866B2 (en) * 2006-07-13 2011-09-06 Cardiac Pacemakers, Inc. Variable voltage compliance for current output generator
AU2007281122A1 (en) * 2006-08-02 2008-02-07 Advanced Neuromodulation Systems, Inc. Methods for treating neurological disorders, including neuropsychiatric and neuropsychological disorders, and associated systems
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
US10925637B2 (en) * 2010-03-11 2021-02-23 Mainstay Medical Limited Methods of implanting electrode leads for use with implantable neuromuscular electrical stimulator
US11679262B2 (en) 2007-03-09 2023-06-20 Mainstay Medical Limited Systems and methods for restoring muscle function to the lumbar spine
US9248278B2 (en) 2010-03-11 2016-02-02 Mainstay Medical Limited Modular stimulator for treatment of back pain, implantable RF ablation system and methods of use
US11679261B2 (en) 2007-03-09 2023-06-20 Mainstay Medical Limited Systems and methods for enhancing function of spine stabilization muscles associated with a spine surgery intervention
US8428728B2 (en) * 2007-03-09 2013-04-23 Mainstay Medical Limited Muscle stimulator
US11331488B2 (en) 2007-03-09 2022-05-17 Mainstay Medical Limited Systems and methods for enhancing function of spine stabilization muscles associated with a spine surgery intervention
US9072897B2 (en) 2007-03-09 2015-07-07 Mainstay Medical Limited Systems and methods for restoring muscle function to the lumbar spine
US8224453B2 (en) 2007-03-15 2012-07-17 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat pain
US20080249591A1 (en) * 2007-04-06 2008-10-09 Northstar Neuroscience, Inc. Controllers for implantable medical devices, and associated methods
WO2008130837A1 (en) * 2007-04-19 2008-10-30 Northstar Neuroscience, Inc. Methods and systems for establishing neural stimulation parameters and providing neural stimulation
US8364273B2 (en) * 2007-04-24 2013-01-29 Dirk De Ridder Combination of tonic and burst stimulations to treat neurological disorders
US7962214B2 (en) 2007-04-26 2011-06-14 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7869884B2 (en) 2007-04-26 2011-01-11 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7904175B2 (en) 2007-04-26 2011-03-08 Cyberonics, Inc. Trans-esophageal vagus nerve stimulation
US7974701B2 (en) 2007-04-27 2011-07-05 Cyberonics, Inc. Dosing limitation for an implantable medical device
US8027737B2 (en) * 2007-08-01 2011-09-27 Intelect Medical, Inc. Lead extension with input capabilities
US20090105786A1 (en) * 2007-10-22 2009-04-23 University Of Washington Method and device for strengthening synaptic connections
JP4488057B2 (en) * 2007-11-09 2010-06-23 セイコーエプソン株式会社 Active matrix device, electro-optical display device, and electronic apparatus
US8180442B2 (en) * 2007-12-14 2012-05-15 Greatbatch Ltd. Deriving patient activity information from sensed body electrical information
US8337404B2 (en) 2010-10-01 2012-12-25 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8571643B2 (en) 2010-09-16 2013-10-29 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8382667B2 (en) 2010-10-01 2013-02-26 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
WO2009097493A2 (en) * 2008-01-30 2009-08-06 New York University Cortical electrode array and method for stimulating and recording brain activity
US8204603B2 (en) 2008-04-25 2012-06-19 Cyberonics, Inc. Blocking exogenous action potentials by an implantable medical device
US8315703B2 (en) * 2008-04-30 2012-11-20 Advanced Neuromodulation Systems, Inc. Methods for targeting deep brain sites to treat mood and/or anxiety disorders
US20090281623A1 (en) * 2008-05-12 2009-11-12 Medtronic, Inc. Customization of implantable medical devices
CA2732293A1 (en) * 2008-07-28 2010-02-04 Boston Scientific Neuromodulation Corporation System and method for increasing relative intensity between cathodes and anodes of neurostimulation system
WO2010014686A1 (en) 2008-07-30 2010-02-04 Aleva Neurotherapeutics, S.A. Apparatus and method for optimized stimulation of a neurological target
US8262714B2 (en) * 2008-08-05 2012-09-11 Advanced Neuromodulation Systems, Inc. Techniques for selecting signal delivery sites and other parameters for treating depression and other neurological disorders, and associated systems and methods
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US8417344B2 (en) * 2008-10-24 2013-04-09 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
US9393432B2 (en) 2008-10-31 2016-07-19 Medtronic, Inc. Non-hermetic direct current interconnect
US8355798B2 (en) * 2008-11-11 2013-01-15 Boston Scientific Neuromodulation Corporation System and method for increasing relative intensity between cathodes and anodes of neurostimulation system using pulse slicing
JP5667987B2 (en) 2008-11-12 2015-02-12 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ (イーピーエフエル) Micromachined nerve stimulation device
US20100185268A1 (en) * 2009-01-16 2010-07-22 Northstar Neuroscience, Inc. Implantable medical devices and associated systems and methods
US20100191304A1 (en) 2009-01-23 2010-07-29 Scott Timothy L Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation
US8396558B2 (en) * 2009-02-11 2013-03-12 University Of Maryland, Baltimore Methods for treating central pain syndrome and other pain related pathologies
US8239028B2 (en) * 2009-04-24 2012-08-07 Cyberonics, Inc. Use of cardiac parameters in methods and systems for treating a chronic medical condition
US8827912B2 (en) 2009-04-24 2014-09-09 Cyberonics, Inc. Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters
US8046077B2 (en) * 2009-06-05 2011-10-25 Intelect Medical, Inc. Selective neuromodulation using energy-efficient waveforms
US8509903B2 (en) 2009-06-05 2013-08-13 Intelect Medical, Inc. Neuromodulation using energy-efficient waveforms
US9314613B2 (en) 2011-09-30 2016-04-19 Adi Mashiach Apparatus and methods for modulating nerves using parallel electric fields
US10806926B2 (en) * 2009-10-20 2020-10-20 Man & Science Sa Implantable electrical stimulator
US9415215B2 (en) 2009-10-20 2016-08-16 Nyxoah SA Methods for treatment of sleep apnea
US8774937B2 (en) 2009-12-01 2014-07-08 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
WO2011069095A2 (en) * 2009-12-04 2011-06-09 University Of Mississippi Stuttering reduction method and device
WO2011091071A2 (en) * 2010-01-20 2011-07-28 The Regents Of The University Of California Systems, devices and methods for cranial implantation of a neuromodulation device
JP2013519418A (en) * 2010-02-12 2013-05-30 サピエンス ステアリング ブレイン スティムレーション ベー ヴィ Method and system for determining settings in deep brain stimulation therapy
US11786725B2 (en) 2012-06-13 2023-10-17 Mainstay Medical Limited Systems and methods for restoring muscle function to the lumbar spine and kits for implanting the same
US11684774B2 (en) 2010-03-11 2023-06-27 Mainstay Medical Limited Electrical stimulator for treatment of back pain and methods of use
US9999763B2 (en) 2012-06-13 2018-06-19 Mainstay Medical Limited Apparatus and methods for anchoring electrode leads adjacent to nervous tissue
US9950159B2 (en) 2013-10-23 2018-04-24 Mainstay Medical Limited Systems and methods for restoring muscle function to the lumbar spine and kits for implanting the same
JP5927176B2 (en) 2010-04-01 2016-06-01 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ (イーピーエフエル) Device for interacting with neural tissue and methods of making and using it
US8562536B2 (en) 2010-04-29 2013-10-22 Flint Hills Scientific, Llc Algorithm for detecting a seizure from cardiac data
US8649871B2 (en) 2010-04-29 2014-02-11 Cyberonics, Inc. Validity test adaptive constraint modification for cardiac data used for detection of state changes
US8831732B2 (en) 2010-04-29 2014-09-09 Cyberonics, Inc. Method, apparatus and system for validating and quantifying cardiac beat data quality
US8679009B2 (en) 2010-06-15 2014-03-25 Flint Hills Scientific, Llc Systems approach to comorbidity assessment
US8641646B2 (en) 2010-07-30 2014-02-04 Cyberonics, Inc. Seizure detection using coordinate data
US8684921B2 (en) 2010-10-01 2014-04-01 Flint Hills Scientific Llc Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US9504390B2 (en) 2011-03-04 2016-11-29 Globalfoundries Inc. Detecting, assessing and managing a risk of death in epilepsy
US8725239B2 (en) 2011-04-25 2014-05-13 Cyberonics, Inc. Identifying seizures using heart rate decrease
US9402550B2 (en) 2011-04-29 2016-08-02 Cybertronics, Inc. Dynamic heart rate threshold for neurological event detection
CN103889502B (en) 2011-08-02 2016-02-24 梅恩斯塔伊医疗公司 For the equipment of the electrode guiding piece that grappling uses together with implantable neuromuscular electric stimulation therapy device
US10206591B2 (en) 2011-10-14 2019-02-19 Flint Hills Scientific, Llc Seizure detection methods, apparatus, and systems using an autoregression algorithm
US8630709B2 (en) 2011-12-07 2014-01-14 Cyberonics, Inc. Computer-implemented system and method for selecting therapy profiles of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8600505B2 (en) 2011-12-07 2013-12-03 Cyberonics, Inc. Implantable device for facilitating control of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8918190B2 (en) 2011-12-07 2014-12-23 Cyberonics, Inc. Implantable device for evaluating autonomic cardiovascular drive in a patient suffering from chronic cardiac dysfunction
US8918191B2 (en) 2011-12-07 2014-12-23 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
WO2013096260A1 (en) 2011-12-19 2013-06-27 Mainstay Medical Limited Apparatus for rehabilitating a muscle and assessing progress of rehabilitation
US8571654B2 (en) 2012-01-17 2013-10-29 Cyberonics, Inc. Vagus nerve neurostimulator with multiple patient-selectable modes for treating chronic cardiac dysfunction
US20130261706A1 (en) * 2012-03-30 2013-10-03 Neuropace, Inc. Systems and methods for applying rapid sequential electrode stimulation
US10448839B2 (en) 2012-04-23 2019-10-22 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
US9186501B2 (en) 2012-06-13 2015-11-17 Mainstay Medical Limited Systems and methods for implanting electrode leads for use with implantable neuromuscular electrical stimulator
US10195419B2 (en) 2012-06-13 2019-02-05 Mainstay Medical Limited Electrode leads for use with implantable neuromuscular electrical stimulator
US8583238B1 (en) * 2012-10-02 2013-11-12 Great Lakes Neuro Technologies Inc. Wearable, unsupervised transcranial direct current stimulation (tDCS) device for movement disorder therapy, and method of using
US9452290B2 (en) 2012-11-09 2016-09-27 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing tachyarrhythmia through vagus nerve stimulation
US8923964B2 (en) 2012-11-09 2014-12-30 Cyberonics, Inc. Implantable neurostimulator-implemented method for enhancing heart failure patient awakening through vagus nerve stimulation
US10946196B2 (en) 2012-11-16 2021-03-16 Stimscience Inc. System for variably configurable, adaptable electrode arrays and effectuating software
US10220211B2 (en) 2013-01-22 2019-03-05 Livanova Usa, Inc. Methods and systems to diagnose depression
US8874233B2 (en) 2013-03-05 2014-10-28 The Charles Stark Draper Laboratory, Inc. Distributed neuro-modulation system with auxiliary stimulation-recording control units
US9731122B2 (en) 2013-04-29 2017-08-15 Rainbow Medical Ltd. Electroosmotic tissue treatment
US10016600B2 (en) 2013-05-30 2018-07-10 Neurostim Solutions, Llc Topical neurological stimulation
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
US9999773B2 (en) 2013-10-30 2018-06-19 Cyberonics, Inc. Implantable neurostimulator-implemented method utilizing multi-modal stimulation parameters
US9511228B2 (en) 2014-01-14 2016-12-06 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing hypertension through renal denervation and vagus nerve stimulation
US9415224B2 (en) 2014-04-25 2016-08-16 Cyberonics, Inc. Neurostimulation and recording of physiological response for the treatment of chronic cardiac dysfunction
US9272143B2 (en) 2014-05-07 2016-03-01 Cyberonics, Inc. Responsive neurostimulation for the treatment of chronic cardiac dysfunction
US9713719B2 (en) 2014-04-17 2017-07-25 Cyberonics, Inc. Fine resolution identification of a neural fulcrum for the treatment of chronic cardiac dysfunction
US9409024B2 (en) 2014-03-25 2016-08-09 Cyberonics, Inc. Neurostimulation in a neural fulcrum zone for the treatment of chronic cardiac dysfunction
US9950169B2 (en) 2014-04-25 2018-04-24 Cyberonics, Inc. Dynamic stimulation adjustment for identification of a neural fulcrum
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US10966620B2 (en) 2014-05-16 2021-04-06 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US9770599B2 (en) 2014-08-12 2017-09-26 Cyberonics, Inc. Vagus nerve stimulation and subcutaneous defibrillation system
US9533153B2 (en) 2014-08-12 2017-01-03 Cyberonics, Inc. Neurostimulation titration process
US9737716B2 (en) 2014-08-12 2017-08-22 Cyberonics, Inc. Vagus nerve and carotid baroreceptor stimulation system
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
WO2016053375A1 (en) 2014-10-01 2016-04-07 James Phillips System and method for transcranial current loop brain stimulation
US10471268B2 (en) 2014-10-16 2019-11-12 Mainstay Medical Limited Systems and methods for monitoring muscle rehabilitation
EP3434318B1 (en) * 2014-10-31 2021-05-12 Avent, Inc. System for monitoring and treating a medical condition via posterior tibial nerve stimulation
US9504832B2 (en) 2014-11-12 2016-11-29 Cyberonics, Inc. Neurostimulation titration process via adaptive parametric modification
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
AU2016316683B2 (en) 2015-09-04 2020-07-23 The Johns Hopkins University Low-profile intercranial device
US10155107B2 (en) 2015-10-07 2018-12-18 Medtronic, Inc. Implantable modular electrode array assembly
US9724515B2 (en) * 2015-10-29 2017-08-08 Rainbow Medical Ltd. Electrical substance clearance from the brain for treatment of Alzheimer's disease
EP3411111A1 (en) 2016-02-02 2018-12-12 Aleva Neurotherapeutics SA Treatment of autoimmune diseases with deep brain stimulation
US11504038B2 (en) 2016-02-12 2022-11-22 Newton Howard Early detection of neurodegenerative disease
US20180093092A1 (en) * 2016-04-22 2018-04-05 Newton Howard Biological co-processor (bcp)
US10327810B2 (en) 2016-07-05 2019-06-25 Mainstay Medical Limited Systems and methods for enhanced implantation of electrode leads between tissue layers
US10912648B2 (en) 2016-08-30 2021-02-09 Longeviti Neuro Solutions Llc Method for manufacturing a low-profile intercranial device and the low-profile intercranial device manufactured thereby
US10737096B1 (en) 2016-10-25 2020-08-11 Maurice M. Klee Charge-based methods for modifying neural activity
EP3684463A4 (en) 2017-09-19 2021-06-23 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US10953225B2 (en) 2017-11-07 2021-03-23 Neurostim Oab, Inc. Non-invasive nerve activator with adaptive circuit
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11589992B2 (en) 2018-01-09 2023-02-28 Longeviti Neuro Solutions Llc Universal low-profile intercranial assembly
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
KR20220025834A (en) 2019-06-26 2022-03-03 뉴로스팀 테크놀로지스 엘엘씨 Non-invasive neural activators with adaptive circuits
US11446084B2 (en) 2019-07-12 2022-09-20 Neuralink Corp. Laser drilling of pia mater
EP4085967B1 (en) * 2019-07-31 2023-09-06 Novocure GmbH Applying tumor treating fields (ttfields) via electrodes embedded into skull implants
WO2021071871A1 (en) * 2019-10-09 2021-04-15 Trustees Of Boston University Electrography system employing layered electrodes for improved spatial resolution
CA3152451A1 (en) 2019-12-16 2021-06-24 Michael Bernard Druke Non-invasive nerve activator with boosted charge delivery
US11571541B2 (en) 2020-10-27 2023-02-07 David Richardson Hubbard, JR. Apparatus and methods of transcranial stimulation to adjust sensory cortical dendritic spine neck membrane potentials for altering consciousness
US11413455B1 (en) 2022-02-08 2022-08-16 Rainbow Medical Ltd. Electrical treatment of Alzheimer's disease
CN115054257A (en) * 2022-06-17 2022-09-16 中国科学院脑科学与智能技术卓越创新中心 Flexible electrode for brain and manufacturing method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3650276A (en) * 1969-03-26 1972-03-21 Inst Demedicina Si Farmacie Method and apparatus, including a flexible electrode, for the electric neurostimulation of the neurogenic bladder
US4140133A (en) * 1977-04-26 1979-02-20 Moskovsky Oblastnoi Nauchno-Issledovatelsky Institut Akusherstva I Ginekolog Ii Device for pulse current action on central nervous system
US5674251A (en) * 1994-04-21 1997-10-07 Medtronic, Inc. Method and apparatus for treatment of atrial fibrillation
US20020077670A1 (en) * 2000-04-05 2002-06-20 Archer Stephen T. Stimulation signal generator for an implantable device
US20020091419A1 (en) * 2000-07-13 2002-07-11 Firlik Andrew D. Methods and apparatus for effectuating a change in a neural-function of a patient
US20030125772A1 (en) * 1995-03-30 2003-07-03 Olson Walter H. Prioritized rule based method and apparatus for diagnosis and treatment of arrhythmias
US20040158298A1 (en) * 2000-07-13 2004-08-12 Gliner Bradford Evan Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US20050004620A1 (en) * 2002-12-09 2005-01-06 Medtronic, Inc. Implantable medical device with anti-infection agent

Family Cites Families (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2716226A (en) 1951-06-22 1955-08-23 Reiner Electronics Co Inc Electrical solderless connector
US2721316A (en) 1953-06-09 1955-10-18 Joseph D Shaw Method and means for aiding the blind
US3628193A (en) 1969-02-19 1971-12-21 Inst Of Medical Sciences The Tactile image projection system
US3850161A (en) 1973-04-09 1974-11-26 S Liss Method and apparatus for monitoring and counteracting excess brain electrical energy to prevent epileptic seizures and the like
US4019518A (en) 1975-08-11 1977-04-26 Medtronic, Inc. Electrical stimulation system
US4030509A (en) 1975-09-30 1977-06-21 Mieczyslaw Mirowski Implantable electrodes for accomplishing ventricular defibrillation and pacing and method of electrode implantation and utilization
US4125116A (en) 1977-02-14 1978-11-14 The Johns Hopkins University Human tissue stimulation electrode structure
CA1065969A (en) 1977-09-28 1979-11-06 Gratien Bouillon Self-blocking cerebral catheter
US4214804A (en) 1978-09-25 1980-07-29 Daig Corporation Press fit electrical connection apparatus
US4431000A (en) 1978-11-29 1984-02-14 Gatron Corporation Transcutaneous nerve stimulator with pseusorandom pulse generator
US4474186A (en) 1979-07-17 1984-10-02 Georgetown University Computerized electro-oculographic (CEOG) system with feedback control of stimuli
US4308868A (en) 1980-05-27 1982-01-05 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Implantable electrical device
US4328813A (en) 1980-10-20 1982-05-11 Medtronic, Inc. Brain lead anchoring system
US4340038A (en) 1980-12-15 1982-07-20 Pacesetter Systems, Inc. Magnetic field concentration means and method for an implanted device
US4390023A (en) 1981-04-30 1983-06-28 Medtronic, Inc. Patterned electrical tissue stimulator
CA1215128A (en) 1982-12-08 1986-12-09 Pedro Molina-Negro Electric nerve stimulator device
US4542752A (en) 1983-04-22 1985-09-24 Cordis Corporation Implantable device having porous surface with carbon coating
US4844075A (en) 1984-01-09 1989-07-04 Pain Suppression Labs, Inc. Transcranial stimulation for the treatment of cerebral palsy
US4607639A (en) 1984-05-18 1986-08-26 Regents Of The University Of California Method and system for controlling bladder evacuation
US4590946A (en) 1984-06-14 1986-05-27 Biomed Concepts, Inc. Surgically implantable electrode for nerve bundles
US4532931A (en) 1984-06-29 1985-08-06 Cardiac Pacemakers, Inc. Pacemaker with adaptive sensing means for use with unipolar or bipolar leads
US4646744A (en) 1984-06-29 1987-03-03 Zion Foundation Method and treatment with transcranially applied electrical signals
CA1292285C (en) 1985-08-21 1991-11-19 Paul H. Stypulkowski External ear canal electrode to be placed proximate the tympanic membrane and method of stimulating/recording utilizing external ear canal electrode placed proximate the tympanic membrane
US5054906A (en) 1986-01-17 1991-10-08 Brimfield Precision, Inc. Indirectly illuminating ophthalmological speculum
US4969468A (en) 1986-06-17 1990-11-13 Alfred E. Mann Foundation For Scientific Research Electrode array for use in connection with a living body and method of manufacture
US4817634A (en) 1987-06-18 1989-04-04 Medtronic, Inc. Epicardial patch electrode
US4869255A (en) 1987-12-04 1989-09-26 Ad-Tech Medical Instrument Corp. Electrical connection device
US4865048A (en) 1987-12-31 1989-09-12 Eckerson Harold D Method and apparatus for drug free neurostimulation
US4903702A (en) 1988-10-17 1990-02-27 Ad-Tech Medical Instrument Corporation Brain-contact for sensing epileptogenic foci with improved accuracy
US5458631A (en) 1989-01-06 1995-10-17 Xavier; Ravi Implantable catheter with electrical pulse nerve stimulators and drug delivery system
US5002053A (en) 1989-04-21 1991-03-26 University Of Arkansas Method of and device for inducing locomotion by electrical stimulation of the spinal cord
DE3914662A1 (en) 1989-05-03 1990-11-08 Alt Eckhard DEVICE FOR TRANSMITTING ELECTRICAL SIGNALS BETWEEN AN IMPLANTABLE MEDICAL DEVICE AND ELECTRICALLY EXPENSIBLE HUMAN TISSUE
US5119832A (en) 1989-07-11 1992-06-09 Ravi Xavier Epidural catheter with nerve stimulators
US5024226A (en) 1989-08-17 1991-06-18 Critikon, Inc. Epidural oxygen sensor
US5063932A (en) 1989-10-03 1991-11-12 Mieczyslaw Mirowski Controlled discharge defibrillation electrode
US5215088A (en) 1989-11-07 1993-06-01 The University Of Utah Three-dimensional electrode device
US5271417A (en) 1990-01-23 1993-12-21 Cardiac Pacemakers, Inc. Defibrillation electrode having smooth current distribution
US5031618A (en) 1990-03-07 1991-07-16 Medtronic, Inc. Position-responsive neuro stimulator
US5044368A (en) 1990-04-23 1991-09-03 Ad-Tech Medical Instrument Corporation Diagnostic electrode for use with magnetic resonance imaging
US5713926A (en) * 1990-04-25 1998-02-03 Cardiac Pacemakers, Inc. Implantable intravenous cardiac stimulation system with pulse generator housing serving as optional additional electrode
US5314458A (en) 1990-06-01 1994-05-24 University Of Michigan Single channel microstimulator
US5095905A (en) 1990-06-07 1992-03-17 Medtronic, Inc. Implantable neural electrode
US5092835A (en) 1990-07-06 1992-03-03 Schurig Janet L S Brain and nerve healing power apparatus and method
US5121754A (en) 1990-08-21 1992-06-16 Medtronic, Inc. Lateral displacement percutaneously inserted epidural lead
US5342410A (en) 1990-10-05 1994-08-30 Eric Braverman Apparatus and method for increasing the amplitude of P300 waves in the human brain
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5224491A (en) 1991-01-07 1993-07-06 Medtronic, Inc. Implantable electrode for location within a blood vessel
US5269303A (en) 1991-02-22 1993-12-14 Cyberonics, Inc. Treatment of dementia by nerve stimulation
US5215086A (en) 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5299569A (en) 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5255678A (en) 1991-06-21 1993-10-26 Ecole Polytechnique Mapping electrode balloon
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5169384A (en) 1991-08-16 1992-12-08 Bosniak Stephen L Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue
US5304206A (en) 1991-11-18 1994-04-19 Cyberonics, Inc. Activation techniques for implantable medical device
US5358514A (en) 1991-12-18 1994-10-25 Alfred E. Mann Foundation For Scientific Research Implantable microdevice with self-attaching electrodes
US5193540A (en) 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5184620A (en) 1991-12-26 1993-02-09 Marquette Electronics, Inc. Method of using a multiple electrode pad assembly
US5406957A (en) 1992-02-05 1995-04-18 Tansey; Michael A. Electroencephalic neurofeedback apparatus for training and tracking of cognitive states
US5303705A (en) 1992-05-01 1994-04-19 Nenov Valeriy I Evoked 23NA MR imaging of sodium currents in the brain
US5423877A (en) 1992-05-04 1995-06-13 David C. Mackey Method and device for acute pain management by simultaneous spinal cord electrical stimulation and drug infusion
US5263967B1 (en) 1992-05-15 2000-12-19 Brimfield Prec Inc Medical instrument with dual action drive
US5476494A (en) 1992-09-11 1995-12-19 Massachusetts Institute Of Technology Low pressure neural contact structure
US5441528A (en) 1992-09-25 1995-08-15 Symtonic, S.A. Method and system for applying low energy emission therapy
US5370672A (en) 1992-10-30 1994-12-06 The Johns Hopkins University Computer-controlled neurological stimulation system
US5358513A (en) 1992-12-09 1994-10-25 Medtronic, Inc. Parameter selection and electrode placement of neuromuscular electrical stimulation apparatus
SE9203734D0 (en) 1992-12-11 1992-12-11 Siemens Elema Ab defibrillation
US5537512A (en) 1993-05-26 1996-07-16 Northrop Grumman Corporation Neural network elements
US5411540A (en) 1993-06-03 1995-05-02 Massachusetts Institute Of Technology Method and apparatus for preferential neuron stimulation
US5593432A (en) 1993-06-23 1997-01-14 Neuroware Therapy International, Inc. Method for neurostimulation for pain alleviation
US5540736A (en) 1993-08-02 1996-07-30 Haimovich; Yechiel Transcranial electrostimulation apparatus having two electrode pairs and independent current generators
US5417719A (en) 1993-08-25 1995-05-23 Medtronic, Inc. Method of using a spinal cord stimulation lead
US5464446A (en) 1993-10-12 1995-11-07 Medtronic, Inc. Brain lead anchoring system
US5470846A (en) 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
US5405375A (en) 1994-01-21 1995-04-11 Incontrol, Inc. Combined mapping, pacing, and defibrillating catheter
US5843093A (en) 1994-02-09 1998-12-01 University Of Iowa Research Foundation Stereotactic electrode assembly
US5697975A (en) 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
US5769778A (en) 1994-04-22 1998-06-23 Somatics, Inc. Medical magnetic non-convulsive stimulation therapy
US6152143A (en) 1994-05-09 2000-11-28 Somnus Medical Technologies, Inc. Method for treatment of air way obstructions
US5685313A (en) 1994-05-31 1997-11-11 Brain Monitor Ltd. Tissue monitor
US5601611A (en) 1994-08-05 1997-02-11 Ventritex, Inc. Optical blood flow measurement apparatus and method and implantable defibrillator incorporating same
US5549655A (en) 1994-09-21 1996-08-27 Medtronic, Inc. Method and apparatus for synchronized treatment of obstructive sleep apnea
US5540734A (en) 1994-09-28 1996-07-30 Zabara; Jacob Cranial nerve stimulation treatments using neurocybernetic prosthesis
US5722401A (en) 1994-10-19 1998-03-03 Cardiac Pathways Corporation Endocardial mapping and/or ablation catheter probe
US5522864A (en) 1994-10-25 1996-06-04 Wallace; Larry B. Apparatus and method for ocular treatment
US5520190A (en) 1994-10-31 1996-05-28 Ventritex, Inc. Cardiac blood flow sensor and method
US6425852B1 (en) 1994-11-28 2002-07-30 Emory University Apparatus and method for transcranial magnetic brain stimulation, including the treatment of depression and the localization and characterization of speech arrest
US5885976A (en) 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US5591216A (en) 1995-05-19 1997-01-07 Medtronic, Inc. Method for treatment of sleep apnea by electrical stimulation
US5772591A (en) 1995-06-06 1998-06-30 Patient Comfort, Inc. Electrode assembly for signaling a monitor
US6111911A (en) 1995-06-07 2000-08-29 Sanconix, Inc Direct sequence frequency ambiguity resolving receiver
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US6057846A (en) 1995-07-14 2000-05-02 Sever, Jr.; Frank Virtual reality psychophysiological conditioning medium
US5707334A (en) 1995-08-21 1998-01-13 Young; Robert B. Method of treating amygdala related transitory disorders
AUPN533195A0 (en) 1995-09-07 1995-10-05 Cochlear Pty. Limited Derived threshold and comfort level for auditory prostheses
US5649936A (en) 1995-09-19 1997-07-22 Real; Douglas D. Stereotactic guide apparatus for use with neurosurgical headframe
US5782873A (en) 1995-10-11 1998-07-21 Trustees Of Boston University Method and apparatus for improving the function of sensory cells
US6480743B1 (en) 2000-04-05 2002-11-12 Neuropace, Inc. System and method for adaptive brain stimulation
US20020169485A1 (en) 1995-10-16 2002-11-14 Neuropace, Inc. Differential neurostimulation therapy driven by physiological context
US6944501B1 (en) 2000-04-05 2005-09-13 Neurospace, Inc. Neurostimulator involving stimulation strategies and process for using it
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
WO1997021324A1 (en) 1995-12-01 1997-06-12 Cochlear Limited A feedback system to control electrode voltages in a cochlear stimulator and the like
NL1001890C2 (en) 1995-12-13 1997-06-17 Cordis Europ Catheter with plate-shaped electrode array.
US5824030A (en) 1995-12-21 1998-10-20 Pacesetter, Inc. Lead with inter-electrode spacing adjustment
US6066163A (en) 1996-02-02 2000-05-23 John; Michael Sasha Adaptive brain stimulation method and system
US6463328B1 (en) 1996-02-02 2002-10-08 Michael Sasha John Adaptive brain stimulation method and system
US5611350A (en) * 1996-02-08 1997-03-18 John; Michael S. Method and apparatus for facilitating recovery of patients in deep coma
US6051017A (en) 1996-02-20 2000-04-18 Advanced Bionics Corporation Implantable microstimulator and systems employing the same
US6126657A (en) 1996-02-23 2000-10-03 Somnus Medical Technologies, Inc. Apparatus for treatment of air way obstructions
US5904916A (en) 1996-03-05 1999-05-18 Hirsch; Alan R. Use of odorants to alter learning capacity
US5833603A (en) 1996-03-13 1998-11-10 Lipomatrix, Inc. Implantable biosensing transponder
DE59712479D1 (en) 1996-03-21 2005-12-22 Biotronik Gmbh & Co Kg Implantable stimulation electrode
US5925070A (en) 1996-04-04 1999-07-20 Medtronic, Inc. Techniques for adjusting the locus of excitation of electrically excitable tissue
US5702429A (en) 1996-04-04 1997-12-30 Medtronic, Inc. Neural stimulation techniques with feedback
US5628317A (en) 1996-04-04 1997-05-13 Medtronic, Inc. Ultrasonic techniques for neurostimulator control
US5713922A (en) 1996-04-25 1998-02-03 Medtronic, Inc. Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain
EP0892654B1 (en) 1996-04-04 2003-06-11 Medtronic, Inc. Apparatus for living tissue stimulation and recording techniques
US5824021A (en) 1996-04-25 1998-10-20 Medtronic Inc. Method and apparatus for providing feedback to spinal cord stimulation for angina
US5716377A (en) 1996-04-25 1998-02-10 Medtronic, Inc. Method of treating movement disorders by brain stimulation
US5683422A (en) 1996-04-25 1997-11-04 Medtronic, Inc. Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation
US6094598A (en) 1996-04-25 2000-07-25 Medtronics, Inc. Method of treating movement disorders by brain stimulation and drug infusion
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US5711316A (en) 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US5713923A (en) 1996-05-13 1998-02-03 Medtronic, Inc. Techniques for treating epilepsy by brain stimulation and drug infusion
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
WO1997045160A1 (en) 1996-05-31 1997-12-04 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
US6609031B1 (en) 1996-06-07 2003-08-19 Advanced Neuromodulation Systems, Inc. Multiprogrammable tissue stimulator and method
US6021352A (en) 1996-06-26 2000-02-01 Medtronic, Inc, Diagnostic testing methods and apparatus for implantable therapy devices
US5782798A (en) 1996-06-26 1998-07-21 Medtronic, Inc. Techniques for treating eating disorders by brain stimulation and drug infusion
US6246912B1 (en) 1996-06-27 2001-06-12 Sherwood Services Ag Modulated high frequency tissue modification
US5865842A (en) 1996-08-29 1999-02-02 Medtronic, Inc. System and method for anchoring brain stimulation lead or catheter
US5797970A (en) 1996-09-04 1998-08-25 Medtronic, Inc. System, adaptor and method to provide medical electrical stimulation
US5843148A (en) 1996-09-27 1998-12-01 Medtronic, Inc. High resolution brain stimulation lead and method of use
US5752979A (en) 1996-11-01 1998-05-19 Medtronic, Inc. Method of controlling epilepsy by brain stimulation
US6057847A (en) 1996-12-20 2000-05-02 Jenkins; Barry System and method of image generation and encoding using primitive reprojection
US6026326A (en) 1997-01-13 2000-02-15 Medtronic, Inc. Apparatus and method for treating chronic constipation
US5871517A (en) 1997-01-15 1999-02-16 Somatics, Inc. Convulsive therapy apparatus to stimulate and monitor the extent of therapeutic value of the treatment
US6432070B1 (en) 1999-05-11 2002-08-13 Exogen, Inc. Method and apparatus for ultrasonic treatment of reflex sympathetic dystrophy
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US5893883A (en) 1997-04-30 1999-04-13 Medtronic, Inc. Portable stimulation screening device for screening therapeutic effect of electrical stimulation on a patient user during normal activities of the patient user
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US5948007A (en) 1997-04-30 1999-09-07 Medtronic, Inc. Dual channel implantation neurostimulation techniques
US5975085A (en) 1997-05-01 1999-11-02 Medtronic, Inc. Method of treating schizophrenia by brain stimulation and drug infusion
US6128537A (en) 1997-05-01 2000-10-03 Medtronic, Inc Techniques for treating anxiety by brain stimulation and drug infusion
AU7566098A (en) 1997-05-06 1998-11-27 Christopher Bock Methods and apparatus for portable delivery of electrical physical therapy mo dalities to a patient
US5861017A (en) 1997-06-06 1999-01-19 Shriners Hospitals For Children Portable functional electrical stimulation (FES) system for upper or lower extremity applications
US6024702A (en) 1997-09-03 2000-02-15 Pmt Corporation Implantable electrode manufactured with flexible printed circuit
US5843150A (en) 1997-10-08 1998-12-01 Medtronic, Inc. System and method for providing electrical and/or fluid treatment within a patient's brain
US5941906A (en) 1997-10-15 1999-08-24 Medtronic, Inc. Implantable, modular tissue stimulator
US5938688A (en) 1997-10-22 1999-08-17 Cornell Research Foundation, Inc. Deep brain stimulation method
US6597954B1 (en) 1997-10-27 2003-07-22 Neuropace, Inc. System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes
US6230049B1 (en) 1999-08-13 2001-05-08 Neuro Pace, Inc. Integrated system for EEG monitoring and electrical stimulation with a multiplicity of electrodes
US6354299B1 (en) 1997-10-27 2002-03-12 Neuropace, Inc. Implantable device for patient communication
US6427086B1 (en) 1997-10-27 2002-07-30 Neuropace, Inc. Means and method for the intracranial placement of a neurostimulator
US6647296B2 (en) 1997-10-27 2003-11-11 Neuropace, Inc. Implantable apparatus for treating neurological disorders
US6016449A (en) 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6459936B2 (en) 1997-10-27 2002-10-01 Neuropace, Inc. Methods for responsively treating neurological disorders
DE19750043A1 (en) 1997-11-12 1999-05-20 Johann W Prof Dr Bartha Novel cuff electrode and method for producing it
US6128527A (en) 1997-12-03 2000-10-03 University Of Iowa Research Foundation Apparatus and method of analyzing electrical brain activity
US6011996A (en) 1998-01-20 2000-01-04 Medtronic, Inc Dual electrode lead and method for brain target localization in functional stereotactic brain surgery
US6205361B1 (en) 1998-02-10 2001-03-20 Advanced Bionics Corporation Implantable expandable multicontact electrodes
US6078838A (en) 1998-02-13 2000-06-20 University Of Iowa Research Foundation Pseudospontaneous neural stimulation system and method
US6631295B2 (en) 1998-02-13 2003-10-07 University Of Iowa Research Foundation System and method for diagnosing and/or reducing tinnitus
US6221908B1 (en) 1998-03-12 2001-04-24 Scientific Learning Corporation System for stimulating brain plasticity
US6295474B1 (en) 1998-03-13 2001-09-25 Intermedics Inc. Defibrillator housing with conductive polymer coating
US6058331A (en) 1998-04-27 2000-05-02 Medtronic, Inc. Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control
US6421566B1 (en) 1998-04-30 2002-07-16 Medtronic, Inc. Selective dorsal column stimulation in SCS, using conditioning pulses
US6161047A (en) 1998-04-30 2000-12-12 Medtronic Inc. Apparatus and method for expanding a stimulation lead body in situ
US6319241B1 (en) 1998-04-30 2001-11-20 Medtronic, Inc. Techniques for positioning therapy delivery elements within a spinal cord or a brain
US6018682A (en) 1998-04-30 2000-01-25 Medtronic, Inc. Implantable seizure warning system
US6006124A (en) 1998-05-01 1999-12-21 Neuropace, Inc. Means and method for the placement of brain electrodes
US5938689A (en) 1998-05-01 1999-08-17 Neuropace, Inc. Electrode configuration for a brain neuropacemaker
US5886769A (en) 1998-05-18 1999-03-23 Zolten; A. J. Method of training and rehabilitating brain function using hemi-lenses
US6198958B1 (en) 1998-06-11 2001-03-06 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for monitoring a magnetic resonance image during transcranial magnetic stimulation
US7890176B2 (en) 1998-07-06 2011-02-15 Boston Scientific Neuromodulation Corporation Methods and systems for treating chronic pelvic pain
US6035236A (en) 1998-07-13 2000-03-07 Bionergy Therapeutics, Inc. Methods and apparatus for electrical microcurrent stimulation therapy
US6104960A (en) 1998-07-13 2000-08-15 Medtronic, Inc. System and method for providing medical electrical stimulation to a portion of the nervous system
US6366813B1 (en) 1998-08-05 2002-04-02 Dilorenzo Daniel J. Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease
US7277758B2 (en) 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
US6304787B1 (en) 1998-08-26 2001-10-16 Advanced Bionics Corporation Cochlear electrode array having current-focusing and tissue-treating features
AU9348098A (en) 1998-08-27 2000-03-21 Novavision Ag Process and device for the training of human vision
US6569654B2 (en) 1998-09-18 2003-05-27 Massachusetts Institute Of Technology Electroactive materials for stimulation of biological activity of stem cells
US6190893B1 (en) 1998-09-18 2001-02-20 Massachusetts Institute Of Technology Electroactive materials for stimulation of biological activity of bone marrow stromal cells
USRE45616E1 (en) 1998-10-13 2015-07-21 Covidien Lp Multi-channel non-invasive tissue oximeter
US7062330B1 (en) * 1998-10-26 2006-06-13 Boveja Birinder R Electrical stimulation adjunct (Add-ON) therapy for urinary incontinence and urological disorders using implanted lead stimulus-receiver and an external pulse generator
US20060217782A1 (en) 1998-10-26 2006-09-28 Boveja Birinder R Method and system for cortical stimulation to provide adjunct (ADD-ON) therapy for stroke, tinnitus and other medical disorders using implantable and external components
US6253109B1 (en) 1998-11-05 2001-06-26 Medtronic Inc. System for optimized brain stimulation
US6161044A (en) 1998-11-23 2000-12-12 Synaptic Corporation Method and apparatus for treating chronic pain syndromes, tremor, dementia and related disorders and for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation
US6507755B1 (en) 1998-12-01 2003-01-14 Neurometrix, Inc. Apparatus and method for stimulating human tissue
US6052624A (en) 1999-01-07 2000-04-18 Advanced Bionics Corporation Directional programming for implantable electrode arrays
JP4288009B2 (en) 1999-03-24 2009-07-01 ロイド アール. サベルスキ, Apparatus and method for pain relief and / or muscle retraining
US6055456A (en) 1999-04-29 2000-04-25 Medtronic, Inc. Single and multi-polar implantable lead for sacral nerve electrical stimulation
US6210417B1 (en) 1999-04-29 2001-04-03 Medtronic, Inc. Medical lead positioning and anchoring system
US6214016B1 (en) 1999-04-29 2001-04-10 Medtronic, Inc. Medical instrument positioning device internal to a catheter or lead and method of use
US6353762B1 (en) 1999-04-30 2002-03-05 Medtronic, Inc. Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6505075B1 (en) 1999-05-29 2003-01-07 Richard L. Weiner Peripheral nerve stimulation method
US6161045A (en) 1999-06-01 2000-12-12 Neuropace, Inc. Method for determining stimulation parameters for the treatment of epileptic seizures
US6633780B1 (en) 1999-06-07 2003-10-14 The Johns Hopkins University Cardiac shock electrode system and corresponding implantable defibrillator system
US6539263B1 (en) 1999-06-11 2003-03-25 Cornell Research Foundation, Inc. Feedback mechanism for deep brain stimulation
US6301493B1 (en) 1999-07-10 2001-10-09 Physiometrix, Inc. Reservoir electrodes for electroencephalograph headgear appliance
US6516227B1 (en) 1999-07-27 2003-02-04 Advanced Bionics Corporation Rechargeable spinal cord stimulator system
US6381496B1 (en) 1999-10-01 2002-04-30 Advanced Bionics Corporation Parameter context switching for an implanted device
US6236892B1 (en) 1999-10-07 2001-05-22 Claudio A. Feler Spinal cord stimulation lead
US6499488B1 (en) 1999-10-28 2002-12-31 Winchester Development Associates Surgical sensor
US6764498B2 (en) 1999-12-09 2004-07-20 Hans Alois Mische Methods and devices for treatment of neurological disorders
US6375666B1 (en) 1999-12-09 2002-04-23 Hans Alois Mische Methods and devices for treatment of neurological disorders
US7300449B2 (en) 1999-12-09 2007-11-27 Mische Hans A Methods and devices for the treatment of neurological and physiological disorders
AU1547101A (en) 1999-11-26 2001-06-04 Applied Spectral Imaging Ltd. System and method for functional brain mapping and an oxygen saturation difference map algorithm for effecting same
AU1618401A (en) 1999-12-06 2001-06-12 Advanced Bionics Corporation Implantable device programmer
US6873872B2 (en) 1999-12-07 2005-03-29 George Mason University Adaptive electric field modulation of neural systems
ATE323528T1 (en) 1999-12-07 2006-05-15 Univ George Mason ADAPTIVE MODULATION OF AN ELECTRICAL FIELD FOR NEURAL SYSTEMS
US6356792B1 (en) 2000-01-20 2002-03-12 Electro Core Technologies, Llc Skull mounted electrode lead securing assembly
US6356786B1 (en) 2000-01-20 2002-03-12 Electrocore Techniques, Llc Method of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain
US6907296B1 (en) 2000-02-15 2005-06-14 Pacesetter, Inc. Implantable cardiac lead having convenient implant location identification and method of manufacture
US6708064B2 (en) 2000-02-24 2004-03-16 Ali R. Rezai Modulation of the brain to affect psychiatric disorders
US6487450B1 (en) 2000-02-24 2002-11-26 Cedars-Sinai Medical Center System and method for preventing Sudden Cardiac Death by nerve sprouting from right stellate ganglion
US6609030B1 (en) 2000-02-24 2003-08-19 Electrocore Techniques, Llc Method of treating psychiatric diseases by neuromodulation within the dorsomedial thalamus
US6418344B1 (en) 2000-02-24 2002-07-09 Electrocore Techniques, Llc Method of treating psychiatric disorders by electrical stimulation within the orbitofrontal cerebral cortex
US6473639B1 (en) 2000-03-02 2002-10-29 Neuropace, Inc. Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures
US6810286B2 (en) 2000-03-06 2004-10-26 Medtronic, Inc Stimulation for delivery of molecular therapy
US6430443B1 (en) * 2000-03-21 2002-08-06 Manuel L. Karell Method and apparatus for treating auditory hallucinations
US6353754B1 (en) 2000-04-24 2002-03-05 Neuropace, Inc. System for the creation of patient specific templates for epileptiform activity detection
US6687525B2 (en) 2000-06-07 2004-02-03 New York University Method and system for diagnosing and treating thalamocortical dysrhythmia
US6549814B1 (en) 2000-06-09 2003-04-15 Juergen Strutz Blade electrode array for insertion under soft tissue of lateral wall of cochlea
WO2001097906A2 (en) 2000-06-20 2001-12-27 Advanced Bionics Corporation Apparatus for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
US7024247B2 (en) 2001-10-15 2006-04-04 Northstar Neuroscience, Inc. Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures
US7010351B2 (en) * 2000-07-13 2006-03-07 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7831305B2 (en) 2001-10-15 2010-11-09 Advanced Neuromodulation Systems, Inc. Neural stimulation system and method responsive to collateral neural activity
US20050021118A1 (en) 2000-07-13 2005-01-27 Chris Genau Apparatuses and systems for applying electrical stimulation to a patient
US7756584B2 (en) 2000-07-13 2010-07-13 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7672730B2 (en) 2001-03-08 2010-03-02 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US20030125786A1 (en) 2000-07-13 2003-07-03 Gliner Bradford Evan Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7236831B2 (en) 2000-07-13 2007-06-26 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US20040176831A1 (en) 2000-07-13 2004-09-09 Gliner Bradford Evan Apparatuses and systems for applying electrical stimulation to a patient
US6497699B1 (en) 2000-08-09 2002-12-24 The Research Foundation Of State University Of New York Hybrid neuroprosthesis for the treatment of brain disorders
DE10039240A1 (en) 2000-08-11 2002-02-28 Hans Ulrich May Electrotherapeutic device
US6591138B1 (en) 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
JP2002072309A (en) 2000-09-01 2002-03-12 Canon Inc Camera and camera system
US6405079B1 (en) 2000-09-22 2002-06-11 Mehdi M. Ansarinia Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions
US6871098B2 (en) 2000-10-30 2005-03-22 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
US6529774B1 (en) 2000-11-09 2003-03-04 Neuropace, Inc. Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation
US6922590B1 (en) 2000-11-21 2005-07-26 Advanced Bionics Corporation Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
US6735475B1 (en) 2001-01-30 2004-05-11 Advanced Bionics Corporation Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain
US6788975B1 (en) 2001-01-30 2004-09-07 Advanced Bionics Corporation Fully implantable miniature neurostimulator for stimulation as a therapy for epilepsy
US7149586B2 (en) 2002-03-28 2006-12-12 Second Sight Medical Products, Inc. Variable pitch electrode array
US7299096B2 (en) 2001-03-08 2007-11-20 Northstar Neuroscience, Inc. System and method for treating Parkinson's Disease and other movement disorders
AU2002303295B2 (en) 2001-04-06 2006-11-30 Univ New York Diagnosis and treatment of neural disease and injury using microvoltammetry
US6684105B2 (en) 2001-08-31 2004-01-27 Biocontrol Medical, Ltd. Treatment of disorders by unidirectional nerve stimulation
US6839594B2 (en) 2001-04-26 2005-01-04 Biocontrol Medical Ltd Actuation and control of limbs through motor nerve stimulation
WO2002087410A2 (en) 2001-04-27 2002-11-07 Yacov Naisberg Diagnosis, treatment and research of mental disorders
US20060241717A1 (en) 2001-08-30 2006-10-26 Whitehurst Todd K Treatment of movement disorders by extra dural motor cortex stimulation
WO2003026738A1 (en) 2001-09-28 2003-04-03 Northstar Neuroscience, Inc. Methods and apparatus for electrically stimulating cells implanted in the nervous system
AU2002334749A1 (en) 2001-09-28 2003-04-07 Northstar Neuroscience, Inc. Methods and implantable apparatus for electrical therapy
US6944497B2 (en) 2001-10-31 2005-09-13 Medtronic, Inc. System and method of treating stuttering by neuromodulation
US7050856B2 (en) 2002-01-11 2006-05-23 Medtronic, Inc. Variation of neural-stimulation parameters
US7110820B2 (en) 2002-02-05 2006-09-19 Tcheng Thomas K Responsive electrical stimulation for movement disorders
US7221981B2 (en) 2002-03-28 2007-05-22 Northstar Neuroscience, Inc. Electrode geometries for efficient neural stimulation
US7146222B2 (en) 2002-04-15 2006-12-05 Neurospace, Inc. Reinforced sensing and stimulation leads and use in detection systems
US20050154426A1 (en) 2002-05-09 2005-07-14 Boveja Birinder R. Method and system for providing therapy for neuropsychiatric and neurological disorders utilizing transcranical magnetic stimulation and pulsed electrical vagus nerve(s) stimulation
US20060004423A1 (en) 2002-05-09 2006-01-05 Boveja Birinder R Methods and systems to provide therapy or alleviate symptoms of chronic headache, transformed migraine, and occipital neuralgia by providing rectangular and/or complex electrical pulses to occipital nerves
US20050182453A1 (en) 2002-05-24 2005-08-18 Whitehurst Todd K. Treatment of epilepsy by high frequency electrical stimulation and/or drug stimulation
WO2003105945A2 (en) 2002-06-13 2003-12-24 Paul Edward L Jr Transcutaneous electrical nerve stimulation device and method using microcurrent
JP4411205B2 (en) 2002-06-28 2010-02-10 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Micro stimulator with built-in power supply and interactive telemetry system
US7006859B1 (en) 2002-07-20 2006-02-28 Flint Hills Scientific, L.L.C. Unitized electrode with three-dimensional multi-site, multi-modal capabilities for detection and control of brain state changes
US6934580B1 (en) 2002-07-20 2005-08-23 Flint Hills Scientific, L.L.C. Stimulation methodologies and apparatus for control of brain states
US20040092809A1 (en) 2002-07-26 2004-05-13 Neurion Inc. Methods for measurement and analysis of brain activity
US7471974B2 (en) 2002-09-13 2008-12-30 Brainlab Ag Method for planning stimulation of hyper/hypometabolic cortical areas
US20050075679A1 (en) 2002-09-30 2005-04-07 Gliner Bradford E. Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system
US20040082847A1 (en) 2002-10-23 2004-04-29 Mcdermott Kathleen B. System and methods for identifying brain regions supporting language
US7236830B2 (en) 2002-12-10 2007-06-26 Northstar Neuroscience, Inc. Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders
US20050075680A1 (en) 2003-04-18 2005-04-07 Lowry David Warren Methods and systems for intracranial neurostimulation and/or sensing
US7302298B2 (en) 2002-11-27 2007-11-27 Northstar Neuroscience, Inc Methods and systems employing intracranial electrodes for neurostimulation and/or electroencephalography
AU2003297761A1 (en) 2002-12-09 2004-06-30 Northstar Neuroscience, Inc. Methods for treating neurological language disorders
US6959215B2 (en) 2002-12-09 2005-10-25 Northstar Neuroscience, Inc. Methods for treating essential tremor
CA2523540A1 (en) 2003-04-24 2005-01-06 Northstar Neuroscience, Inc. Systems and methods for facilitating and/or effectuating development, rehabilitation, restoration, and/or recovery of visual function through neural stimulation
US7463928B2 (en) 2003-04-25 2008-12-09 Medtronic, Inc. Identifying combinations of electrodes for neurostimulation therapy
US7065412B2 (en) 2003-04-25 2006-06-20 Medtronic, Inc. Implantable trial neurostimulation device
US7107104B2 (en) 2003-05-30 2006-09-12 Medtronic, Inc. Implantable cortical neural lead and method
CA2432810A1 (en) 2003-06-19 2004-12-19 Andres M. Lozano Method of treating depression, mood disorders and anxiety disorders by brian infusion
CA2534363A1 (en) 2003-08-01 2005-02-10 Brad Fowler Apparatus and methods for applying neural stimulation to a patient
FR2860722B1 (en) 2003-10-14 2006-09-22 Commissariat Energie Atomique IMPROVED BRAIN ELECTRO-STIMULATION DEVICE
US7187968B2 (en) 2003-10-23 2007-03-06 Duke University Apparatus for acquiring and transmitting neural signals and related methods
WO2005051480A2 (en) 2003-11-20 2005-06-09 Advanced Neuromodulation Systems, Inc. Electrical stimulation system, lead, and method providing reduced neuroplasticity effects
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US7107097B2 (en) 2004-01-14 2006-09-12 Northstar Neuroscience, Inc. Articulated neural electrode assembly
WO2005087314A1 (en) 2004-03-11 2005-09-22 Advanced Neuromodulation Systems, Inc. Brain stimulation system and method
WO2005107858A1 (en) 2004-04-30 2005-11-17 Advanced Neuromodulation Systems, Inc. Method of treating mood disorders and/or anxiety disorders by brain stimulation
EP1786510A4 (en) 2004-07-15 2009-12-02 Northstar Neuroscience Inc Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
US20060020297A1 (en) 2004-07-20 2006-01-26 Gerber Martin T Neurostimulation system with distributed stimulators
US20050154425A1 (en) 2004-08-19 2005-07-14 Boveja Birinder R. Method and system to provide therapy for neuropsychiatric disorders and cognitive impairments using gradient magnetic pulses to the brain and pulsed electrical stimulation to vagus nerve(s)
US7613520B2 (en) 2004-10-21 2009-11-03 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
US20060106430A1 (en) 2004-11-12 2006-05-18 Brad Fowler Electrode configurations for reducing invasiveness and/or enhancing neural stimulation efficacy, and associated methods
US7565200B2 (en) 2004-11-12 2009-07-21 Advanced Neuromodulation Systems, Inc. Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects
US8000795B2 (en) 2004-12-17 2011-08-16 Lozano Andres M Cognitive function within a human brain
US20060173522A1 (en) 2005-01-31 2006-08-03 Medtronic, Inc. Anchoring of a medical device component adjacent a dura of the brain or spinal cord

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3650276A (en) * 1969-03-26 1972-03-21 Inst Demedicina Si Farmacie Method and apparatus, including a flexible electrode, for the electric neurostimulation of the neurogenic bladder
US4140133A (en) * 1977-04-26 1979-02-20 Moskovsky Oblastnoi Nauchno-Issledovatelsky Institut Akusherstva I Ginekolog Ii Device for pulse current action on central nervous system
US5674251A (en) * 1994-04-21 1997-10-07 Medtronic, Inc. Method and apparatus for treatment of atrial fibrillation
US20030125772A1 (en) * 1995-03-30 2003-07-03 Olson Walter H. Prioritized rule based method and apparatus for diagnosis and treatment of arrhythmias
US20020077670A1 (en) * 2000-04-05 2002-06-20 Archer Stephen T. Stimulation signal generator for an implantable device
US20020091419A1 (en) * 2000-07-13 2002-07-11 Firlik Andrew D. Methods and apparatus for effectuating a change in a neural-function of a patient
US20040158298A1 (en) * 2000-07-13 2004-08-12 Gliner Bradford Evan Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US20050004620A1 (en) * 2002-12-09 2005-01-06 Medtronic, Inc. Implantable medical device with anti-infection agent

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786508A2 (en) * 2004-07-15 2007-05-23 Northstar Neuroscience, Inc. Methods and systems for intracranial neurostimulation and/or sensing
EP1786508A4 (en) * 2004-07-15 2013-01-16 Northstar Neuroscience Inc Methods and systems for intracranial neurostimulation and/or sensing
JP2007021225A (en) * 2005-07-20 2007-02-01 Cyberonics Inc Vagal stimulation by electrical signal for controlling cerebellar tremor
EP1948300A2 (en) * 2005-10-19 2008-07-30 Northstar Neuroscience, Inc. Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders
EP1948300A4 (en) * 2005-10-19 2009-03-18 Northstar Neuroscience Inc Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders
JP2009531154A (en) * 2006-03-29 2009-09-03 カソリック ヘルスケア ウエスト Cranial nerve microburst electrical stimulation for medical treatment
US8116875B2 (en) 2006-06-16 2012-02-14 Neuropoint Medical, Inc. Implantable neurostimulation systems
US7917231B2 (en) 2006-08-07 2011-03-29 Alpha Omega Neuro Technologies Ltd. Directional stimulation of neural tissue
WO2008018067A3 (en) * 2006-08-07 2008-03-20 Alpha Omega Engineering Ltd Cerebral electrodes and methods of operating same
WO2008018067A2 (en) * 2006-08-07 2008-02-14 Alpha Omega Engineering Ltd. Cerebral electrodes and methods of operating same
JP2010501269A (en) * 2006-08-25 2010-01-21 カーディアック ペースメイカーズ, インコーポレイテッド System for sedating the side effects of neural stimulation
US8897881B2 (en) 2006-08-25 2014-11-25 Cardiac Pacemakers, Inc. System for abating neural stimulation side effects
US8527042B2 (en) 2006-08-25 2013-09-03 Cardiac Pacemakers, Inc. System for abating neural stimulation side effects
US10898717B2 (en) 2009-10-20 2021-01-26 Nyxoah SA Device and method for snoring detection and control
US11857791B2 (en) 2009-10-20 2024-01-02 Nyxoah SA Arced implant unit for modulation of nerves
US11273307B2 (en) 2009-10-20 2022-03-15 Nyxoah SA Method and device for treating sleep apnea
US10716940B2 (en) 2009-10-20 2020-07-21 Nyxoah SA Implant unit for modulation of small diameter nerves
US9849289B2 (en) 2009-10-20 2017-12-26 Nyxoah SA Device and method for snoring detection and control
US10751537B2 (en) 2009-10-20 2020-08-25 Nyxoah SA Arced implant unit for modulation of nerves
US9943686B2 (en) 2009-10-20 2018-04-17 Nyxoah SA Method and device for treating sleep apnea based on tongue movement
US9950166B2 (en) 2009-10-20 2018-04-24 Nyxoah SA Acred implant unit for modulation of nerves
US8577458B1 (en) 2011-12-07 2013-11-05 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with leadless heart rate monitoring
US10188856B1 (en) 2011-12-07 2019-01-29 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8700150B2 (en) 2012-01-17 2014-04-15 Cyberonics, Inc. Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
US8688212B2 (en) 2012-07-20 2014-04-01 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation
US9919157B2 (en) 2012-07-20 2018-03-20 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation
US10052097B2 (en) 2012-07-26 2018-08-21 Nyxoah SA Implant unit delivery tool
US10716560B2 (en) 2012-07-26 2020-07-21 Nyxoah SA Implant unit delivery tool
US9855032B2 (en) 2012-07-26 2018-01-02 Nyxoah SA Transcutaneous power conveyance device
US10814137B2 (en) 2012-07-26 2020-10-27 Nyxoah SA Transcutaneous power conveyance device
US10918376B2 (en) 2012-07-26 2021-02-16 Nyxoah SA Therapy protocol activation triggered based on initial coupling
US11730469B2 (en) 2012-07-26 2023-08-22 Nyxoah SA Implant unit delivery tool
US11253712B2 (en) 2012-07-26 2022-02-22 Nyxoah SA Sleep disordered breathing treatment apparatus
US9643008B2 (en) 2012-11-09 2017-05-09 Cyberonics, Inc. Implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation
US9643011B2 (en) 2013-03-14 2017-05-09 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation
US11298549B2 (en) 2013-06-17 2022-04-12 Nyxoah SA Control housing for disposable patch
US11642534B2 (en) 2013-06-17 2023-05-09 Nyxoah SA Programmable external control unit
US9643022B2 (en) 2013-06-17 2017-05-09 Nyxoah SA Flexible control housing for disposable patch
US10512782B2 (en) 2013-06-17 2019-12-24 Nyxoah SA Remote monitoring and updating of a medical device control unit
US11376422B2 (en) 2015-07-08 2022-07-05 Rainbow Medical Ltd. Electrical treatment of Alzheimer's disease
US11819685B2 (en) 2015-07-08 2023-11-21 Rainbow Medical Ltd. Electrical treatment of Alzheimer's disease
US11141588B2 (en) 2015-10-29 2021-10-12 Rainbow Medical Ltd. Electrical substance clearance from the brain
US10898716B2 (en) 2015-10-29 2021-01-26 Rainbow Medical Ltd. Electrical substance clearance from the brain
US11285317B2 (en) 2015-12-29 2022-03-29 Rainbow Medical Ltd. Disc therapy
US11484706B2 (en) 2015-12-29 2022-11-01 Discure Technologies Ltd Disc therapy
US11612742B2 (en) 2015-12-29 2023-03-28 Discure Technologies Ltd. Disc therapy
US11202905B2 (en) 2018-03-14 2021-12-21 Rainbow Medical Ltd. Electrical substance clearance from the brain
US11298530B1 (en) 2021-05-03 2022-04-12 Discure Technologies Ltd. Synergistic therapies for intervertebral disc degeneration
US11344721B1 (en) 2021-08-16 2022-05-31 Rainbow Medical Ltd. Cartilage treatment

Also Published As

Publication number Publication date
US20090182391A1 (en) 2009-07-16
US7684866B2 (en) 2010-03-23
US20050070971A1 (en) 2005-03-31
US8126562B2 (en) 2012-02-28
AU2004261290A1 (en) 2005-02-10
WO2005011805A3 (en) 2005-10-27
CA2534363A1 (en) 2005-02-10
US20060190056A1 (en) 2006-08-24
EP1654032A2 (en) 2006-05-10
JP2007501067A (en) 2007-01-25

Similar Documents

Publication Publication Date Title
US7684866B2 (en) Apparatus and methods for applying neural stimulation to a patient
US7742820B2 (en) Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of parkinson's disease, other movement disorders, and/or drug side effects
US8926676B2 (en) Systems and methods for applying signals, including contralesional signals, to neural populations
US6959215B2 (en) Methods for treating essential tremor
US7236831B2 (en) Methods and apparatus for effectuating a lasting change in a neural-function of a patient
AU2003293541B2 (en) Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders
US20080139870A1 (en) Systems and methods for treating patient hypertonicity
US20070088404A1 (en) Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders
CA2454184A1 (en) Method and apparatus for treating neurological disorders by electrical stimulation of the brain
US7774068B1 (en) System and method for treating movement disorders, including restless leg syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2534363

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006522666

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004779931

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004261290

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004261290

Country of ref document: AU

Date of ref document: 20040802

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004261290

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004779931

Country of ref document: EP